Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds
NEWS 25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 26	NOV 19	WPIX enhanced with XML display format
NEWS 27	NOV 30	ICSD reloaded with enhancements
NEWS 28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:41:18 ON 07 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:41:39 ON 07 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 DEC 2007 HIGHEST RN 957014-20-9
DICTIONARY FILE UPDATES: 6 DEC 2007 HIGHEST RN 957014-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10518819\Struc 1.str





chain nodes :
7 8 15 17
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
2-15 7-8 8-10 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
2-15 7-8 15-17
exact bonds :
8-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

G1:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 17:CLASS 18:Atom

L1 STRUCTURE UPLOADED

=> d

10518819.trn

L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> l1
SAMPLE SEARCH INITIATED 10:41:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 312362 TO ITERATE

0.6% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 6214848 TO 6279632
PROJECTED ANSWERS: 335749 TO 351447

L2 50 SEA SSS SAM L1

=> log h
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.90 1.11

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:43:06 ON 07 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 10:45:38 ON 07 DEC 2007
FILE 'REGISTRY' ENTERED AT 10:45:38 ON 07 DEC 2007

COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 1.35 1.56

=>
Uploading C:\Program Files\Stnexp\Queries\10518819\Struc 2.str

chain nodes :
7 8 15 17 21
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
2-15 5-7 7-8 12-21 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
2-15 5-7 7-8 15-17
exact bonds :
12-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

G1:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 17:CLASS 20:CLASS 21:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> l3
SAMPLE SEARCH INITIATED 10:45:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10378 TO ITERATE

19.3% PROCESSED 2000 ITERATIONS 15 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 201455 TO 213665
PROJECTED ANSWERS: 1027 TO 2085

L4 15 SEA SSS SAM L3

=> l3 full
FULL SEARCH INITIATED 10:46:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 208862 TO ITERATE

100.0% PROCESSED 208862 ITERATIONS 1761 ANSWERS
SEARCH TIME: 00.00.03

L5 1761 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	173.66

FILE 'CAPLUS' ENTERED AT 10:46:14 ON 07 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 6 Dec 2007 (20071206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l5
L6 151 L5

=> d ibib abs hitstr 1-151

L6 ANSWER 1 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:961545 CAPLUS
DOCUMENT NUMBER: 147:486486
TITLE: Suzuki-Miyaura reaction in water, conducted by employing an amphiphilic dendritic phosphine-palladium catalyst: A positive dendritic effect on chemical yield
AUTHOR(S): Hattori, Hatsuhiko; Fujita, Ken-ichi; Muraki, Takahito; Sakaba, Ai
CORPORATE SOURCE: AIST Tsukuba Central 5, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, 305-8565, Japan
SOURCE: Tetrahedron Letters (2007), 48(38), 6817-6820
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Amphiphilic triphenylphosphines containing dendrimeric carboxybenzyloxy moieties at the para positions are prepared; complexes generated from bis(allylchloropalladium) and the potassium salts of the dendrimers are effective catalysts for Suzuki-Miyaura coupling reactions of aryl iodides and an aryl bromide with arylboronic acids in water to yield biaryls. The yields of biaryls prepared by Suzuki coupling reactions in the presence of palladium complexes generated from the dendrimeric ligands increase as the generation of the dendrimeric ligand increases (a pos. dendritic effect). Catalysts generated from dendrimeric phosphines give higher yields of biaryls than catalysts generated from a nondendrimeric phosphine and added potassium benzoate (under conditions where the concns. of both phosphine and potassium carboxylate moieties are identical).

IT 953812-78-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dendrimeric (carboxybenzyloxy)aryl phosphines as amphiphilic ligands for palladium-catalyzed Suzuki-Miyaura coupling reactions of aryl iodides and a bromide with arylboronic acids in water to give biaryls)
RN 953812-78-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L6 ANSWER 1 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:910521 CAPLUS
DOCUMENT NUMBER: 147:419269
TITLE: Prediction of Protein-Protein Interaction Inhibitors by Chemoinformatics and Machine Learning Methods
AUTHOR(S): Neugebauer, Alexander; Hartmann, Rolf W.; Klein, Christian D.
CORPORATE SOURCE: Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbruecken, Germany
SOURCE: Journal of Medicinal Chemistry (2007), 50(19), 4665-4668
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We describe a collection of structurally diverse inhibitors of protein-protein-interactions (PPIs). This collection is compared against the FDA drug database and a subset of the ZINC database by machine learning methods which rely on classical QSAR descriptors. We obtain a decision tree that contains three descriptors. Of particular importance is a constitutional descriptor related to mol. shape and size. Validation of the decision tree by various procedures indicates that it does not result from chance correlations and has predictive value. We conclude that constitutional descriptors may be valuable tools in the preselection of potential PPI inhibitors from compound databases.

IT 229948-52-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods)
RN 229948-52-1 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 2 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 3 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 330982-78-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(electro-optic dendrimer-based glass composites)
RN 330982-78-0 CAPLUS
CN Benzoic acid, 4,4',4''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (CA INDEX NAME)



L6 ANSWER 3 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:731145 CAPLUS
DOCUMENT NUMBER: 147:153672
TITLE: Electro-optic dendrimer-based glass composites
INVENTOR(S): Jen, Kwan-Yue; Luo, Jingdong; Kim, Tae-Dong; Chen, Baoquan; Kang, Jae-Wook; Sullivan, Philip A.; Akelaitis, Andrew; Dalton, Larry R.; Cheng, Yen-Ju
PATENT ASSIGNEE(S): University of Washington, USA
SOURCE: U.S. Pat. Appl. Publ., 47pp., Cont.-in-part of U.S. Ser. No. 335,834.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2007152198	A1	20070705	US 2006-462339		20060803
PRIORITY APPLN. INFO.:			US 2005-644960P	P	20050118
			US 2005-646321P	P	20050121
			US 2006-335834	A2	20060118

AB An electrooptical dendrimer-based composite is described comprising (a) a chromophore compound having a π-electron donor group electronically conjugated to a π-electron acceptor group through π-electron bridge group, the compound having the formula: D1-π1-B1-π2-A1 wherein D1 is a π-electron donor group, B1 is a π-electron bridge group, A1 is a π-electron acceptor group, π1 is a π bridge electronically conjugating D1 to B1, π2 is a π bridge electronically conjugating B1 to A1, wherein π1 and π2 may each be present or absent; and (b) a dendronized chromophore compound having a π-electron donor group electronically conjugated to a π-electron acceptor group through π-electron bridge group, the compound having the formula: D2-π3-B2-π4-A2 wherein D2 is a π-electron donor group, B2 is a π-electron bridge group, A2 is a π-electron acceptor group, π3 is a π bridge electronically conjugating D2 to B2, π3 is a π bridge electronically conjugating B2 to A2, wherein π3 and π4 may each be present or absent, wherein one or more of the donor, bridge, or acceptor groups is substituted with a dendron; and wherein D1 and D2 are the same or different, B1 and B2 are the same or different, A1 and A2 are the same or different, and π1, π2, π3, and π4 are the same or different. A method for forming the at least partially aligned chromophore composite is also described entailing (a) depositing a composite onto a substrate; (b) subjecting the composite to a temperature equal or higher than the glass transition temperature of the composite; (c) applying an aligning force to the composite; and (d) reducing the temperature of the composite below the glass transition temperature of the composite to provide a hardened, at least partially aligned chromophore composite. An electrooptical device comprising the composite is also described.

L6 ANSWER 4 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:729249 CAPLUS
DOCUMENT NUMBER: 147:129173
TITLE: Multi-layer liquid crystal cell substrates having optical anisotropic layer for liquid crystal displays and method for manufacturing the same
INVENTOR(S): Morishima, Shinichi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 52pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007171800	A	20070705	JP 2005-372370	20051226
PRIORITY APPLN. INFO.:			JP 2005-372370	20051226

AB The title multi layer consists of an optical anisotropic layer and a photosensitive layer, wherein the optical anisotropic layer contains a cationically polymerizable compound and wherein photosensitive layer contains a compound having a reactive group and a cationically polymerizing initiator for polymerizing materials in the optical anisotropic layer and the photosensitive layer together. The substrate provides easy fabrication of tical compensation film.
IT 943220-12-0
RL: TEM (Technical or engineered material use); USES (Uses)
(polymerizable compound in optically anisotropic layer; multi-layer liquid crystal cell substrates for liquid crystal displays and method for manufacturing the same)
RN 943220-12-0 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-[[3,4,5-tris[4-[(3-methyl-3-oxetanyl)methoxy]butoxy]benzoyl]oxy]-, 1-[3,4,5-tris[4-[(3-methyl-3-oxetanyl)methoxy]butoxy]phenyl] ester (CA INDEX NAME)

L6 ANSWER 4 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Me3CNH2 followed by slow evapn. of EtOAc and Me3CNH2 to give II tert-butylammonium salt.

IT 936365-14-9P 936365-16-1P 936365-17-2P
936365-19-4P 936365-23-0P 936365-24-1P
936365-25-2P 936365-26-3P 936365-27-4P
936365-28-5P 936365-30-9P 936365-32-1P
936365-33-2P 936365-34-3P 936365-36-5P
936365-37-6P 936365-38-7P 936365-39-8P
936365-40-1P 936365-41-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(claimed compound: preparation of tert-butylammonium or adamantylammonium salts of benzylaminooxoalkylphenoxymethylbenzoic acids and related compds.)

RN 936365-14-9 CAPLUS

CN Benzoic acid, 2-[[4-[3-[hexyl(phenylmethyl)amino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637014-98-3
CMF C30 H35 N O4



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-16-1 CAPLUS

CN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-05-5
CMF C29 H33 N O4

L6 ANSWER 5 OF 151 CAPLUS 'COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:510463 CAPLUS
DOCUMENT NUMBER: 146:500740
TITLE: Preparation of tert-butylammonium or adamantylammonium salts of benzylaminooxoalkylphenoxymethylbenzoic acids and related compounds.
INVENTOR(S): Dahlstrom, Mikael Ulf Johan; Ohlsson, Bengt
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051995	A2	20070510	WO 2006-GB4035	20061031
WO 2007051995	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: GB 2005-22433 A 20051103

OTHER SOURCE(S): MARPAT 146:500740
GI



I

AB Tert-butylammonium salt or adamantylammonium salts of title compds. (I; n = 0-2; R1 = halo, alkyl, fluoroalkyl, alkoxy, fluoroalkyl; R2 = alkyl optionally interrupted by O; Y = null, methylene; X = O, S), were prepared
Thus, 2-[[4-[2-[ethyl[4-(trifluoromethyl)benzyl]amino]-2-oxoethyl]phenyl]thiomethyl]benzoic acid (II) in EtOAc was treated with

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-17-2 CAPLUS

CN Benzoic acid, 2-[[4-[2-[[(2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-07-7
CMF C30 H33 F2 N O4



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-19-4 CAPLUS

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-10-2
CMF C31 H35 F2 N O4



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-23-0 CAPLUS
CN Benzoic acid, 2-[[4-[3-[butyl[(2,3-dimethoxyphenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-18-0
CMF C30 H35 N O6



L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 637015-26-0
CMF C32 H39 N O5



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-26-3 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]propylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-30-6
CMF C27 H27 F2 N O4



CM 2

CRN 75-64-9
CMF C4 H11 N

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-24-1 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,3-dimethoxyphenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-22-6
CMF C33 H41 N O6



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-25-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[(3-ethoxypropyl)[[4-(1-methylethyl)phenyl]methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with
2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 936365-27-4 CAPLUS
CN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-oxoethyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-33-9
CMF C25 H24 F N O4



CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-28-5 CAPLUS
CN Benzoic acid, 2-[[4-[3-[ethyl[(2-fluorophenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-36-2
CMF C26 H26 F N O4



L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 75-64-9
CMF C4 H11 N

RN 936365-30-9 CAPLUS
CN Benzoic acid, 2-[[4-[3-[hexyl(phenylmethyl)amino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637014-98-3
CMF C30 H35 N O4



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-32-1 CAPLUS
CN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-05-5
CMF C29 H33 N O4

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 936365-34-3 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-10-2
CMF C31 H35 F2 N O4



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-36-5 CAPLUS
CN Benzoic acid, 2-[[4-[3-[butyl[(2,3-dimethoxyphenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-18-0
CMF C30 H35 N O6

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-33-2 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-07-7
CMF C30 H33 F2 N O4



CM 2

CRN 768-94-5
CMF C10 H17 N

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-37-6 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,3-dimethoxyphenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-22-6
CMF C33 H41 N O6



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-38-7 CAPLUS

L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzoic acid, 2-[[4-[3-[(3-ethoxypropyl)[[4-(1-methylethyl)phenyl]methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with
tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-26-0
CMF C32 H39 N O5



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-39-8 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]propylamino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-30-6
CMF C27 H27 F2 N O4



L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 768-94-5
CMF C10 H17 N



L6 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-40-1 CAPLUS
CN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-oxoethyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-33-9
CMF C25 H24 F N O4



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 936365-41-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[ethyl[(2-fluorophenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (CA INDEX NAME)

CM 1

CRN 637015-36-2
CMF C26 H26 F N O4

L6 ANSWER 6 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:181489 CAPLUS
DOCUMENT NUMBER: 146:521696
TITLE: Novel polycyclic compounds and novel intermediates useful as PDE IV inhibitors; processes for their preparation and composition containing them
INVENTOR(S): Duvvuri, Subrahmanyam; Thomas, Abraham; Balasubramanian, Gopalan; Balvantsinh, Raolji Gajendrasinh; Lingam, Vs Prasada Rao; Lakdawal, Aftab Dawoodbhai
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Ltd., India
SOURCE: Indian Pat. Appl., 90pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2001MU00754	A	20050304	IN 2001-MU754	20010806
PRIORITY APPLN. INFO.:			IN 2001-MU754	20010806

OTHER SOURCE(S): CASREACT 146:521696
GI



I



II

AB The invention relates to a series of polycyclic compds. of formula I, their analogs, their tautomers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compns. containing them. The invention more particularly relates to novel phosphodiesterase 4 (PDE4) inhibitors of the formula I, their analogs, their tautomers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compns. containing them. Compds. of formula I wherein R1 is (un)substituted (hetero)cycloalkoxy; R2 and R3 are independently (un)substituted lower

L6 ANSWER 6 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
alkyl(oxy), OH, halo, CN, carboxyl, alkoxycarbonyl, (un)substituted lower alkanoyl, etc.; or R1 and R2 may be combined together to form (un)substituted cyclic ring system; and X1-X3 is -O-CH2-, -NH-CH2- and derivs., -S-CH2-, -SO-CH2, -SO2-CH2, -CH2-CH2-CH=CH-, -CH2-O, etc.; B and/or
D is C or N; R4 is no bond, H, OH and derivs., (un)substituted alkanoyl, (un)substituted (hetero)aroyl, etc.; Q is (un)substituted alkoxy, aminocarbonyloxy, alkanoyl, etc.; and their analogs, tautomers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compns. contg. them, as well the process for prepg. them are claimed. Example compd. II was prepd. by addn. of magnesium to 4-fluorobenzyl bromide followed by Grignard addn. to 9-ethoxymethyl-5-oxo-8,9,13-trihydro-7,10,12-trioxabenzo[4,5]cyclohepta[1,2-b]naphthalene; the resulting 5-(4-fluorophenyl)-5-hydroxy-9-ethoxymethyl-o-8,9,13-trihydro-7,10,12-trioxabenzo[4,5]cyclohepta[1,2-b]naphthalene, which underwent dehydration to give compd. II. The invention compds. evaluated for their PDE IV inhibitory activity (no data).
IT 936627-29-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dibenzoxepines and related compds. and their intermediates
useful as PDE IV inhibitors)
RN 936627-29-1 CAPLUS
CN Benzoic acid, 2-[[4-(cyclopentyloxy)-3-methoxyphenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 7 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1350318 CAPLUS
DOCUMENT NUMBER: 146:93582
TITLE: β-Amyloid formation inhibitors containing bis(substituted benzyl)tetrahydro(thio)furans
INVENTOR(S): Maruyama, Takashi; Takeda, Shigetumi; Satomi, Takanori
PATENT ASSIGNEE(S): Tsumura and Co., Japan; Saitama Medical University
SOURCE: Jpn. Kokai Tokkyo Koho, 13pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006347942	A	20061228	JP 2005-175333	20050615
PRIORITY APPLN. INFO.:			JP 2005-175333	20050615

OTHER SOURCE(S): MARPAT 146:93582
GI



I

AB The inhibitors, useful as prophylactic or therapeutic agents for Alzheimer's disease, contain the compds. I (R = H, C1-6 alkyl, acyl, sugar residue; X, Y = O, S) or their pharmacol. acceptable salts. Thus, (2R,3R)-3-(3,4-dimethoxybenzyl)-2-[4-[4-(4-methylpiperazinomethyl)benzoyloxy]-3-methoxybenzyl]butyrolactone, prepared from arctigenin and 4-(4-methylpiperazinomethyl)benzoyl chloride dihydrochloride, showed 80% inhibition against expression of Aβ1-40 by human nervous system cell transformed with APP695NL Swedish mutation precursor protein gene.
IT 917377-57-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bis(substituted benzyl)tetrahydro(thio)furans as β-amyloid formation inhibitors for treatment of Alzheimer's disease)
RN 917377-57-2 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 1-[4-[[(3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]tetrahydro-2-oxo-3-thienyl]methyl]-2-methoxyphenyl] ester (CA INDEX NAME)

L6 ANSWER 7 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



L6 ANSWER 8 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1337834 CAPLUS
DOCUMENT NUMBER: 146:62460
TITLE: Preparation of 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol derivatives as prodrugs for treatment of depression
INVENTOR(S): Zhang, Luping
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006133652	A1	20061221	WO 2006-CN1370	20060616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 1955159	A	20070502	CN 2006-10073308	20060407
PRIORITY APPLN. INFO.:			CN 2005-10077510 A	20050617
			CN 2006-10073308 A	20060407

OTHER SOURCE(S): CASREACT 146:62460; MARPAT 146:62460
GI



I II

AB The title 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol (desvenlafaxine) derivs. I [wherein R1 = formyl, acetyl, benzoyl, etc.; R2

L6 ANSWER 8 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
= H, (cyclo)alkyl, aryl, etc.; R3 and R4 = independently H, (cyclo)alkyl, aryl, etc.], optical or racemic isomers, or pharmaceutically acceptable salts thereof were prepd. as inhibitors of 5-hydroxytryptamine and norepinephrine for treatment of central nervous system diseases, such as depression. For example, desvenlafaxine was reacted with benzoyl chloride
to give II (55.2%). II showed 99% metabolic rate after 2 h in human liver
cell. Formulations as tablets and capsules were described.
IT 916918-97-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of desvenlafaxine derivs. as prodrugs for treatment of depression)
RN 916918-97-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 1-[4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenyl] ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 9 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1221676 CAPLUS
DOCUMENT NUMBER: 146:45289
TITLE: Preparation of carboxylic acid derivatives for treatment of type II diabetes
INVENTOR(S): Shen, Jianhua; Jiang, Hualiang; Huang, Wei; Shen, Xu; Liu, Hong; Luo, Xiaomin; Zhang, Xu; Tang, Jin
PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 34pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1861560	A	20061115	CN 2005-10025809	20050513
PRIORITY APPLN. INFO.:			CN 2005-10025809	20050513

OTHER SOURCE(S): MARPAT 146:45289
GI



I

II

AB Title carboxylic acid derivs. I [wherein A = -C6H4-CH2O-, alkylene, (un)substituted -CH2-O-, etc.; B = O, S, SO, SO2, NH, CO, etc.; C = -C6H4-CH2O-, alkylene, (un)substituted -CH2-O-, etc.; n = 0 or 1; Ar= (un)substituted benzene or benzoheteroarylene], or geometrical isomers, enantiomers, racemic mixts. or pharmaceutically acceptable salts thereof are prepared as excitants or antagonists of peroxisome proliferator-activated receptors (PPAR) for the treatment of type II diabetes. For example, the compound II was prepared in a multi-step synthesis in good yield.
Some of compds. I showed good antagonistic activities against peroxisome proliferator-activated receptors in rat. Different formulations were also
claimed.
IT 916607-59-5P 916607-98-2P 916608-00-9P
916608-02-1P 916608-05-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L6 ANSWER 9 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Uses)
(prepn. of carboxylic acid derivs. for treatment of type II diabetes)
RN 916607-59-5 CAPLUS
CN Tyrosine, N-(2-benzoylphenyl)-O-[(3-carboxyphenyl)methyl]- (CA INDEX NAME)



RN 916607-98-2 CAPLUS
CN Benzoic acid, 3-[[4-[[4-(1-carboxy-1-methylethoxy)phenyl]sulfonyl]phenoxy]methyl]- (CA INDEX NAME)



RN 916608-00-9 CAPLUS
CN Benzoic acid, 3,3'-[sulfonylbis(4,1-phenyleneoxymethylene)]bis- (CA INDEX NAME)



RN 916608-02-1 CAPLUS
CN Benzoic acid, 4,4'-[sulfonylbis(4,1-phenyleneoxymethylene)]bis- (CA INDEX NAME)

L6 ANSWER 9 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 916608-05-4 CAPLUS
CN Benzoic acid, 3-[[4-[[4-[(4-carboxyphenyl)methoxy]phenyl]sulfonyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 10 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1041239 CAPLUS
DOCUMENT NUMBER: 145:389305
TITLE: Phenethanolamine-derived haptens, immunogens, antibodies and conjugates for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine
INVENTOR(S): Mcconnell, Robert Ivan; Fitzgerald, Stephen Peter; Benchikh, El Ouard; Lowry, Andrew Philip
PATENT ASSIGNEE(S): Randox Laboratories Limited, UK
SOURCE: U.S. Pat. Appl. Publ., 22pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006223132	A1	20061005	US 2005-271282	20051110
US 7192722	B2	20070320		
EP 1657234	A1	20060517	EP 2004-78100	20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
EP 1657235	A2	20060517	EP 2005-77582	20051110
EP 1657235	A3	20060607		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.: EP 2004-78100 A 20041110

OTHER SOURCE(S): MARPAT 145:389305
AB The invention discloses a method for preparing phenethanolamine-derived haptens that are useful in the preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine. The haptens are prepared by reacting a phenylethanolamine derivative with a phenylalkylcarbonyl derivative
IT 911196-31-1DP, albumin conjugates
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenethanolamine-derived haptens, immunogens, antibodies and conjugates for use in immunoassays for detection of ractopamine, isoxsuprine and ritodrine)
RN 911196-31-1 CAPLUS
CN Benzoic acid, 4-[[4-[3-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]butyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 10 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 911196-31-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenethanolamine-derived haptens, immunogens, antibodies and conjugates for use in immunoassays for detection of ractopamine, isoxsuprine and ritodrine)
RN 911196-31-1 CAPLUS
CN Benzoic acid, 4-[[4-[3-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]butyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1031178 CAPLUS
DOCUMENT NUMBER: 145:419138
TITLE: Preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivatives as prophylactic/therapeutic agents for diabetes
INVENTOR(S): Cho, Nobuo; Kasai, Shizuo; Yamashita, Toshiro
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 743pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006104280	A1	20061005	WO 2006-JP307402	20060331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2005-102913 A 20050331
JP 2005-306397 A 20051020

GI



I

AB 11β-Hydroxysteroid dehydrogenase 1 inhibitors comprising compds. represented by the formula (I) or salts thereof or prodrugs of the compds.
or the salts [R1 = (un)substituted cyclic group; R2 = H, (un)substituted cyclic group; X = N, CR3; R3 = H, substituent; L1, L2 = a bond, (un)substituted bivalent aliphatic hydrocarbon group, -(aknl)m-Y-(akn2)n; aknl, akn2 = (un)substituted C1-6 alkylene; m, n = 0, 1; Y = O, S, SO, SO2, NR4, SO2NR4, NR4SO2; R4 = H, (un)substituted C1-6 alkyl; ring A = (un)substituted 4- to 7-membered nonarom. heterocyclic ring optionally fused to a ring] are disclosed. These compds. have an excellent inhibitory activity against 11β-hydroxysteroid dehydrogenase 1 and are useful as prophylactic/therapeutic agents for diabetes, insulin resistance, obesity, lipid metabolic abnormality, hypertension, or arteriosclerosis. Thus, 2 M lithium diisopropylamide/THF (1.32 M, 1.32

L6 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
mL) was added to a mixt. of 0.50 g 1-(2-methylbenzyl)pyrrolidin-2-one in 10 mL THF at -78° and the resulting mixt. was stirred for 10 min. The resulting soln. was treated with a soln. of 0.52 g α,2,6-trichlorotoluene in 5 mL THF, stirred at -78° for 10 min, and warmed to room temp. to give, after workup and silica gel chromatog., 80% 3-(2,6-dichlorobenzyl)-1-(2-methylbenzyl)pyrrolidin-2-one (II). 1-Cyclohexyl-3-(2,6-dichlorobenzyl)pyrrolidin-2-one (similarly prepd. from 1-cyclohexylpyrrolidin-2-one and α,2,6-trichlorotoluene) showed IC50 of 7.9 nM against of human 11β-Hydroxysteroid dehydrogenase 1. A gelatin capsule and a tablet formulation contg. the compd. II were described.
IT 911721-40-9P 911721-46-5P 911723-52-9P 911723-66-5P 911723-73-4P 911724-87-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivs. as 11β-Hydroxysteroid dehydrogenase 1 inhibitors and prophylactic/therapeutic agents for diabetes)
RN 911721-40-9 CAPLUS
CN Benzoic acid, 4-[[3-chloro-4-[(1-cyclohexyl-2-oxo-3-pyrrolidinyl)methyl]phenoxy]methyl]- (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 911721-46-5 CAPLUS
CN Benzoic acid, 3-[[3-chloro-4-[(1-cyclohexyl-2-oxo-3-pyrrolidinyl)methyl]phenoxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L6 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 911723-73-4 CAPLUS
CN Benzoic acid,
3-[[3-chloro-4-[[1-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-2-oxo-3-pyrrolidinyl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 911724-87-3 CAPLUS
CN Benzoic acid,
2-[[3-chloro-4-[[1-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-2-oxo-3-pyrrolidinyl]methyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 911723-52-9 CAPLUS
CN Benzoic acid, 4-[[3-chloro-4-[[1-(4-hydroxy-4-methylcyclohexyl)-2-oxo-3-pyrrolidinyl]methyl]phenoxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 911723-66-5 CAPLUS
CN Benzoic acid,
4-[[3-chloro-4-[[1-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-2-oxo-3-pyrrolidinyl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 12 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:845716 CAPLUS
DOCUMENT NUMBER: 145:293345
TITLE: Preparation of N-acyl-amino acid derivatives for controlling function of GPR34 receptor as antagonists or inverse agonists
INVENTOR(S): Ito, Fumio; Kimura, Eiji; Imai, Tomomi; Mori, Masaaki;
Aramaki, Yoshio; Kohara, Yasuhisa; Sugo, Tsukasa; Hayase, Yoji; Kobayashi, Hiromi; Ogi, Kazuhiro
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 597pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088246	A1	20060824	WO 2006-JP303357	20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1849465	A1	20071031	EP 2006-714496	20060217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: JP 2005-41775 A 20050218
JP 2005-315146 A 20051028
WO 2006-JP303357 W 20060217

OTHER SOURCE(S): MARPAT 145:293345
GI



AB There are provided agents for controlling the function of a GPR34 receptor
which contain compds. represented by the formula (I) [wherein ring A represents an optionally substituted homocycle or heterocycle; P represents a bond or spacer; ring D represents an optionally substituted, monocyclic aromatic ring optionally fused to a 5- to 7-membered ring; V represents a bond or a group represented by -CR14:CR15- or -N:CR16- (wherein R14, R15, and R16 each represents hydrogen or an optionally

L6 ANSWER 12 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
substituted hydrocarbon group); Q represents a bond or spacer; W represents carboxy or a group biol. equiv. to carboxy], salts of the compds., or prodrugs of either. These agents are useful for the prevention and/or treatment of immune diseases, inflammatory diseases, respiratory diseases, urol. diseases (urinary system diseases), central nervous system diseases, or cardiovascular diseases. Thus, 4-(4-chlorophenyl)-3-methyl-1-benzofuran-2-carboxylic acid was condensed with Me O-benzyl-L-tyrosinate hydrochloride using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and HOBt in the presence of
Et3N in a 1:1 mixt. of DMF and CH2Cl2 (93% yield) followed by sapon. with NaOH in aq. methanol and acidification with 1 N aq. HCl soln. to give 28% O-benzyl-N-[[6-(4-chlorophenyl)-3-methyl-1-benzofuran-2-yl]carbonyl]-L-tyrosine (II). II in vitro showed antagonist activity against human GPR34
receptor expressed in CHO cells with IC50 of ≤1 μM. Pharmaceutical tablet formulations were described.
IT 907948-71-4P 907948-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acyl-amino acid derivs. for controlling function of GPR34
receptor as antagonists or inverse agonists)
RN 907948-71-4 CAPLUS
CN 1H-Indene-2-carboxylic acid, 2-[[[4-[(3-carboxyphenyl)methoxy]phenyl]acetyl]amino]-5-(4-chlorophenyl)-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 907948-78-1 CAPLUS
CN 1H-Indene-2-carboxylic acid, 2-[[[4-[(2-carboxyphenyl)methoxy]phenyl]acetyl]amino]-5-(4-chlorophenyl)-2,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 12 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:677588 CAPLUS
DOCUMENT NUMBER: 145:124570
TITLE: Preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivatives and related compounds for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome
INVENTOR(S): Nagano, Tomokazu
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 181 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006182668	A	20060713	JP 2004-375862	20041227
PRIORITY APPLN. INFO.:			JP 2004-375862	20041227

OTHER SOURCE(S): MARPAT 145:124570
GI



I



II

AB The title compds. [e.g. I; Zb = (un)substituted pyrrole, pyrazole, imidazole, triazole, indole, indazole, or benzimidazole; W2b = a single bond, SO, SO2, (un)substituted CONH or SO2NH, (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene optionally two H atoms of methylene group substituted with O to form a CO group; Ar1b, Ar2b = (un)substituted aryl or heteroaryl; W1b = (un)substituted C1-5 alkylene, C2-5 alkenylene, or C2-5 alkynylene, -Yb-W3b- (Yb = O, S, (un)substituted NH; W3b = (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene), etc.; X1b = SO2, OCO2, SO2O, (un)substituted CONHSO2, NHSO2, NHCO, SO2NHCO, SO2NH, CONH, OCONH, NHCONH, or NHC(NH2):N-, etc.; R1b = CO2H, alkoxycarbonyl, (un)substituted CONH2, cyclic aminocarbonyl, alkylsulfonylcarbamoyl, arylsulfonylcarbonyl, or heteroarylsulfonylcarbonyl, tetrazolyl, 2,4-dioxooxazolidin-5-yl, etc.] are prepared These compds. are agonists (activators) of PPARα and/or PPARγ and not only improve hyperglycemia but also possess lipid

L6 ANSWER 13 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
improving activity such as improving hypertriglyceridemia and increasing HDL cholesterol. They are useful for the treatment or prevention of hyperlipidemia, arteriosclerosis, and/or the metabolic syndrome. For example, compd. (II).Na activated human PPARα and human PPARγ by 15.1 and 7.0%, resp., at 10 μM. When it was administered to mice at 30 mg/kg for 2 wk p.o., it lowered blood sugar and triglyceride by 70 and 89%, resp., and increased HDL by 41%.
IT 874828-01-0P, 2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole
derivs. and related compds. for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome)
RN 874828-01-0 CAPLUS
CN Benzoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 14 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:600074 CAPLUS
DOCUMENT NUMBER: 145:180201
TITLE: Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists: Homology Modeling, Docking and Three-Dimensional Quantitative Structure-Activity Relationship Analysis
AUTHOR(S): Tuccinardi, Tiziano; Calderone, Vincenzo; Rapposelli, Simona; Martinelli, Adriano
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Pisa, Pisa, 56126, Italy
SOURCE: Journal of Medicinal Chemistry (2006), 49(14), 4305-4316
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A three-dimensional model of the AT1 receptor was constructed by means of a homol. modeling procedure, using the x-ray structure of bovine rhodopsin as the initial template and taking into account the available site-directed mutagenesis data. The docking of losartan and its active metabolite EXP3174, followed by 1 ns of mol. dynamics (MD) simulation inserted into the phospholipid bilayer, suggested a different binding orientation for these antagonists from those previously proposed. Furthermore, the docking of several nonpeptide antagonists was used as an alignment tool for the development of a three-dimensional quant. structure-activity relationship (3D-QSAR) model, and the good results confirmed our binding hypothesis and the reliability of the model.

IT 114799-46-1 114799-47-2 114799-48-3
114799-49-4 114799-61-0 125848-45-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proposal of a new binding orientation for non-peptide AT1 antagonists based on homol. modeling, docking and three-dimensional quant. structure-activity relationship anal.)

RN 114799-46-1 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 14 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-47-2 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-48-3 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 14 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-49-4 CAPLUS
CN Benzoic acid, 2-[[4-[[5-[(acetyloxy)methyl]-2-butyl-4-chloro-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-61-0 CAPLUS
CN Benzoic acid, 2-[[4-[[5-(hydroxymethyl)-2-(propylthio)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 14 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 125848-45-5 CAPLUS
CN Benzoic acid, 2-[[4-[[2-(ethylthio)-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:149198 CAPLUS
DOCUMENT NUMBER: 144:205770
TITLE: Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
INVENTOR(S): Dessy, Chantal; Balligand, Jean-Luc
PATENT ASSIGNEE(S): Universite Catholique de Louvain, Belg.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015830	A1	20060216	WO 2005-EP8569	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2576255	A1	20060216	CA 2005-2576255	20050808
EP 1781331	A1	20070509	EP 2005-773375	20050808
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2004-600093P P 20040809
WO 2005-EP8569 W 20050808

AB The invention relates to the use of one or more first compound(s) having a β3-adrenoceptor agonistic effect and one or more second compound(s) having a β1/β2-adrenoceptor antagonistic effect for the preparation of a medicament for treating and/or preventing cardiovascular diseases and diseases related thereto, such as arterial diseases, ischemic and failing cardiac diseases, including heart failure, conditions related to metabolic syndrome, or angiogenesis-related diseases, wherein said one or more first compound(s) and said one or more second compound(s) are used as combined preparation for simultaneous, sep. or sequential use. The invention further provides methods and composition for treating the above diseases.

IT 211917-61-2, SB 246982
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of agonists and antagonists of β-adrenoceptors for treating

L6 ANSWER 15 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
arterial diseases)
RN 211917-61-2 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-[(phenylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:121579 CAPLUS
DOCUMENT NUMBER: 144:192255
TITLE: Preparation of pyrrole derivatives for treatment of diabetes
INVENTOR(S): Yoshida, Kozo; Maruta, Katsunori; Nagata, Ryu
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006036730	A	20060209	JP 2004-222700	20040730

PRIORITY APPLN. INFO.: JP 2004-222700 20040730

OTHER SOURCE(S): MARPAT 144:192255

GI



AB The title compds. (I) or prodrugs thereof or pharmacol. acceptable salts of either [R2 = one or a plural number of groups selected from H, each (un)substituted alkyl and aryl, and halogen atoms; Ar1, Ar2, Ar3 = each (un)substituted aryl or heteroaryl; W2 = each (un)substituted lower alkylene or alkenylene, -Y1-W6- (wherein Y1 = O, S, SO, SO2; W6 = each (un)substituted lower alkylene or alkenylene); W2 = a single bond, each (un)substituted lower alkylene or alkenylene, -Y2-W7-, -W7-Y2- (wherein Y2 = O, S, SO, SO2, NR11, CONR11; R11 = H, (un)substituted lower alkyl; W7 = each (un)substituted lower alkylene or alkenylene); W4 = a single bond, (un)substituted lower alkylene, -W8-Y3- (wherein Y3 = O, S, SO, SO2; W8 = each (un)substituted lower alkylene or alkenylene); R1 = H, (un)substituted lower alkyl] are prepared. These compds. activate or regulate peroxisome proliferator-activated receptor α (PPARα), PPARγ, or PPARα/γ activity and improve insulin resistance and are useful as antidiabetic agents for safely controlling blood sugar. Thus, a solution of 3-(3-hydroxyphenyl)thiophene-2-carboxylic acid Me ester 243, [1-(2-Hydroxyethyl)-1H-pyrrol-2-yl](4-methylphenyl)methanone 230, Ph3P 288 mg in THF was treated with 500 mg 40% di-Et azocarboxylate/toluene solution at 0° and stirred at room temperature for 18 h, after workup and silica gel chromatog., 52% 3-[3-[2-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]ethoxy]phenyl]thiophene-2-carboxylic acid Me ester which (230 mg) was dissolved in THF 3, 2 N aqueous NaOH solution

L6 ANSWER 16 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
MeOH 3 mL, stirred at 50° for 6 h, cooled to room temp., concd. under reduced pressure, treated with dil. aq. HCl soln., and filtered to give, after washing with water and drying under reduced pressure, 95% 3-[3-[2-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]ethoxy]phenyl]thiophene-2-carboxylic acid (II). II and 5-[3-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]-1,3-oxazole-4-carboxylic acid at 10 μM showed 26.4- and 38.8-fold increase in activity of PPARα in COS-1 cells, resp., and 7.2- and 7.5-fold increase in activity of PPARγ, resp.

IT 874828-01-0P, 2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole derivs. as agonists of peroxisome proliferator-activated receptor α and/or γ for treatment of diabetes)

RN 874828-01-0 CAPLUS
CN Benzoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 17 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:23258 CAPLUS
DOCUMENT NUMBER: 144:254656
TITLE: Hydrodynamic, optical, and conformational properties of an aromatic polyester containing a benzoyl substituent in the main-chain mesogenic fragment
AUTHOR(S): Bushin, S. V.; Andreeva, L. N.; Belyaeva, E. V.; Bol'shakov, M. N.; Rudaya, L. I.; Shamanin, V. V.; Skorokhodov, S. S.
CORPORATE SOURCE: Inst. Macromol. Compounds, Russian Acad. Sci., St. Petersburg, 199004, Russia
SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A i Seriya B (2005), 47(12), 2172-2179
CODEN: VSSBEE; ISSN: 1023-3091
PUBLISHER: Izdatel'stvo Nauka
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Hydrodynamic, optical, and conformational properties of a thermo-tropically mesogenic aromatic polyester with a nonlinear T-shaped structure of the rigid fragment related to the presence of the benzoyl substituent were studied. Dilute solns. in dichloroacetic acid were investigated in the range M = (1.7-18.6) × 10³. On the basis of hydrodynamic and dynamo optical measurements, the Kuhn segment length was estimated as A = (125 ± 5) × 10⁻⁸ cm. The conformational anal. of the polyester performed in terms of the flexibility additivity principle showed that, upon incorporation of a benzoyl substituent into a mesogenic fragment separated by a single-atom (oxygen) bridge, steric interactions between mesogenic rigid moieties increase: the degree of hindrance of internal rotation becomes equal to 1.4.

IT 852057-53-5P 852057-56-8P
RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (aromatic polyester containing a benzoyl substituent in the main-chain mesogenic fragment)

RN 852057-53-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester, polymer with 1,6-hexanediol (9CI) (CA INDEX NAME)

CM 1

CRN 524951-01-7
CMF C29 H18 O9



CM 2

L6 ANSWER 17 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 629-11-8
CMF C6 H14 O2



RN 852057-56-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester, polymer with 4,4'-oxybis[phenol] (9CI) (CA INDEX NAME)

CM 1

CRN 524951-01-7
CMF C29 H18 O9



CM 2

CRN 1965-09-9
CMF C12 H10 O3



L6 ANSWER 18 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1331244 CAPLUS
DOCUMENT NUMBER: 144:51445
TITLE: Preparation of 2-(pyrrolidin-1-ylmethyl)pyrrolidine derivatives as histamine H3 receptor antagonists
INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Jesudason, Cynthia Darshini; Pickard, Richard Todd; Stevens, Freddie Craig
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121080	A1	20051222	WO 2005-US18249	20050524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005252178	A1	20051222	AU 2005-252178	20050524
CA 2567513	A1	20051222	CA 2005-2567513	20050524
EP 1756051	A1	20070228	EP 2005-754884	20050524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1956952	A	20070502	CN 2005-80016836	20050524
IN 2006KN03536	A	20070615	IN 2006-KN3536	20061127

PRIORITY APPLN. INFO.: US 2004-576421P P 20040602
WO 2005-US18249 W 20050524

OTHER SOURCE(S): MARPAT 144:51445
GI

L6 ANSWER 18 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

II

AB The title compds. I [wherein Ar = (un)substituted (hetero)aryl; R1 and R2 = independently H, OH, halo, CF3, etc.; R3 = H, halo, CF3, NH2, etc.] or enantiomers or pharmaceutically acceptable salts thereof were prepared as histamine-H3 receptor antagonists. For example, the compound II•CF3CO2H was prepared II•CF3CO2H showed antagonistic activity to [35S]GTP γ[S] with Ki of 4.1 nM. I are useful for the treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases (no data).

IT 871489-38-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of (pyrrolidinylmethyl)pyrrolidine derivs. as histamine H3 receptor antagonists)

RN 871489-38-2 CAPLUS
CN Benzoic acid, 4-[[4-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, lithium salt (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Li

IT 871488-79-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (pyrrolidinylmethyl)pyrrolidine derivs. as
histamine H3 receptor antagonists)
RN 871488-79-8 CAPLUS
CN Benzoic acid, 4-[[4-[[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]phenoxy]methyl]-, lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 18 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Li

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1221157 CAPLUS
DOCUMENT NUMBER: 143:477861
TITLE: Preparation of tetrahydroquinolinyl PGD2 receptor antagonists for the treatment of inflammatory diseases
INVENTOR(S): Ghosh, Shomir; Elder, Amy M.; Carson, Kenneth G.; Sprott, Kevin T.; Harrison, Sean J.; Hicks, Frederick A.; Renou, Christelle C.; Reynolds, Dominic
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 296 pp., Cont.-in-part of U.S. Ser. No. 678,872.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005256158	A1	20051117	US 2005-101208		20050407
US 2004082609	A1	20040429	US 2003-678872		20031003
US 7211672	B2	20070501			
JP 2006124396	A	20060518	JP 2005-351372		20051205
US 2006106061	A1	20060518	US 2005-312960		20051220
PRIORITY APPLN. INFO.:			US 2002-416501P	P	20021004
			US 2003-678872	A2	20031003
			US 2004-560410P	P	20040407
			JP 2004-543358	A3	20031003

OTHER SOURCE(S): MARPAT 143:477861
GI



I II

AB Title compds. I [A = (un)substituted monocyclic aromatic ring; R = X1R1; R5 = X2R4; X1, X2 = independently SO2, CO, CONH; R1 = (un)substituted hetero/aryl; hetero/aryl fused to a monocyclic non/aromatic or heteroarom. ring, with provisos; R2 = alkyl; R3 = (un)substituted monocyclic or

L6 ANSWER 19 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
bicyclic group; R4 = hydroxyalkyl, (un)substituted cyclo/alkyl; and their pharmaceutically acceptable salts] were prepd. For instance, acylation of (2S,4R)-4-(((benzyloxy)carbonyl)amino)-2-Methyl-1,2,3,4-tetrahydroquinoline (prepn. given) with 4-fluorobenzoyl chloride, deprotection, reaction of the amine (no data) with 4-chlorophenylboronic acid, and acetylation gave II. Compds. I inhibited binding of PGD2 to the CRTh2 receptor; selected examples had Ki < 1 μM. I are useful for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous mol. expressed on CRTh2 for the treatment of inflammatory disorders.
IT 868211-41-0P, 3-[[4-[[4-[(Acetyl)(4-chlorophenyl)amino]-(2S,4R)-2-methyl-3,4-dihydro-2H-quinolin-1-yl]carbonyl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroquinolinyl PGD2 receptor antagonists for treatment
of inflammatory diseases)
RN 868211-41-0 CAPLUS
CN Benzoic acid, 3-[[4-[[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-3,4-dihydro-2-methyl-1(2H)-quinolinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 20 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1207714 CAPLUS
DOCUMENT NUMBER: 144:423116
TITLE: Switching of chirality from racemic to homochiral state in new liquid crystalline monomers with bent-core molecules
AUTHOR(S): Novotna, Vladimira; Hamplova, Vera; Kaspar, Miroslav; Glogarova, Milada; Pociecha, Damian
CORPORATE SOURCE: Institute of Physics, Academy of Sciences of the Czech Republic, Prague, 182 21, Czech Rep.
SOURCE: Liquid Crystals (2005), 32(9), 1115-1123
CODEN: LICRE6; ISSN: 0267-8292
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis and phys. properties of bent-shaped mols. with ester linkages and methoxy substitution on a noncentral ring are presented. Terminal chains of most mesogens contain a group with double bond, which promotes polymerization In all the compds. studied a B2 phase just below the isotropic phase was found. Polarization current profiles indicate that this phase is antiferroelec., and dielec. spectroscopy data with a pronounced high frequency mode support this fact. For several compound chirality switching from racemic to the homochiral state was seen after application of a low frequency a.c. field. Another phase, which could be assigned to the B7 family, appears below the B2 phase on cooling.

IT 883884-03-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with oxalyl chloride)

RN 883884-03-5 CAPLUS

CN 1,3-Benzenedicarboxylic acid, mono[4-[[[4'-(decyloxy)[1,1'-biphenyl]-4-yl]oxy]carbonyl]-2-methoxyphenyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1154529 CAPLUS
DOCUMENT NUMBER: 143:422264
TITLE: Preparation of tetrahydroquinolinyl PGD2 receptor antagonists for the treatment of inflammatory diseases
INVENTOR(S): Ghosh, Shomir; Elder, Amy M.; Carson, Kenneth G.; Sprott, Kevin T.; Harrison, Sean J.; Hicks, Frederick A.; Renou, Christelle C.; Reynolds, Dominic
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 393 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100321	A1	20051027	WO 2005-US11643	20050407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005233125	A1	20051027	AU 2005-233125	20050407
CA 2561564	A1	20051027	CA 2005-2561564	20050407
EP 1740547	A1	20070110	EP 2005-733968	20050407
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101018770	A	20070815	CN 2005-80018590	20050407
BR 2005009668	A	20071009	BR 2005-9668	20050407
JP 2007532555	T	20071115	JP 2007-507467	20050407
IN 2006DN05764	A	20070831	IN 2006-DN5764	20061004
NO 2006005107	A	20061201	NO 2006-5107	20061106
KR 2007002085	A	20070104	KR 2006-723323	20061107

PRIORITY APPLN. INFO.: US 2004-560410P P 20040407
WO 2005-US11643 W 20050407

OTHER SOURCE(S): MARPAT 143:422264
GI

L6 ANSWER 21 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [A = (un)substituted monocyclic aromatic ring; R = X1R1; R5 = X2R4; X1-X2 = independently SO2, CO, CONH; R1 = (un)substituted hetero/aryl; hetero/aryl fused to a monocyclic non/aromatic or heteroarom. ring, with provisos: R2 = alkyl; R3 = (un)substituted monocyclic or bicyclic group; R4 = hydroxyalkyl, (un)substituted cyclo/alkyl; and their pharmaceutically acceptable salts; with the exception of certain compds.] were prepared For instance, acylation of (2S,4R)-4-(((benzyloxy)carbonyl)amino)-2-Methyl-1,2,3,4-tetrahydroquinoline (preparation given) with 4-fluorobenzoyl chloride, deprotection, reaction of the amine (no data) with 4-chlorophenylboronic acid, and acetylation gave II. Compds. I inhibited binding of PGD2 to the CRTh2 receptor; selected examples had Ki < 1 μM. I are useful for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous mol. expressed on CRTh2 for the treatment of inflammatory disorders.

IT 868211-41-0P, 3-[[4-[[4-[(Acetyl)(4-chlorophenyl)amino]-(2S,4R)-2-methyl-3,4-dihydro-2H-quinolin-1-yl]carbonyl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PGD2 receptor antagonists for treatment of inflammatory diseases)

RN 868211-41-0 CAPLUS

CN Benzoic acid, 3-[[4-[[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-3,4-dihydro-2-methyl-1(2H)-quinolinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 21 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1088761 CAPLUS
DOCUMENT NUMBER: 144:43514
TITLE: Ten isomeric five-ring bent-core mesogens: The influence of the direction of the carboxyl connecting groups on the mesophase behavior
AUTHOR(S): Weissflog, Wolfgang; Naumann, Gisela; Kosata, Bedrich; Schroeder, Martin W.; Eremin, Alexey; Diele, Siegmar; Vakhovskaya, Zinaida; Kresse, Horst; Friedemann, Rudolf; Krishnan, S. Ananda Rama; Pelzl, Gerhard
CORPORATE SOURCE: Institut fuer Physikalische Chemie, Martin-Luther-Universitaet Halle-Wittenberg, Halle (Saale), 06108, Germany
SOURCE: Journal of Materials Chemistry (2005), 15(40), 4328-4337
CODEN: JMACEP; ISSN: 0959-9428
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:43514

AB In order to study the role of the direction of the connecting groups in bent-core mesogens we synthesized two series of ten possible achiral isomeric five-ring bent-core compds. in which all aromatic rings are connected by ester groups and each of which possesses the same length of the terminal chains (octyloxy or dodecyloxy, resp.). The structure of the isomers is distinguished by the direction of at least one ester group, only. The mesophase behavior of the compds. has been studied by polarizing microscopy, differential scanning calorimetry, X-ray expts. and electro-optical measurements. We have found that in spite of the minor structural differences a variety of mesophases occur (SmCPA, Colrec, Colob) whereby the clearing temps. vary from 121 to 193 °C (octyloxy isomers) and 112 to 189 °C (dodecyloxy isomers). Depending on the direction of the ester groups some of these isomers show interesting properties, such as field-induced inversion of chirality in SmCPA and columnar phases, the field-induced enhancement of the clearing temperature, a second-order phase transition Colob → SmCPA or the reversible field-induced phase transition Colob → SmCPF. The unexpectedly strong influence of the direction of the connecting groups is discussed on the base of theor. calcns. and mol. dynamics simulation on isolated mols.

IT 870720-32-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(esterification; influence of the direction of the carboxyl connecting groups on the mesophase behavior of isomeric five-ring bent-core mesogens)
RN 870720-32-4 CAPLUS
CN 1,3-Benzenedicarboxylic acid, mono[4-[[4-(dodecyloxy)benzoyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 914466-81-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(influence of the direction of the carboxyl connecting groups on the mesophase behavior of isomeric five-ring bent-core mesogens)
RN 914466-81-2 CAPLUS
CN 1,3-Benzenedicarboxylic acid, mono[4-[[4-(octyloxy)benzoyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1021730 CAPLUS
DOCUMENT NUMBER: 143:326089
TITLE: Preparation of bisphenyl compounds useful as vitamin D3 receptor agonists
INVENTOR(S): Wallace, David; Arrhenius, Thomas; Russell, Anna; Liu, Dingguo; Xing, Amy; Tith, Sovouthy; Hou, Zheng; Takahashi, Tadakatsu; Ono, Yoshiyuki; Kashiwagi, Hirotaka; Shimizu, Kazuki; Ikura, Hitoshi
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan; et al.
SOURCE: PCT Int. Appl., 645 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087700	A2	20050922	WO 2005-US7747	20050308
WO 2005087700	A3	20061019		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006025474	A1	20060202	US 2005-76584	20050308
EP 1740522	A2	20070110	EP 2005-727224	20050308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-551193P	P 20040308
			WO 2005-US7747	W 20050308

OTHER SOURCE(S): MARPAT 143:326089
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = (un)substituted methylene, ethylene, vinylene, NH, etc.; Y = CO2R8; CONH2 and derivs., S-alkyl, etc.; W = OH, CO2H, O-SO2-CF3, etc.; R1, R2 = independently (un)substituted cyclo/alkyl, alkenyl, alkynyl, etc.; R3, R4, R5, R6 = independently H, halo, (un)substituted cyclo/alkyl; with provisos; and their pharmaceutically acceptable salts and prodrugs] were prepared as vitamin D receptor modulators, particularly vitamin D3 agonists. Thus, O-alkylation of phenol II (preparation given) with 4-bromomethylbenzoic acid Me ester and saponification gave bisphenyl (E)-III. Bisphenyl compds. I show similar

L6 ANSWER 23 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
properties of 1,25(OH)2D3, but with reduced serum calcium level, and may be used to treat psoriasis, secondary hyperparathyroidism, etc.

IT 865239-24-3P, 3-[[[4-[1-Ethyl-1-[4-((E)-3-ethyl-3-hydroxypent-1-enyl)-3-methylphenyl]propyl]-2-methylphenyl]oxy]methyl]benzoic acid
865239-25-4P, 4-[[[4-[1-Ethyl-1-[4-((E)-3-ethyl-3-hydroxypent-1-enyl)-3-methylphenyl]propyl]-2-methylphenyl]oxy]methyl]benzoic acid
865241-17-4P, 4-[[[4-[1-Ethyl-1-[4-((S)-3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-2-methylphenyl]oxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bisphenyl compds. useful as vitamin D3 receptor agonists)
RN 865239-24-3 CAPLUS
CN Benzoic acid, 3-[[4-[1-ethyl-1-[4-[(1E)-3-ethyl-3-hydroxy-1-pentenyl]-3-methylphenyl]propyl]-2-methylphenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 865239-25-4 CAPLUS
CN Benzoic acid, 4-[[4-[1-ethyl-1-[4-[(1E)-3-ethyl-3-hydroxy-1-pentenyl]-3-methylphenyl]propyl]-2-methylphenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 865241-17-4 CAPLUS
CN Benzoic acid, 4-[[4-[1-ethyl-1-[4-[(3S)-3-hydroxy-4,4-dimethylpentyl]-3-methylphenyl]propyl]-2-methylphenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 23 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 24 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:729530 CAPLUS
DOCUMENT NUMBER: 143:211917
TITLE: Preparation of 3-phenyl-N-(1,3,4-thiadiazol-2-yl)acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of diseases such as cancer, rheumatoid arthritis or neurological disorders
INVENTOR(S): Busch, Brett; Johnson, Alan T.; Martin, Richard; Mohan, Raju; Stevens, William C., Jr.
PATENT ASSIGNEE(S): X-Ceptor Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072731	A1	20050811	WO 2005-US2736	20050128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-540958P P 20040129

OTHER SOURCE(S): MARPAT 143:211917
GI

L6 ANSWER 24 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1 = NH2 and derivs., (un)substituted halo/cyclo/cycloalkyl/ar/alkyl, aryl, alkenyl, etc.; R2 = H, halo, CN, NO2, N3, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; R3 = H, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; R30, R31, R32, R33, R34 independently H, halo, CN, NO2, N3, OH and derivs., (un)substituted halo/alkyl, halo/alkenyl, hetero/aryl, etc.; or one of R30CCR31, R31CCR32, R32CCR33, and R33CCR34 = (un)substituted cycloalkyl, heterocyclyl, hetero/aryl; and their pharmaceutically acceptable derivs.] were prepared as estrogen-related receptors (ERRs), particularly ERRα, modulators for treating cancer, rheumatoid arthritis, neurol. disorders, etc. Thus, Knoevenagel condensation of 4-[2-[(2,6-dimethylphenyl)oxy]ethoxy]-3-methoxybenzaldehyde (preparation given) with 2-cyano-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)acetamide (preparation given) in DMF/EtOH in the presence of TEA gave II in 43% yield. Selected I displayed average IC50 values ≤ 0.5 μM for inverse agonist activity in a GAL4-ERRα assay. I, and their compns., are useful for the treatment, prevention, or amelioration of ERRα-related diseases, disorders or conditions, such as cancer, diabetes, obesity, hyperlipidemia, arthritis, atherosclerosis, osteoporosis, anxiety, depression, Parkinson's disease and Alzheimer's disease.

IT 862182-59-0P, 4-[[4-[2-Cyano-2-[(5-ethyl-[1,3,4]thiadiazol-2-yl)carbamoyl]vinyl]-2-methoxyphenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 3-Ph-N-(1,3,4-thiadiazol-2-yl)acrylamides

L6 ANSWER 24 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
and related compds. as ERR, particularly ERRα, modulators)

RN 862182-59-0 CAPLUS
CN Benzoic acid, 4-[[4-[2-cyano-3-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-3-oxo-1-propenyl]-2-methoxyphenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:695845 CAPLUS
DOCUMENT NUMBER: 143:163304
TITLE: Reverse wavelength dispersion liquid crystal retardation film for optical polarizer plate in optical imaging device such as liquid crystal displays
INVENTOR(S): Omori, Hiroshi; Nakano, Shusaku
PATENT ASSIGNEE(S): Nitto Denko Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005208416	A	20050804	JP 2004-16009	20040123
PRIORITY APPLN. INFO.:			JP 2004-16009	20040123

AB The title film is made from liquid crystal monomers having a fluorene cardo unit and polymerizable group-terminated main-chain mesogen connected with the cardo unit, wherein the main chain mesogen's optical axis, which is parallel to the aligning direction of an alignment film, and the cardo unit alignment direction, which is perpendicular to alignment direction of the main chain mesogen, are fixed in the film. The film is easily manufactured and shows good reverse wavelength dispersion.
IT 860033-10-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reverse wavelength dispersion retardation film for optical polarizer plate in optical imaging device such as liquid crystal displays)
RN 860033-10-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[[4-[2-[(1-oxo-2-propenyl)oxy]ethoxy]benzoyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)



L6 ANSWER 26 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:527397 CAPLUS
DOCUMENT NUMBER: 143:78096
TITLE: Preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases
INVENTOR(S): Collini, Michael D.; Singhaus, Robert R.; Hu, Baihua; Jetter, James W.; Morris, Robert L.; Kaufman, David H.; Miller, Christopher P.; Ullrich, John W.; Unwalla, Rayomand J.; Wrobel, Jay E.; Quinet, Elaine; Nambi, Ponnal; Bernotas, Ronald C.; Elloso, Merle
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 169 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131014	A1	20050616	US 2004-10236	20041210
AU 2004298486	A1	20050630	AU 2004-298486	20041210
CA 2547518	A1	20050630	CA 2004-2547518	20041210
WO 2005058834	A2	20050630	WO 2004-US41399	20041210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1692111	A2	20060823	EP 2004-813688	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1914173	A	20070214	CN 2004-80041595	20041210
BR 2004017543	A	20070327	BR 2004-17543	20041210
JP 2007516258	T	20070621	JP 2006-544016	20041210
IN 2006KN01443	A	20070504	IN 2006-KN1443	20060529
NO 2006002561	A	20060908	NO 2006-2561	20060602
MX 2006PA06533	A	20060731	MX 2006-PA6533	20060608
KR 2007001922	A	20070104	KR 2006-714042	20060712
PRIORITY APPLN. INFO.:			US 2003-529009P	P 20031212
			US 2004-600296P	P 20040810
			WO 2004-US41399	W 20041210

OTHER SOURCE(S): MARPAT 143:78096
GI

L6 ANSWER 26 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB This invention provides quinolines of formula I (R1 = H or C1-C3 alkyl; X1 = a bond or an appropriate group to link R2 which is an optionally substituted heterocycle; X2 = a bond or CH2; R3 = optionally substituted Ph, naphthyl, or heterocycle; R4, R5, and R6 = H or F, R7 = H, C1-C4 alkyl, C1-C4 perfluoroalkyl, halogen, NO2, CN, optionally substituted phenyl) that are useful in the treatment or inhibition of LXR mediated diseases (no data). The LXR mediated diseases specifically claimed are, for example, atherosclerosis, Alzheimer's disease, dementia, diabetes, multiple sclerosis, and thyroiditis. Pharmaceutical compns. containing the compds. of the invention and synthetic procedures for preparing them are also claimed.
IT 854771-05-4P, 4-[[4-[3-[3-Benzyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Phenoxy]Methyl]Benzoic Acid 854774-33-7P, 3-[[4-[3-(3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases)
RN 854771-05-4 CAPLUS
CN Benzoic acid, 4-[[4-[3-[3-(phenylmethyl)-8-(trifluoromethyl)-4-quinolinyl]phenoxy]phenoxy]methyl]- (CA INDEX NAME)



RN 854774-33-7 CAPLUS
CN Benzoic acid, 3-[[4-[3-[3-(phenylmethyl)-8-(trifluoromethyl)-4-

L6 ANSWER 26 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
quinolinyl]phenoxy]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 27 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:487956 CAPLUS
DOCUMENT NUMBER: 143:16612
TITLE: Optical element made from liquid crystal polymer, manufacture thereof, and liquid crystal display device
INVENTOR(S): Ishizaki, Takeshi
PATENT ASSIGNEE(S): Dainippon Printing Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005148345	A	20050609	JP 2003-384702	20031114
PRIORITY APPLN. INFO.:			JP 2003-384702	20031114

AB Disclosed is an optical element comprising a layer on a substrate, an area of which exhibites light scattering property, and which is made from a 3 dimensionally crosslinked liquid crystal polymer. Also disclosed are a process for forming said layer using a patterned photoresist and a liquid crystal display device having said optical element.
IT 852638-52-9D, derivs, polymer with acrylic monomer
RL: DEV (Device component use); USES (Uses)
(optical element made from liquid crystal polymer for liquid crystal display device)
RN 852638-52-9 CAPLUS
CN D-Glucitol, 1,4:3,6-dianhydro-, bis[4-[(4-carboxybenzoyl)oxy]benzoate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 27 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:271766 CAPLUS
DOCUMENT NUMBER: 142:482416
TITLE: Synthesis and properties of new alkylene-aromatic and aromatic polyesters with linear V- and T-shaped mesogenic groups in the backbone
AUTHOR(S): Dil'dina, E. V.; Bol'shakov, M. N.; Rudaya, L. I.; Klimova, N. V.; Yurre, T. A.; Ramsh, S. M.; Shamanin, V. V.; Skorokhodov, S. S.
CORPORATE SOURCE: St. Petersburg Technological Institute (Technical University), St. Petersburg, 190013, Russia
SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A i Seriya B (2005), 47(2), 220-227
CODEN: VSSBEE; ISSN: 1023-3091
PUBLISHER: Izdatel'stvo Nauka
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Based on 2,5- and 3,4-dihydroxy benzophenones, two nonlinear mesogenic sequences were prepared The targeted synthesis of a series of polyesters with identical compns. and bearing T- and V-shaped mesogens with bulky photoactive substituents, benzoyl groups, was accomplished, and the properties of these polyesters were compared. Polyesters were synthesized with varying the length of arms, the value of the bend angle, the rigidity of the corner fragment, and the nature and length of flexible spacers connecting mesogens. It was shown that the introduction of a bulky substituent, a benzoyl group, does not hamper alkylene-aromatic polyester containing T-shaped mesogens from manifestation of the LC behavior. Polymers with V-shaped mesogenic fragments and aliphatic spacers synthesized by similar methods did not exhibit the tendency toward transition to the mesomorphic state. If a polymethylene spacer was substituted by a di-Ph oxide one; i.e., the mesogenic sequence was completed to five rigid fragments, the wedging of the V-shaped mesogen did not prevent transition of the polymer to the mesomorphic state.
IT 852057-52-4P 852057-53-5P 852057-54-6P
852057-55-7P 852057-56-8P 852057-57-9P
852057-58-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(alkylene-aromatic and aromatic polyesters with linear mesogenic groups in backbone)
RN 852057-52-4 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester, polymer with 1,3-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 524951-01-7
CMF C29 H18 O9

L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 504-63-2
CMF C3 H8 O2

$HO-CH_2-CH_2-CH_2-OH$

RN 852057-53-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester, polymer with 1,6-hexanediol (9CI) (CA INDEX NAME)

CM 1

CRN 524951-01-7
CMF C29 H18 O9



CM 2

CRN 629-11-8
CMF C6 H14 O2

$HO-(CH_2)_6-OH$

RN 852057-54-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester, polymer with 1,6-hexanediol (9CI) (CA INDEX NAME)

CM 1

CRN 537712-38-2
CMF C29 H18 O9

L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





CM 2

CRN 629-11-8
CMF C6 H14 O2



RN 852057-55-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester, polymer with 1,10-decanediol (9CI) (CA INDEX NAME)

CM 1

CRN 537712-38-2
CMF C29 H18 O9





CM 2

L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





CM 2

CRN 1965-09-9
CMF C12 H10 O3



RN 852057-58-0 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester, polymer with 1,3-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 537712-38-2
CMF C29 H18 O9





CM 2

CRN 504-63-2
CMF C3 H8 O2

L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 112-47-0
CMF C10 H22 O2



RN 852057-56-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester, polymer with 4,4'-oxybis[phenol] (9CI) (CA INDEX NAME)

CM 1

CRN 524951-01-7
CMF C29 H18 O9



CM 2

CRN 1965-09-9
CMF C12 H10 O3



RN 852057-57-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester, polymer with 4,4'-oxybis[phenol] (9CI) (CA INDEX NAME)

CM 1

CRN 537712-38-2
CMF C29 H18 O9

L6 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 524951-01-7 537712-38-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting mesogenic monomer; alkylene-aromatic and aromatic polyesters with
linear mesogenic groups in backbone)
RN 524951-01-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



RN 537712-38-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester (9CI) (CA INDEX NAME)





L6 ANSWER 29 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1067769 CAPLUS
DOCUMENT NUMBER: 142:192932
TITLE: Unusual Ligand Discrimination by a Myoglobin Reconstituted with a Hydrophobic Domain-Linked Heme
AUTHOR(S): Satō, Hideaki; Watanabe, Masahiro; Hisaeda, Yoshio; Hayashi, Takashi
CORPORATE SOURCE: Department of Chemistry and Biochemistry, Graduate School of Engineering, Kyushu University, Fukuoka, 812-8581, Japan
SOURCE: Journal of the American Chemical Society (2005), 127(1), 56-57
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:192932

AB New, reconstituted horse heart myoglobins possessing a hydrophobic domain at the terminal of the two heme propionate side chains were constructed. The O2 and CO bindings for the reconstituted deoxymyoglobins were examined in detail by laser flash photolysis and stopped-flow rapid mixing techniques. The artificially created domain worked as a barrier against exogenous ligand penetration into the heme pocket, whereas the bound O2 was stabilized in the reconstituted myoglobin as well as in the native one. In contrast, the CO dissociation rate for the reconstituted myoglobin increased by 20-fold compared to the native protein, suggesting that the incorporation of the hydrophobic domain onto the heme pocket perturbs the distal-site structure of the reconstituted myoglobin. As a result, the substantial ligand selectivity for the reconstituted myoglobin significantly increases in favor of O2 over CO with the M' value (= KCO/KO2) of 0.88, whereas, to the best of our knowledge, there is no myoglobin mutant in which the O2 affinity exceeds the CO one. The present work concludes that the O2 selectivity of myoglobin over CO is markedly improved by chemical modifying the heme propionates without any mutation of the amino acid residues in the distal site.

IT 835883-36-8P
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(unusual ligand discrimination by myoglobin reconstituted with hydrophobic domain-linked heme)

RN 835883-36-8 CAPLUS
CN Ferrate(8-), [[4,4',4'',4''',4'''',4''''',4'''''',4'''''''-[(7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-κN21,κN22,κN23,κN24)bis[(1-oxo-3,1-propanediyl)iminomethylene-5,1,3-benzenetriylbis(oxymethylene-5,1,3-benzenetriylbis(oxymethylene))]]octakis[benzoato]](10-)]-, octahydrogen, (SP-4-2)- (9CI) (CA INDEX NAME)

L6 ANSWER 29 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L6 ANSWER 29 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B



PAGE 3-A



L6 ANSWER 29 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-B

PAGE 4-A



●8 H+

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 30 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1036192 CAPLUS
DOCUMENT NUMBER: 142:40226
TITLE: Benzophenone compound and ink composition including the same
INVENTOR(S): Lee, Kyung-Hoon; Ryu, Seung-Min; Jung, Yeon-Kyoung
PATENT ASSIGNEE(S): Samsung Electronics Co., Ltd., S. Korea
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004237836	A1	20041202	US 2004-851124	20040524
US 7164036	B2	20070116		
KR 2004101861	A	20041203	KR 2003-33837	20030527
PRIORITY APPLN. INFO.:			KR 2003-33837 A	20030527

AB The invention relates to a benzophenone compound, and an ink composition that includes the benzophenone compound can absorb UV light, and thus improve lightfastness of images produced with the ink composition containing the compound Due to the function of the benzophenone compound as a lightfast dispersant, the dispersibility and the lightfastness of an ink composition are improved with the benzophenone compound, without requiring an addnl. lightfastness enhancer. An example of the compds. is 2-hydroxy-4-(4-carboxy)phenyloxybenzophenone which was synthesized.

IT 801321-18-6P, 2-Hydroxy-4-(4-carboxy)benzyloxybenzophenone
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT
(Reactant or reagent)
(manufacture of benzophenone compds. useful as lightfast dispersants for use in inks with good resistance to light)

RN 801321-18-6 CAPLUS
CN Benzoic acid, 4-[(4-benzoyl-3-hydroxyphenoxy)methyl]- (CA INDEX NAME)



IT 801321-19-7, 2-Hydroxy-4-(4-carboxy)benzoyloxybenzophenone
RL: RCT (Reactant); RACT (Reactant or reagent)
(manufacture of benzophenone compds. useful as lightfast dispersants for use

CM 4

CRN 75-21-8
CMF C2 H4 O

RN 804475-80-7 CAPLUS
CN Oxirane, methyl-, polymer with oxirane, mono(4-benzoyl-3-hydroxyphenyl 1,4-benzenedicarboxylate), triblock (9CI) (CA INDEX NAME)

CM 1

CRN 801321-19-7
CMF C21 H14 O6



CM 2

CRN 691397-13-4
CMF (C3 H6 O . C2 H4 O)x
CCI PMS

CM 3

CRN 75-56-9
CMF C3 H6 O

CM 4

CRN 75-21-8
CMF C2 H4 O

in inks with good resistance to light)

RN 801321-19-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono(4-benzoyl-3-hydroxyphenyl) ester (9CI) (CA INDEX NAME)



IT 804475-79-4P 804475-80-7P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(oligomeric, lightfast dispersant; manufacture of benzophenone compds. useful as lightfast dispersants for use in inks with good resistance to light)

RN 804475-79-4 CAPLUS
CN Oxirane, methyl-, polymer with oxirane, mono[4-[(4-benzoyl-3-hydroxyphenoxy)methyl]benzoate], triblock (9CI) (CA INDEX NAME)

CM 1

CRN 801321-18-6
CMF C21 H16 O5



CM 2

CRN 691397-13-4
CMF (C3 H6 O . C2 H4 O)x
CCI PMS

CM 3

CRN 75-56-9
CMF C3 H6 O

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:701970 CAPLUS
DOCUMENT NUMBER: 141:225511
TITLE: Preparation of substituted azoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Yarragunta, Ravindra R.; Xie, Rongyuan; Ren, Tan; Subramanian, Govindan; Quada, James C., Jr.
PATENT ASSIGNEE(S): Transtech Pharma Inc., USA
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071448	A2	20040826	WO 2004-US4076	20040212
WO 2004071448	A3	20041014		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004186151	A1	20040923	US 2004-777471	20040212
PRIORITY APPLN. INFO.:			US 2003-446924P	P 20030212

OTHER SOURCE(S): MARPAT 141:225511
GI



I



II

AB Title imidazoles and analogs I [wherein m, n = independently 0, 1; A = H, alkyl, alkenyl, alkynyl; L1 = a bond, O, alkylene, CO, NHCO, NH, NHSO2, etc.; T = H, (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, etc.; W = O, S, NR4; X = a bond, CO, CH2, SO2; R1 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, perfluoroalkyl, alkylene optionally interrupted by one or more heteroatoms, (hetero)aryl, heterocyclyl, etc.; R3 = H, alkyl, (cyclo)alkylalkylene, (hetero)aryl(alkylene); R4 = H, alkyl, (hetero)aryl(alkyl), heterocyclyl(alkyl), etc.; Ar1 = (un)substituted optionally fused (hetero)aryl; Ar2 = (un)substituted optionally fused (hetero)arylene; and pharmaceutically acceptable salts, solvates, and prodrugs thereof] were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, 3-[(tert-butoxycarbonyl)amino]-2-(4-butoxy-3-butoxycarbonylphenyl)-2-ethyl-4-(4-nitrophenyl)imidazole was coupled with 4-nitrophenacyl bromide to give the keto ester, which was treated with ammonium acetate in glacial acetic acid/anhydrous DMF to afford the imidazole
II (40%). Compds. of the invention inhibited PTP 1B activity with IC50 values ranging from about 0.01 μM to about 20 μM. Thus, I and pharmaceutical compns. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone
or cytokines, of Alzheimer's disease (no data).

IT 745833-30-1P 745833-59-4P 745833-74-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(PTPase inhibitor; prepn. of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)

RN 745833-30-1 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1-oxo-2-propenyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 745833-59-4 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[trans-4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-74-3 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-ethylcyclohexyl)carbonyl]amino]ethyl]-2-nitrophenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 745833-07-2P, 4-[[4-[(2S)-2-[(tert-Butoxycarbonyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]benzoic acid 745833-11-8P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[2-(4-methoxyphenyl)acetyl]amino]ethyl]phenoxy]methyl]benzoic acid 745833-12-9P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[2-(4-tert-butylphenyl)acetyl]amino]ethyl]phenoxy]methyl]benzoic acid 745833-14-1P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

imidazol-2-yl]-2-[[2-(naphthalen-1-yl)acetyl]amino]ethyl]phenoxy]methyl]be
nzoic acid 745833-16-3P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-

dichlorophenyl)-1H-imidazol-2-yl]-2-[[[1-(4-methoxyphenyl)cyclopentyl]carb
onyl]amino]ethyl]phenoxy]methyl]benzoic acid 745833-18-5P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[2-(4-
chlorophenyl)-2-methylpropionyl]amino]ethyl]phenoxy]methyl]benzoic acid
745833-20-9P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-[(phenylacetyl)amino]ethyl]phenoxy]methyl]benzoic acid
745833-22-1P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-

imidazol-2-yl]-2-[[2-(1-methyl-1H-indol-2-yl)acetyl]amino]ethyl]phenoxy]me
thyl]benzoic acid 745833-24-3P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-

dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(4-methoxyphenyl)butyryl]amino]eth
yl]phenoxy]methyl]benzoic acid 745833-25-4P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-(4-
methoxyphenyl)propionyl]amino]ethyl]phenoxy]methyl]benzoic acid
745833-26-5P 745833-27-6P 745833-28-7P
745833-29-8P 745833-31-2P 745833-32-3P,

4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(1H-
indol-2-yl)butyryl]amino]ethyl]phenoxy]methyl]benzoic acid
745833-33-4P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(3-fluorobenzoylamino)ethyl]phenoxy]methyl]benzoic acid
745833-34-5P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(3-cyanobenzoylamino)ethyl]phenoxy]methyl]benzoic acid
745833-35-6P, 4-[[4-[(2S)-2-(4-tert-Butylbenzoylamino)-2-[1-butyl-
4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]benzoic acid
745833-36-7P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(3,4-difluorobenzoylamino)ethyl]phenoxy]methyl]benzoic
acid 745833-37-8P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-

1H-imidazol-2-yl]-2-(2-chloro-4-fluorobenzoylamino)ethyl]phenoxy]methyl]be
nzoic acid 745833-38-9P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-

dichlorophenyl)-1H-imidazol-2-yl]-2-(4-phenoxybenzoylamino)ethyl]phenoxy]m
ethyl]benzoic acid 745833-39-0P, 4-[[4-[(2S)-2-(4-
Butoxybenzoylamino)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-
yl]ethyl]phenoxy]methyl]benzoic acid 745833-40-3P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-
[[(pyridin-3-yl)carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid
745833-41-4P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-

imidazol-2-yl]-2-[[(isoquinolin-3-yl)carbonyl]amino]ethyl]phenoxy]methyl]b
enzoic acid 745833-42-5P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-

dichlorophenyl)-1H-imidazol-2-yl]-2-(2-cyclopentylacetylamino)ethyl]phenox
y]methyl]benzoic acid 745833-43-6P, 4-[[4-[(2S)-2-[1-Butyl-4-

(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclohexylcarbonyl)amino]ethyl]
phenoxy]methyl]benzoic acid 745833-44-7P, 4-[[4-[(2S)-2-[1-Butyl-

4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclopropylcarbonyl)amino]eth

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

yl]phenoxy]methyl]benzoic acid 745833-45-8P 745833-46-9P
745833-47-0P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(3-cyclohexylpropionylamino)ethyl]phenoxy]methyl]benzoic
acid 745833-48-1P 745833-49-2P 745833-50-5P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-(2-
cyclohexylacetylamino)ethyl]phenoxy]methyl]benzoic acid
745833-51-6P 745833-52-7P, 4-[[4-[(2S)-2-[(4-tert-

Butylbenzenesulfonyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-
2-yl]ethyl]phenoxy]methyl]benzoic acid 745833-53-8P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-
[[(naphthalen-1-yl)sulfonyl]amino]ethyl]phenoxy]methyl]benzoic acid.
745833-54-9P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-

imidazol-2-yl]-2-[(4-methoxybenzenesulfonyl)amino]ethyl]phenoxy]methyl]ben
zoic acid 745833-55-0P, 4-[[4-[(2S)-2-[(4-

Butylbenzenesulfonyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-
2-yl]ethyl]phenoxy]methyl]benzoic acid 745833-56-1P,
4-[[(1S)-1-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[4-(4-
carboxybenzyloxy)phenyl]ethyl]carbamoyl]piperidine-1-carboxylic acid
tert-butyl ester 745833-57-2P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-
dichlorophenyl)-1H-imidazol-2-yl]-2-[[(pyrrolidin-1-
yl)carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid 745833-58-3P
745833-60-7P 745833-61-8P 745833-62-9P
745833-63-0P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(4,4-dimethylpentanoylamino)ethyl]phenoxy]methyl]benzoic
acid 745833-64-1P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-
1H-imidazol-2-yl]-2-heptanoylaminoethyl]phenoxy]methyl]benzoic acid
745833-65-2P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(6-methylheptanoylamino)ethyl]phenoxy]methyl]benzoic
acid
745833-66-3P, 4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-
imidazol-2-yl]-2-(6,6-dimethylheptanoylamino)ethyl]phenoxy]methyl]benzoic
acid 745833-67-4P 745833-71-0P 745833-73-2P
745833-78-7P 745833-81-2P, 4-[[4-[(2S)-2-[4-(2,4-
Dichlorophenyl)oxazol-2-yl]-2-[[2-(4-methoxyphenyl)acetyl]amino]ethyl]-2-
nitrophenoxy]methyl]benzoic acid 745833-83-4P,
4-[[4-[(2S)-2-[1-Butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-
(dimethylcarbamoyl)butyryl]amino]ethyl]phenoxy]methyl]benzoic acid
746657-96-5P 746657-97-6P 746657-98-7P
746657-99-8P 746658-00-4P 746658-01-5P
746658-02-6P 746658-03-7P 746658-04-8P
746658-06-0P 746658-07-1P 746658-08-2P
746658-09-3P 746658-10-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(PTPase inhibitor; prepn. of substituted imidazoles as PTPase
inhibitors for treatment of diabetes and other PTPase mediated
conditions)
RN 745833-07-2 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-
yl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]phenoxy]methyl]- (CA

L6. ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 745833-11-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-
yl]-2-[[(4-methoxyphenyl)acetyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 745833-12-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-
yl]-2-[[[4-(1,1-dimethylethyl)phenyl]acetyl]amino]ethyl]phenoxy]methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-14-1 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-
yl]-2-[(1-naphthalenylacetyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.



RN 745833-16-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-

yl]-2-[[[1-(4-methoxyphenyl)cyclopentyl]carbonyl]amino]ethyl]phenoxy]methy
l]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-18-5 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[2-(4-chlorophenyl)-2-methyl-1-oxopropyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-20-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(phenylacetyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-25-4 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-(4-methoxyphenyl)-1-oxopropyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-26-5 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-(2,4-difluorophenyl)-1-oxo-2-propenyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-22-1 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(1-methyl-1H-indol-2-yl)acetyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-24-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(4-methoxyphenyl)-1-oxobutyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-27-6 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 745833-28-7 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[3-(4-ethoxyphenyl)-1-oxo-2-propenyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-29-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[[3-(4-butoxyphenyl)-1-oxo-2-propenyl]amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 745833-31-2 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[[3-(4-aminophenyl)-1-oxo-2-propenyl]amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl]-2-[(3-fluorobenzoyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-34-5 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(3-cyanobenzoyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-35-6 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(1,1-dimethylethyl)benzoyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A

● HCl

RN 745833-32-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(1H-indol-2-yl)-1-oxobutyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-33-4 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-36-7 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(3,4-difluorobenzoyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-37-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(2-chloro-4-fluorobenzoyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-38-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(4-phenoxybenzoyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-39-0 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[(4-butoxybenzoyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-42-5 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclopentylacetyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-43-6 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclohexylcarbonyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-40-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(3-pyridinylcarbonyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-41-4 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(3-isoquinolinylcarbonyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-44-7 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclopropylcarbonyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-45-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-methylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-46-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-ethylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-47-0 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(3-cyclohexyl-1-oxopropyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 745833-50-5 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(cyclohexylacetyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-51-6 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(2-methyl-1-oxopropyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 745833-48-1 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-pentylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-49-2 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(2-phenylcyclopropyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-52-7 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-53-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(1-naphthalenylsulfonyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-54-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(4-methoxyphenyl)sulfonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-55-0 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(4-butylphenyl)sulfonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-58-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[2-[[[(1,1-dimethylethyl)amino]carbonyl]cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-60-7 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[[[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-56-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(1S)-1-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[4-[(4-carboxyphenyl)methoxy]phenyl]ethyl]amino]carbonyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-57-2 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(1-pyrrolidinylcarbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

RN 745833-61-8 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(1-oxo-2-hexynyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-62-9 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(1-oxo-5-hexynyl)amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-63-0 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(4,4-dimethyl-1-oxopentyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-64-1 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(1-oxoheptyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-65-2 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(6-methyl-1-oxoheptyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-66-3 CAPLUS
CN Benzoic acid,
4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[(6,6-dimethyl-1-oxoheptyl)amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-67-4 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(2E)-2-pentenyl-1H-imidazol-2-yl]-2-[[(trans-4-ethylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 745833-71-0 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-(2E)-2-butenyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-ethylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-73-2 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-(2-butynyl)-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(trans-4-ethylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-78-7 CAPLUS
CN Benzoic acid,
4-[[2-amino-4-[(2S)-2-[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[[(cis-4-ethylcyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 745833-81-2 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[[(4-methoxyphenyl)acetyl]amino]ethyl]-2-nitrophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-83-4 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[5-(dimethylamino)-1,5-dioxopentyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746657-96-5 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746657-97-6 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(4-methoxycyclohexyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 746657-98-7 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[4-(trifluoromethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746657-99-8 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[4-hydroxycyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746658-00-4 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[(2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-01-5 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[(bicyclo[2.2.1]hept-5-en-2-ylcarbonyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746658-02-6 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]-2-[1-butyl-4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-03-7 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746658-04-8 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-06-0 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(2-oxobutyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746658-07-1 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(3-methylbutyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-08-2 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(3-hydroxypropyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 746658-09-3 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-10-6 CAPLUS
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1-(2-pentenyl)-1H-imidazol-2-yl]-2-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L6 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:701969 CAPLUS
DOCUMENT NUMBER: 141:207209
TITLE: Preparation of substituted imidazoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Yarragunta, Ravindra R.; Xie, Rongyuan; Subramanian, Govindan; Quada, James C., Jr.; Arimilli, Murty N.; Polisetti, Dharma R.
PATENT ASSIGNEE(S): Transtech Pharma Inc., USA
SOURCE: PCT Int. Appl., 281 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071447	A2	20040826	WO 2004-US4074	20040212
WO 2004071447	A3	20041223		
WO 2004071447	B1	20050310		
WO 2004071447	A9	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210711	A1	20040826	AU 2004-210711	20040212
CA 2514363	A1	20040826	CA 2004-2514363	20040212
US 2004192743	A1	20040930	US 2004-777488	20040212
EP 1594847	A2	20051116	EP 2004-710607	20040212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1747936	A	20060315	CN 2004-80004085	20040212
JP 2006518738	T	20060817	JP 2006-503512	20040212
PRIORITY APPLN. INFO.:			US 2003-446977P	P 20030212
			WO 2004-US4074	W 20040212

OTHER SOURCE(S): MARPAT 141:207209
GI

L6 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title imidazoles and analogs I [wherein m, n = independently 0-2; W = O, S, NR2; R1 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, alkyl, (hetero)aryl(alkyl), heterocyclyl(alkyl), etc.; Ar1 = (un)substituted optionally fused (hetero)aryl; Ar2 = (un)substituted optionally fused (hetero)arylene; L1 = a bond, (un)substituted ethylene, NHCO, NH, NHSO2, etc.; L2 = CH2, O, alkylene, (hetero)arylene, etc.; T = H, (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, etc.; and pharmaceutically acceptable salts, solvates, and prodrugs thereof] were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, reaction of trans-4-methoxycinnamic acid with 2,4-dichlorophenacyl bromide in the presence of DIEA in DMF gave the keto-ester (no data), which was treated with ammonium acetate in glacial AcOH to afford (E)-II (56%). Compds. of the invention inhibited PTP 1B activity with IC50 values ranging from about 0.01 μM to about 20 μM. Thus, I and pharmaceutical compns. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone or cytokines, of Alzheimer's disease (no data).

IT 744236-97-3P, 4-[[4-[2-[4-(2,4-Dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-ethenyl]phenoxy]methyl]benzoic acid 744236-98-4P, 3-[[4-[2-[4-(2,4-Dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-ethenyl]phenoxy]methyl]benzoic acid 744237-35-2P, 4-[[4-[2-[4-(2,4-Dichlorophenyl)-1-[[[1-(naphthalen-1-yl)ethyl]carbamoyl]methyl]-1H-imidazol-2-yl]-(E)-ethenyl]phenoxy]methyl]benzoic acid 744237-36-3P, 3-[[4-[2-[4-(2,4-Dichlorophenyl)-1-[[[1-(naphthalen-1-yl)ethyl]carbamoyl]methyl]-1H-imidazol-2-yl]-(E)-ethenyl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)

L6 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 744236-97-3 CAPLUS
CN Benzoic acid, 4-[[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]ethenyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 744236-98-4 CAPLUS
CN Benzoic acid, 3-[[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]ethenyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 744237-35-2 CAPLUS
CN Benzoic acid, 4-[[4-[[(1E)-2-[4-(2,4-dichlorophenyl)-1-[2-[[1-(1-naphthalenyl)ethyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]ethenyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 744237-36-3 CAPLUS
CN Benzoic acid, 3-[[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[2-[[1-(1-naphthalenyl)ethyl]amino]-2-oxoethyl]-1H-imidazol-2-yl]ethenyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L6 ANSWER 33 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:665197 CAPLUS
DOCUMENT NUMBER: 141:360200
TITLE: QSAR of human steroid 5α-reductase inhibitors: Where are the differences between isoenzyme type 1 and 2?
AUTHOR(S): Hutter, Michael C.; Hartmann, Rolf W.
CORPORATE SOURCE: Center of Bioinformatics, Saarland University, Saarbruecken, D-66041, Germany
SOURCE: QSAR & Combinatorial Science (2004), 23(6), 406-415
CODEN: QCSSAU; ISSN: 1611-020X
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Quant. Structure Activity Relationships have been established for inhibitors of human steroid 5α-reductase including 6-azasteroids and non-steroidal compds. From the applied descriptors, those related to the mol. geometry, electronic properties, and the electrostatic surface were derived from semi-empirical AM1 calcns. A chemical reaction as part of the inhibitory action is indicated by the presence of the ionization potential in the descriptor space. Strong similarities between the variables for the prediction of the binding affinity to the type 1 and IC50 values for the type 2 isoform of the 5α-reductase were observed The most pronounced differences in the linear regression QSAR equations were found for the descriptors accounting for the hydrogen-bonding interaction, suggesting a different hydrogen-bonding pattern in the binding pocket of both isoforms. Furthermore, the topol. indexes together with the surface related descriptors point towards a lower content of aromatic amino acids in the binding site of the type 2 isoenzyme. Consequences for the design of new inhibitors are discussed.

IT 777875-42-0
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(QSAR of human steroid 5α-reductase inhibitors)
RN 777875-42-0 CAPLUS
CN Benzoic acid, 4-[(4-benzoylphenoxy)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 34 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:565185 CAPLUS
DOCUMENT NUMBER: 141:106267
TITLE: Preparation of salicylic acid derivatives as ligands of adenine nucleotide translocase
INVENTOR(S): Ghosh, Soumitra S.; Pei, Yazhong; Tang, Xiao-qing; Liras, Spiros J.; Ahlijanian, Michael K.
PATENT ASSIGNEE(S): Mitokor, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058679	A2	20040715	WO 2003-US41211	20031219
WO 2004058679	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511178	A1	20040715	CA 2003-2511178	20031219
AU 2003300358	A1	20040722	AU 2003-300358	20031219
US 2004192740	A1	20040930	US 2003-741595	20031219
US 6936638	B2	20050830		
EP 1581472	A2	20051005	EP 2003-814376	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017613	A	20051129	BR 2003-17613	20031219
JP 2006511587	T	20060406	JP 2004-564036	20031219
US 2006004093	A1	20060105	US 2005-146933	20050607
MX 2005PA06798	A	20060309	MX 2005-PA6798	20050620
US 2006194825	A1	20060831	US 2006-539539	20060203
PRIORITY APPLN. INFO.:			US 2002-435420P	P 20021220
			US 2003-741595	A1 20031219
			WO 2003-US41211	W 20031219

OTHER SOURCE(S): MARPAT 141:106267
GI

L6 ANSWER 34 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [R1 = H, halo, NO2, CN, (substituted)alkyl, alkoxy, (substituted)aryl, (substituted)heteroaryl; R2, R3, R5, R6 = H, halo, NO2, CN, (substituted)alkyl, alkoxy, OH, (substituted)aryl, (substituted)heteroaryl; R4 = H, halo, NO2, CN, (substituted)alkyl, (substituted)aryl, (substituted)heteroaryl, (substituted)heteroarylalkyl, etc; R4 and R5 or R5 and R6, taken together with the carbon atoms to which they are attached, optionally form a (un)substituted homocycle] were prepared for use as ligands of adenine nucleotide translocase in the treatment of conditions associated with altered mitochondrial function. For example, compound II was prepared from 3-methylsalicylic acid in a multi-step synthesis. All the compds. in this invention showed satisfied bioactivity in the ANT ligand binding assay.

IT 721447-20-7P 721447-24-1P 721447-43-4P
721448-54-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of salicylic acid derivs. as ligands of adenine nucleotide translocase)

L6 ANSWER 34 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 34 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 721447-20-7 CAPLUS
CN Benzoic acid, 3-[(4-benzoylphenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-24-1 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[4-(phenylmethoxy)phenoxy]methyl]- (CA INDEX NAME)



RN 721447-43-4 CAPLUS
CN Benzoic acid, 3,3'-[[2,5-bis(1,1-dimethylethyl)-1,4-phenylene]bis(oxymethylene)]bis[2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721448-54-0 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[(4-phenoxyphenoxy)methyl]- (CA INDEX NAME)

L6 ANSWER 35 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:467875 CAPLUS
DOCUMENT NUMBER: 141:23525
TITLE: Preparation of isoxazole derivs. as farnesoid x receptor agonists
INVENTOR(S): Boggs, Sharon D.; Collins, Jon L.; Hyatt, Stephen M.; Maloney, Patrick R.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048349	A1	20040610	WO 2003-US35808	20031112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003290700	A1	20040618	AU 2003-290700	20031112
EP 1562915	A1	20050817	EP 2003-783282	20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515838	T	20060608	JP 2004-555406	20031112
US 2006258725	A1	20061116	US 2005-535228	20050517
PRIORITY APPLN. INFO.:			US 2002-428374P P	20021122
			WO 2003-US35808 W	20031112

OTHER SOURCE(S): MARPAT 141:23525
GI

L6 ANSWER 35 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [R1 = halo, alkyl, alkenyl, cyano, etc.; R2 = alkyl, alkenyl, cycloalkyl, cycloalkenyl, etc.; Y = -O-, -N(R7)-; R3 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, etc.; Z = -OR4-, -R4O-, -S(O)qR4-; -R4S(O)q-, etc.; R4 = alkylene or alkenylene; R5 = R6O-, R6O2C-, and (R9)r-A-, where A = aryl, or 5-12 membered heterocycle or heteroaryl; R6 = H, alkyl, alkenyl, cycloalkyl, cycloalkenyl; R7 = H, or alkyl; R9 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; m = 0-3; n = 1-5; p = 0-4; r = 0-4] were prepared as as farnesoid x receptor agonists for the treatment or prevention of FXR mediated diseases or conditions, including cardiovascular disease and atherosclerosis (no data). For example, reaction of N-(4-[[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy]-2-methylphenyl)-N-methylamine (preparation given) with Me 3-(bromomethyl)benzoate, followed by treatment of aqueous lithium hydroxide furnished compound II. The latter displayed activity against human farnesoid X receptor alpha with pEC50 value > 7.

IT 700835-78-5P 700835-79-6P 700835-80-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of isoxazole derivs. as farnesoid x receptor agonists)

RN 700835-78-5 CAPLUS
CN Benzoic acid, 3-[[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenoxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 700835-79-6 CAPLUS
CN Benzoic acid, 3-[[4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-2-methylphenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 35 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 700835-80-9 CAPLUS
CN Benzoic acid, 4-[[4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-2-methylphenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 35 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 36 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:342029 CAPLUS
DOCUMENT NUMBER: 141:54868
TITLE: Hydrodynamic, optical, and conformational properties of an aromatic polyester containing a nonlinear T-shaped mesogenic fragment in the backbone
AUTHOR(S): Andreeva, L. N.; Bushin, S. V.; Belyaeva, E. V.; Bezrukova, M. A.; Bol'shakov, M. N.; Klimova, N. V.; Rudaya, L. I.; Yurre, T. A.; Shamanin, V. V.; Skorokhodov, S. S.
CORPORATE SOURCE: Inst. Vysokomol. Soedinenii, Ross. Akad. Nauk, St. Petersburg, 199004, Russia
SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A i Seriya B (2004), 46(3), 510-520
CODEN: VSSBEE; ISSN: 1023-3091
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB A thermotropic mesogenic aromatic polyester with a nonlinear T-shaped structure of the rigid fragment related to the presence of a benzoyl substituent was synthesized. Intervals of LC phase existence in bulk as dependent on the polymer mol. mass were determined; for polyester fractions in dioxane, intrinsic viscosities [η], translational diffusion coeffs. D, and optical shear coeffs. were estimated The mol. masses of fractions MηD = (2.4-13.4) × 103 were calculated from [η] and D values using the hydrodynamic invariant A0 = 3.2 × 10-10 erg/K. The hydrodynamic behavior of macromols. was described within the framework of the draining wormlike coil model. The Kuhn segment length A = 35 × 10-8 cm was evaluated from dynamic measurements. A difference in the polarizabilities of the monomer unit a.dblvert.a.dblvert. derived from dynamo-optical and hydrodynamic expts. agrees with its structure. The conformational properties of the polyester of interest were analyzed in terms of the flexibility additivity concept. It was shown that the introduction of the benzoyl substituent into the mesogenic fragment leads to a reduction in the conjugation energy and disturbs the coplanarity of an ester group.

IT 2225-00-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(monomer synthesis; aromatic polyester containing nonlinear T-shaped mesogenic fragment in backbone)

RN 2225-00-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,4-phenylene ester (9CI) (CA INDEX NAME)

L6 ANSWER 36 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 37 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:267336 CAPLUS
DOCUMENT NUMBER: 140:303699
TITLE: Preparation of triazaspiro[5.5]undecane derivatives as chemokine receptor CCR5 antagonists and drugs comprising the same as the active ingredients
INVENTOR(S): Takaoka, Yoshikazu; Nishizawa, Rena; Shibayama, Shiro; Sagawa, Kenji; Matsuo, Masayoshi
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 288 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026879	A1	20040401	WO 2003-JP11834	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497903	A1	20040401	CA 2003-2497903	20030917
AU 2003272879	A1	20040408	AU 2003-272879	20030917
EP 1541574	A1	20050615	EP 2003-753933	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014304	A	20050726	BR 2003-14304	20030917
CN 1688577	A	20051026	CN 2003-824386	20030917
MX 2005PA02771	A	20050606	MX 2005-PA2771	20050311
US 2005267114	A1	20051201	US 2005-527435	20050311
NO 2005001379	A	20050617	NO 2005-1379	20050316
ZA 2005002222	A	20050930	ZA 2005-2222	20050316
PRIORITY APPLN. INFO.:			JP 2002-270849 A	20020918
			WO 2003-JP11834 W	20030917

OTHER SOURCE(S): MARPAT 140:303699
GI

L6 ANSWER 37 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB The title compds. [I; R1 = (a) each (un)substituted and partially or completely saturated C3-15 mono-, di-, or tricarbocyclic aryl or 3- to 15-membered mono-, di-, or triheterocyclic aryl latter containing heteroatoms selected from 1-4 N atoms, 1 or 2 O atoms, and/or 1 or 2 S atoms, or (b) C1-8 alkyl, C2-4 alkenyl, or C2-4 alkynyl each substituted by 1-3 substituents selected from each (un)substituted HO, acyl, NH2, CONH2, acylamino, sulfonylamino, :NH, and :NOH; R2 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, each (un)substituted Ph, pyridinyl, or C3-8 cycloalkyl, group (b); R3, R4 = (i) H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, or (ii) C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl each substituted by 1-5 substituents selected from group (a), HO, and tetrahydropyran-4-ylidene], quaternary ammonium salts, N-oxides, or salts thereof are prepared These compds. are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immune diseases (autoimmune disease, transplant rejection, immune suppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immune deficiency syndrome), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis, etc. (no data). They are improved in bioavailability when administered orally, metabolic stability, liver or systemic clearance, or affinity for chemokine receptor CCR compared to prior art compds. and exhibit very low toxicity. Thus, 1-benzyl-4-piperidone, (2R,3R)-2-(tert-butoxycarbonylamino)-3-cyclohexyl-3-hydroxypropanoic acid, n-butylamine, and 2-(morpholin-4-yl)ethyl isocyanide were stirred in MeOH at 50° overnight to give, after workup, 1-benzyl-4-[2-(morpholin-4-yl)ethylaminocarbonyl]-4-[N-butyl-N-[(2R,3R)-2-amino-3-hydroxy-3-cyclohexylpropanoyl]amino]piperidine which was stirred in AcOH at 70° for 1 h to give, after workup, (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-phenylmethyl-1,4,9-triazaspiro[5.5]undecane (II). A tablet and an ampule formulation containing specific compound I were described.

IT 676450-17-2P 676450-98-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazaspiro[5.5]undecane derivs. as chemokine receptor CCR5 antagonists and drugs)

L6 ANSWER 37 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 676450-17-2 CAPLUS
CN Benzoic acid, 4-[[4-[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 676450-98-9 CAPLUS
CN Benzoic acid, 4-[[4-[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:189168 CAPLUS
DOCUMENT NUMBER: 140:399338
TITLE: Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-α-induced VCAM-1 expression
AUTHOR(S): Meng, Charles Q.; Zheng, X. Sharon; Ni, Liming; Ye, Zhihong; Simpson, Jacob E.; Worsencroft, Kimberly J.; Hotema, Martha R.; Weingarten, M. David; Skudlarek, Jason W.; Gilmore, Joshua M.; Hoong, Lee K.; Hill, Russell R.; Marino, Elaine M.; Suen, Ki-Ling; Kunsch, Charles; Wasserman, Martin A.; Sikorski, James A.
CORPORATE SOURCE: AtheroGenics, Inc., Alpharetta, GA, 30004, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(6), 1513-1517
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:399338
AB Novel chalcone derivs. have been discovered as potent inhibitors of TNF-α-induced VCAM-1 expression. Thienyl or benzothienyl substitution at the meta-position of ring B helps boost potency while large substitution at the para-position on ring B is detrimental. Various substitutions are tolerated on ring A. A lipophilicity-potency relationship has been observed in several sub-series of compds.
IT 690666-01-4
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and structure-activity relationship of novel heteroaryl-substituted chalcones as inhibitors of TNF-α-induced VCAM-1 expression)
RN 690666-01-4 CAPLUS
CN Benzoic acid, 4-[[2-methoxy-4-[(2E)-3-[2-methoxy-5-(2-thienyl)phenyl]-1-oxo-2-propenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:2838 CAPLUS
DOCUMENT NUMBER: 140:41910
TITLE: Preparation of ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
INVENTOR(S): Li, Lanna
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000790	A1	20031231	WO 2003-GB2584	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489834	A1	20031231	CA 2003-2489834	20030617
CA 2489834	C	20061003		
AU 2003240099	A1	20040106	AU 2003-240099	20030617
AU 2003240099	B2	20070201		
BR 2003011932	A	20050322	BR 2003-11932	20030617
EP 1517883	A1	20050330	EP 2003-732713	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675171	A	20050928	CN 2003-819474	20030617
JP 2005529970	T	20051006	JP 2004-515007	20030617
JP 3782818	B2	20060607		
NO 2004005353	A	20050120	NO 2004-5353	20041207
IN 2004DN03904	A	20070427	IN 2004-DN3904	20041209
US 2005256198	A1	20051117	US 2004-518007	20041214
MX 2004PA12686	A	20050323	MX 2004-PA12686	20041215
ZA 2004010161	A	20051020	ZA 2004-10161	20041215
JP 2006182782	A	20060713	JP 2006-19068	20060127
PRIORITY APPLN. INFO.:			SE 2002-1935	A 20020620
			SE 2002-3826	A 20021220
			JP 2004-515007	A3 20030617
			WO 2003-GB2584	W 20030617

OTHER SOURCE(S): MARPAT 140:41910
GI

L6 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

II

AB Title compds. I [n = 0-2; R1 = halo, alkyl, alkoxy, etc.; R2 = alkyl; Y = absent, CH2; X = O, S] are prepared For instance, N-benzyl-N-hexyl-3-(4-hydroxyphenyl)propanamide (preparation given) is reacted with Me 2-(bromomethyl)benzoate (CH3CN, K2CO3, 66°) and the product saponified (THF/H2O, LiOH, microwave, 120°, 40 min) to give II. Example compds. have EC50 < 50 μmol/L for PPAR-α. I are useful for treating clin. conditions associated with insulin resistance.

IT 637014-98-3P, 2-[[4-[3-[Benzyl(hexyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-05-5P, 2-[[4-[2-[Benzyl(hexyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-07-7P, 2-[[4-[2-[(2,4-Difluorobenzyl)(heptyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-10-2P, 2-[[4-[3-[(2,4-Difluorobenzyl)(heptyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-18-0P, 2-[[4-[3-[Butyl(2,3-dimethoxybenzyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-22-6P, 2-[[4-[3-[(2,3-Dimethoxybenzyl)(heptyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-26-0P, 2-[[4-[3-[(3-Ethoxypropyl)(4-isopropylbenzyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-30-6P, 2-[[4-[3-[(2,4-Difluorobenzyl)(propyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637015-33-9P, 2-[[4-[2-[Ethyl(2-fluorobenzyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-36-2P, 2-[[4-[3-[Ethyl(2-fluorobenzyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ortho-substituted benzoic acid derivs. for treatment of insulin resistance)

RN 637014-98-3 CAPLUS
CN Benzoic acid, 2-[[4-[3-[hexyl(phenylmethyl)amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 637015-22-6 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,3-dimethoxyphenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-26-0 CAPLUS
CN Benzoic acid, 2-[[4-[3-[(3-ethoxypropyl)[[4-(1-methylethyl)phenyl]methyl]amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-30-6 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]propylamino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-33-9 CAPLUS
CN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 637015-05-5 CAPLUS
CN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-07-7 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-10-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[(2,4-difluorophenyl)methyl]heptylamino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637015-18-0 CAPLUS
CN Benzoic acid, 2-[[4-[3-[butyl[(2,3-dimethoxyphenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 637015-36-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[ethyl[(2-fluorophenyl)methyl]amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:2679 CAPLUS
DOCUMENT NUMBER: 140:76898
TITLE: Preparation of benzoic acid derivatives as modulators of PPAR-α and PPAR-γ
INVENTOR(S): Li, Lanna
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000295	A1	20031231	WO 2003-GB2598	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490687	A1	20031231	CA 2003-2490687	20030617
AU 2003240101	A1	20040106	AU 2003-240101	20030617
BR 2003011840	A	20050315	BR 2003-11840	20030617
EP 1517680	A1	20050330	EP 2003-732715	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662230	A	20050831	CN 2003-814319	20030617
JP 2006502105	T	20060119	JP 2004-515010	20030617
NZ 536972	A	20060630	NZ 2003-536972	20030617
NO 2004005222	A	20050119	NO 2004-5222	20041129
ZA 2004009690	A	20051011	ZA 2004-9690	20041130
IN 2004DN03844	A	20070427	IN 2004-DN3844	20041203
MX 2004PA12694	A	20050323	MX 2004-PA12694	20041215
US 2005267149	A1	20051201	US 2004-518819	20041220

PRIORITY APPLN. INFO.: SE 2002-1937 A 20020620
WO 2003-GB2598 W 20030617

OTHER SOURCE(S): MARPAT 140:76898
GI

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [R1 = (un)substituted aryl, alkyl, acyl, etc.; (CH2)m-T-(CH2)n-U-(CH2)p = attached at either the meta or para position (to V) and is O(CH2)2, O(CH2)3, etc.; V = O, S, amino, single bond; q = 1-3; W = O, S, amido, amino, single bond; R2 = halo, alkyl, alkoxy, etc.; r = 0-3; R3 = halo, alkyl, alkoxy, etc.; s = 0-3; with some provisions] are prepared For instance, tert-Bu [3-[[[(1,1'-biphenyl-4-yl)carbonyl]amino]methyl]phenyl]carbamate (preparation given) is deprotected (CH2Cl2, TFA) and alkylated with 3-carboxybenzaldehyde (HOAc, NaBH4) to give II. Compds. of the invention have an EC50 < 50μmol/L for PPAR-α and PPAR-γ. I are useful in treating clin. conditions associated with insulin resistance.

IT 637358-31-7P, 2-[[4-[2-Oxo-2-[[[4-(trifluoromethyl)benzyl]amino]ethyl]phenoxy]methyl]benzoic acid 637358-44-2P, 2-[[4-[3-[[2-(3,4-Dimethoxyphenyl)ethyl](methyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637358-47-5P, 2-[[4-[2-[[[4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid 637358-49-7P

2-[[4-[2-[[[(2,4-Difluorophenyl)amino]carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid 637358-51-1P, 2-[[4-[2-[[(2-Methyl-5-phenylfuran-3-yl)carbonyl]amino]ethyl]phenoxy]methyl]benzoic acid 637358-53-3P, 2-[[4-[2-[(Benzylsulfonyl)amino]ethyl]phenoxy]methyl]benzoic acid 637358-56-6P, 2-[[4-[2-[Benzyl(hexyl)amino]-2-oxoethyl]-2-fluorophenoxy]methyl]benzoic acid 637358-59-9P, 2-[[4-[2-[Benzyl(hexyl)amino]-2-oxoethyl]-2-methoxyphenoxy]methyl]benzoic

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
acid 637358-62-4P, 2-[[4-[3-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-3-oxopropyl]phenoxy]methyl]benzoic acid 637358-66-8P, 2-[[4-[2-[4-(1H-Imidazol-1-yl)phenoxy]ethyl]phenoxy]methyl]benzoic acid 637358-70-4P, 2-[[4-[2-[4-[(Methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]benzoic acid 637358-79-3P, 2-[[4-[3-[4-(Benzyloxy)phenoxy]propyl]phenoxy]methyl]benzoic acid 637358-82-8P, 2-[[4-[3-[4-[(Methylsulfonyl)oxy]phenoxy]propyl]phenoxy]methyl]benzoic acid 637358-83-9P, 2-[[4-[3-(4-Hydroxyphenoxy)propyl]phenoxy]methyl]benzoic acid 637358-86-2P, 2-[[4-[3-[[2-(2-Ethoxyphenyl)ethyl]amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637358-89-5P, 2-[[4-[3-[Ethyl(2-(pyridin-2-yl)ethyl)amino]-3-oxopropyl]phenoxy]methyl]benzoic acid 637358-90-8P, 2-[[4-[2-[Heptyl[2-(2-methoxyphenyl)ethyl]amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637359-01-4P, 2-[[4-[2-[[2-(4-Chlorophenyl)ethyl](heptyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637359-04-7P, 2-[[4-[2-[Heptyl(2-phenylethyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637359-07-0P, 2-[[4-[2-[Ethyl(2-fluorobenzyl)amino]-2-oxoethoxy]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoic acid derivs. as modulators of PPAR-α and PPAR-γ)

RN 637358-31-7 CAPLUS
CN Benzoic acid, 2-[[4-[2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-44-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-47-5 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 637358-49-7 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-51-1 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 637358-53-3 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(phenylmethyl)sulfonyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 637358-70-4 CAPLUS
CN Benzoic acid, 2-[[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-79-3 CAPLUS
CN Benzoic acid, 2-[[4-[3-[4-(phenylmethoxy)phenoxy]propyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 637358-56-6 CAPLUS
CN Benzoic acid, 2-[[2-fluoro-4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-59-9 CAPLUS
CN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]-2-methoxyphenoxy]methyl]- (CA INDEX NAME)



RN 637358-62-4 CAPLUS
CN Benzoic acid, 2-[[4-[3-(3,4-dihydro-2(1H)-isoquinolinyl)-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-66-8 CAPLUS
CN Benzoic acid, 2-[[4-[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 637358-82-8 CAPLUS
CN Benzoic acid, 2-[[4-[3-[4-[(methylsulfonyl)oxy]phenoxy]propyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-83-9 CAPLUS
CN Benzoic acid, 2-[[4-[3-(4-hydroxyphenoxy)propyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-86-2 CAPLUS
CN Benzoic acid, 2-[[4-[3-[[2-(2-ethoxyphenyl)ethyl]amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637358-89-5 CAPLUS
CN Benzoic acid, 2-[[4-[3-[ethyl[2-(2-pyridinyl)ethyl]amino]-3-oxopropyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 637358-98-6 CAPLUS
CN Benzoic acid, 2-[[4-[2-[heptyl[2-(2-methoxyphenyl)ethyl]amino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637359-01-4 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[2-(4-chlorophenyl)ethyl]heptylamino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637359-04-7 CAPLUS
CN Benzoic acid, 2-[[4-[2-[heptyl(2-phenylethyl)amino]-2-oxoethyl]phenoxy]methyl]- (CA INDEX NAME)



RN 637359-07-0 CAPLUS
CN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-oxoethoxy]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 41 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:818385 CAPLUS
DOCUMENT NUMBER: 139:323344
TITLE: Preparation of aralkoxyphenoxyindanylcarboxylates as thyroid receptor ligands
INVENTOR(S): Rahimi-Ghadim, Mahmoud; Garg, Neeraj; Malm, Johan
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084915	A1	20031016	WO 2003-EP1304	20030210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481976	A1	20031016	CA 2003-2481976	20030210
AU 2003210234	A1	20031020	AU 2003-210234	20030210
EP 1492756	A1	20050105	EP 2003-745755	20030210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522476	T	20050728	JP 2003-582114	20030210
CN 1649819	A	20050803	CN 2003-809937	20030210
US 2005171104	A1	20050804	US 2005-510645	20050401
PRIORITY APPLN. INFO.:			GB 2002-8384 A	20020411
			WO 2003-EP1304 W	20030210

OTHER SOURCE(S): MARPAT 139:323344
GI



I

AB Title compds. [I; R1 = CO2H, PO(OH)2, PO(OH)NH2, SO2OH, CONHOH, NHCOCO2H, NHCOCH2CO2H, any other possible bioisosteric equivalent of the groups above; R2, R3 = Cl, Br, iodo, alkyl, (Ra-substituted) biosteric equivalent; R4, R6 = H, halo, alkyl, bioisosteric equivalent optionally substituted with Ra; R5 =

L6 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 41 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Rb-(substituted) aryl, heteroaryl; Ra = F, Cl; Rb = halo, CN, CO2H, CHO, NH2, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, alkylthio, alkenylthio, alkynylthio, aryl, heteroaryl, cycloalkyl, amino, bioisosteric equiv.; n = 1, 2, 3; stereoisomers thereof; prodrug ester forms thereof; and radioactive forms thereof], were prepd. as antagonists,
partial antagonists or partial agonists for the treatment of cardiac and metabolic disorders such as cardiac arrhythmias, thyrotoxicosis, subclin. hyperthyroidism, and liver diseases. Thus, Et [4,6-dibromo-5-(3-isopropyl-4-hydroxyphenoxy)indan-1-yl]acetate (prepn. given), K2CO3, and MeCN were stirred at room temp. for 30 min; 2-bromomethylnaphthalene in MeN was added and the reaction mixt. was stirred at 80° for 16 h to give 17% 4,6-dibromo-5-[3-isopropyl-4-(naphthalen-2-ylmethoxy)phenoxylindan-1-yl]acetic acid. I bound to the ThRα receptor with affinities in the range of 100-500 nM.

IT 612842-88-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aralkoxyphenoxyindanylcarboxylates as thyroid receptor ligands)

RN 612842-88-3 CAPLUS
CN 1H-Indene-1-acetic acid, 4,6-dibromo-5-[4-[[4-carboxyphenyl]methoxy]-3-(1-methylethyl]phenoxy]-2,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 42 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777749 CAPLUS
DOCUMENT NUMBER: 139:277029
TITLE: Preparation and formulation of menthol substituted antithrombotic PAI-1 inhibitors
INVENTOR(S): Bauer, Shawn; Mohan, Raju; Shaw, Kenneth J.; Wu, Qingyu; Ye, Bin; Buckman, Brad O.; Ghannam, Ameen; Griedel, Brian D.; Khim, Seock-Kyu; Zhao, Zuchun
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080564	A1	20031002	WO 2003-US7506	20030312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003222278	A1	20031008	AU 2003-222278	20030312
PRIORITY APPLN. INFO.:			US 2002-365932P	P 20020320
			WO 2003-US7506	W 20030312

OTHER SOURCE(S): MARPAT 139:277029
GI

L6 ANSWER 42 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Menthol-substituted compds. of formula I [R1 = H, alkyl, alkylene, aryl, haloalkyl, menthoxyalkyl, heterocyclo, absent; R2 = H, alkoxy, amino, alkylaminocarbonyl, alkyl, etc.; R3 = Ph, CO2H, alkoxy, etc.; R4 = dibenzodioxepinone, pyridinyl, etc.; A = carbonyl, absent; B = N, O, absent; AB = heterocyclo; D = N, O, absent; X = C, N; Y = alkylene, aryl, carbonyl, absent; DY = heterocyclo; Z = alkylene, sulfonyl, aminocarbonyl, carbonyl, absent; m, n, p = 0-2] are prepared which are useful as antithrombotic agents by inhibiting plasminogen activator inhibitor-1 (PAI-1). The compds. are useful in the treatment of disease-states characterized by thrombotic activity. Pharmaceutical compns. containing I are described. Thus, II was prepared from 4-nitrobenzylamine hydrochloride, menthoxyacetyl chloride and 2-hydroxy-3-carboxybenzaldehyde in 90% yield.

IT 606965-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of menthol derivs. as antithrombotic PAI-1 inhibitors)

RN 606965-78-0 CAPLUS
CN Benzoic acid, 4-[[4-[[[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]oxy]acetyl]amino]-3-(trifluoromethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 42 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:758370 CAPLUS
DOCUMENT NUMBER: 140:42982
TITLE: Bulk and surface properties of blends with semifluorinated polymers and block copolymers
AUTHOR(S): Pospiech, Doris; Haeussler, Liane; Jehnichen, Dieter; Kolling, Wolfram; Eckstein, Kathrin; Grundke, Karina
CORPORATE SOURCE: Institute of Polymer Research Dresden, Dresden, 01069, Germany
SOURCE: Macromolecular Symposia (2003), 198(7th European Symposium on Polymer Blends, 2002), 421-434
CODEN: MSYMEC; ISSN: 1022-1360
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The study relates to the development of extremely hydrophobic materials based on polysulfone that can be applied, for instance, as fouling-resistant membrane materials. The concept used is the addition of semifluorinated polymers to polysulfone in suitable blend compns. The influence of mol. parameters like chain structure of the semifluorinated polymer (segmented block copolymers, random copolymers) and segment mol. weight on the state of phase separation in the bulk and its influence on the surface properties have been systematically examined The segmented block copolymers with semifluorinated polyester segments having intermediate segment mol. weight are more suitable in blends with polysulfones than random polysulfone copolymers having semifluorinated side chains with respect to form homogeneous thin films (coatings) with highly non-wetting properties.

IT 635314-93-1
RL: POF (Polymer in formulation); PRP (Properties); USES (Uses)
(blends of semifluorinated polyesters and block copolymers with ultrahydrophobic properties)

RN 635314-93-1 CAPLUS
CN Poly(oxy-1,4-phenylenesulfonyl-1,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenylene), α-[4-[1-[4-[[3-carboxy-5-[(11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-heneicosafluoroeicosyl)oxy]benzoyl]oxy]phenyl]-1-methylethyl]phenyl]-ω-hydroxy-, α-ester with α-hydro-ω-hydroxypoly[oxy-1,4-phenyleneoxycarbonyl[5-[(11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-heneicosafluoroeicosyl)oxy]-1,3-phenylene]carbonyl] (1:1), diblock (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:396829 CAPLUS
DOCUMENT NUMBER: 138:401499
TITLE: Preparation of benzophenone derivatives as AP-1 inhibitors for treatment of arthritis
INVENTOR(S): Hirono, Shuichi; Shiozawa, Shunichi; Chaki, Hisaaki; Kotsubo, Hironori; Tanaka, Tadashi; Aikawa, Yukihiko
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 258 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042150	A1	20030522	WO 2002-JP11846	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2467261	A1	20030522	CA 2002-2467261	20021113
AU 2002349777	A1	20030526	AU 2002-349777	20021113
EP 1445249	A1	20040811	EP 2002-781763	20021113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014177	A	20040914	BR 2002-14177	20021113
HU 2004002025	A2	20050228	HU 2004-2025	20021113
NZ 532810	A	20050324	NZ 2002-532810	20021113
CN 1602291	A	20050330	CN 2002-824812	20021113
ZA 2004003373	A	20051118	ZA 2004-3373	20021113
CN 101054345	A	20071017	CN 2007-10101148	20021113
IN 2004KN00591	A	20060421	IN 2004-KN591	20040505
MX 2004PA04654	A	20050517	MX 2004-PA4654	20040514
NO 2004002495	A	20040811	NO 2004-2495	20040615
US 2005113400	A1	20050526	US 2004-493223	20041215

PRIORITY APPLN. INFO.: JP 2001-351217 A 20011116
JP 2002-209382 A 20020718
CN 2002-824812 A3 20021113
WO 2002-JP11846 W 20021113

OTHER SOURCE(S): MARPAT 138:401499
GI

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [wherein R1 = (un)substituted heterocyclyl, Ph, or alkyl; Z = (un)substituted alkylene; R2 = (un)substituted heterocyclyl(carbonyl) or CO2H; R3 = H, halo, CN, NO2, SH, carbamoyl, (un)substituted CO2H, OH, NH2, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy, acyl, alkoxy-CO, aryloxy-CO, alkylthio, alkyl-SO, alkyl-SO2, alkylamino, acylamino, alkyl-SO2-amino, aryl-SO2-amino, or heterocyclyl; R4 = (un)substituted alkoxy, cycloalkyloxy, cycloalkenyloxy, alkyl, cycloalkyl, or heterocyclyl(oxy); R5 = H, halo, or OH; with provisos] and salts thereof are prepared as AP-1 inhibitors for the treatment of autoimmune diseases and chronic articular rheumatism. For example, the benzophenone derivative II was prepared in a multi-step synthesis. II showed IC50 of 110 μM against AP-1.

IT 530141-70-9P 530141-81-2P 530141-85-6P 530141-99-2P 530142-08-6P 530142-09-7P 530143-44-3P 530143-45-4P 530143-51-2P 530143-52-3P 530143-54-5P 530143-55-6P 530143-58-9P 530143-59-0P 530143-60-3P 530143-61-4P 530143-63-6P 530143-64-7P 530143-65-8P 530143-69-2P 530143-70-5P 530143-72-7P 530143-73-8P 530143-74-9P 530143-76-1P 530143-77-2P 530143-82-9P 530143-83-0P 530143-84-1P 530143-85-2P 530143-86-3P 530143-87-4P 530143-88-5P 530143-89-6P 530143-90-9P 530143-92-1P 530143-93-2P 530143-94-3P 530143-95-4P 530143-96-5P 530143-98-7P 530143-99-8P 530144-00-4P 530144-02-6P 530144-04-8P 530144-35-5P 530144-43-5P 530144-60-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(AP-1 inhibitor; preparation of benzophenone derivs. as AP-1 inhibitors for

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
treatment of arthritis)

RN 530141-70-9 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-2-hydroxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530141-81-2 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530141-85-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-3-methoxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530141-99-2 CAPLUS
CN Benzenepropanoic acid, 5-[2-(acetyloxy)-4-(2-methylpropoxy)benzoyl]-2-[(4-carboxyphenyl)methoxy]-, α-methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530142-08-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-, α-ethyl ester (9CI) (CA INDEX NAME)



RN 530142-09-7 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]-, α-ethyl ester (9CI) (CA INDEX NAME)



RN 530143-44-3 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-3-methylphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-54-5 CAPLUS
CN Benzenepropanoic acid, 2-[1-(4-carboxyphenyl)ethoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-55-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(3-cyclopenten-1-yloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)

RN 530143-58-9 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-thienyl)benzoyl]- (CA INDEX NAME)



RN 530143-59-0 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-fluorobenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-45-4 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-2-methylphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-51-2 CAPLUS
CN Benzenepropanoic acid, 5-[2,4-bis(2-methylpropoxy)benzoyl]-2-[(4-carboxyphenyl)methoxy]- (CA INDEX NAME)



RN 530143-52-3 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-methoxybenzoyl]- (CA INDEX NAME)



L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-60-3 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(3-methylbutoxy)benzoyl]- (CA INDEX NAME)



RN 530143-61-4 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(2,2-dimethylpropoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-63-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclohexyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-64-7 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-2-(methoxymethoxy)phenyl]methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-65-8 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentylmethyl)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-69-2 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(1-methylethyl)benzoyl]- (CA INDEX NAME)



RN 530143-70-5 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-[(1-methylcyclopentyl)methyl]benzoyl]- (CA INDEX NAME)



RN 530143-72-7 CAPLUS

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-77-2 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(phenylmethoxy)benzoyl]- (CA INDEX NAME)



RN 530143-82-9 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-(4-cyclopentyl-2-hydroxybenzoyl)- (CA INDEX NAME)



RN 530143-83-0 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(2-furanylmethoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-84-1 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-thienylmethoxy)benzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentylmethoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-73-8 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(3-pyridinylmethoxy)benzoyl]- (CA INDEX NAME)



RN 530143-74-9 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-3,5-dimethoxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-76-1 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclobutyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-85-2 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-3-fluorophenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-86-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 4-[[2-(2-carboxyethyl)-4-[4-(cyclopentyloxy)-2-hydroxybenzoyl]phenoxy]methyl]- (CA INDEX NAME)



RN 530143-87-4 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(2-methylpropoxy)benzoyl]- (CA INDEX NAME)



RN 530143-88-5 CAPLUS
CN Benzenepropanoic acid, 2-[[4-carboxy-2-(1-methylethoxy)phenyl]methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-89-6 CAPLUS
CN Benzenepropanoic acid, 2-[[4-carboxy-3-(2-methylpropoxy)phenyl]methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-90-9 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]- (CA INDEX NAME)



RN 530143-92-1 CAPLUS
CN Benzenepropanoic acid, 2-[(3-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-96-5 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-methylbenzoyl]- (CA INDEX NAME)



RN 530143-98-7 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(1-ethylpropoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-99-8 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclohexylmethoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530143-93-2 CAPLUS
CN Benzenepropanoic acid, 2-[(2-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]- (CA INDEX NAME)



RN 530143-94-3 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxy-2-fluorophenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530143-95-4 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-fluoro-6-hydroxybenzoyl]- (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530144-00-4 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cyclopropylmethoxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530144-02-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[4-(cycloheptyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



RN 530144-04-8 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(pyrazinylmethoxy)benzoyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 530144-35-5 CAPLUS
CN Benzoic acid, 4-[[4-[2-hydroxy-4-(2-methylpropoxy)benzoyl]-2-[2-(1H-tetrazol-5-yl)ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L6 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 530144-43-5 CAPLUS
CN Benzenepropanoic acid, 5-[4-[(4-carboxyphenyl)methoxy]-2-hydroxybenzoyl]-2-(2-methylpropoxy)- (CA INDEX NAME)



RN 530144-60-6 CAPLUS
CN Benzenepropanoic acid, 2-[(4-carboxyphenyl)methoxy]-5-[2-hydroxy-4-(2-methylpropoxy)benzoyl]-, α-methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:368604 CAPLUS
DOCUMENT NUMBER: 138:362668
TITLE: Cosalane compounds and methods for their use
INVENTOR(S): Cushman, Mark S.; Howard, O. M. Zack
PATENT ASSIGNEE(S): Purdue Research Foundation, USA; The United States of America as Represented by the Department of Health and Human Services
SOURCE: U.S., 17 pp., Cont. of U.S. Ser. No. 726,101abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6562805	B1	20030513	US 2001-771769	20010129
US 2003212045	A1	20031113	US 2003-436845	20030513
US 7122533	B2	20061017		
PRIORITY APPLN. INFO.:			US 1999-167874P P	19991129
			US 2000-726101 B1	20001129
			US 1999-167864P P	19991129
			US 2001-771769 A3	20010129

OTHER SOURCE(S): MARPAT 138:362668

AB The present invention relates to methods, compds. and compns. for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof. The invention further relates to methods, compds. and compns. for treating inflammatory diseases. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof.

IT 229948-56-5 229948-57-6 229948-58-7
329328-09-8 521918-99-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosalane compds. and methods for their use to inhibit binding of chemokines to cellular receptors and thus inhibit cellular migration in relation to treatment of inflammatory diseases)

RN 229948-56-5 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-57-6 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



●4 Na

RN 229948-58-7 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



●4 Na

RN 329328-09-8 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



●2 Na

RN 521918-99-0 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxy-2-methoxyphenyl)methoxy]-5-chloro-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



●2 Na

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 46 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:364617 CAPLUS
DOCUMENT NUMBER: 139:117898
TITLE: Structural origin of the enhanced electro-optic response of dendrimer systems
AUTHOR(S): Pereverzev, Yuriy V.; Prezhdo, Oleg V.; Dalton, Larry R.
CORPORATE SOURCE: Department of Chemistry, University of Washington, Seattle, WA, 98195-1700, USA
SOURCE: Chemical Physics Letters (2003), 373(1,2), 207-212
CODEN: CHPLBC; ISSN: 0009-2614
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The correlation between structure and enhanced electro-optic (EO) activity of NLO dendrimer having phenylene(tetracyanobutadienyl)thiophenylstilbene chromophore group moieties was studied and compared to that of a guest-host polymer system. Chemical bonding between the chromophore fragments in the dendrimer suppresses the antiferroelec. correlation of the chromophore dipoles and assists in the macroscopic ordering of the dipoles by an applied field. The developed analytic model quant. agrees with the exptl. data both for the increased EO coefficient of the cross-linkable dendrimer, and the decreased EO coefficient of the non-cross-linkable dendrimer. The model facilitates optimization of the structural and mol. properties of dendrimers and chromophore fragments to achieve materials with better EO response.

IT 330982-78-0
RL: PRP (Properties)
(core; role of mol. structure on enhanced electrooptic response of phenylene-cyanobutadienyl-thiophenylstilbene dendrimer)

RN 330982-78-0 CAPLUS
CN Benzoic acid, 4,4',4''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR

L6 ANSWER 46 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 47 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:356419 CAPLUS
DOCUMENT NUMBER: 138:368770
TITLE: Preparation of pyridinylethylamines and amides as anticancer drugs.
INVENTOR(S): Menon, Sanjay R.; Lu, Yingchun; Sakamuri, Sukumar; Chen, Quin-Zene; Khazak, Vladimir; Agarwal, Seema
PATENT ASSIGNEE(S): Morphochem Aktiengesellschaft fuer Kombinatorische Chemie, Germany
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037865	A1	20030508	WO 2002-EP12222	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468761	A1	20030508	CA 2002-2468761	20021031
AU 2002351814	A1	20030512	AU 2002-351814	20021031
EP 1442018	A1	20040804	EP 2002-787539	20021031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005228017	A1	20051013	US 2005-497449	20050330
PRIORITY APPLN. INFO.:			US 2001-335300P	P 20011031
			WO 2002-EP12222	W 20021031

OTHER SOURCE(S): MARPAT 138:368770
AB (R3Y)(R1X)NUR2 [n = 0-5; X, Y = CH2, CO, SO2, CONH; R1 = (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; R2 = (substituted) heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, heteroarylalkyl, aralkyl], were prepared Thus, N-(4-benzyloxy-3-methoxybenzyl)-N-(2-pyridin-2-ylethyl)amine (preparation given) in ClCH2CH2Cl was treated with polymer-supported morpholine and 2-chlorobenzoyl chloride followed by stirring for 24 h. Polymer-supported isocyanate, polymer-supported tris(2-aminoethyl)amine, and ClCH2CH2Cl were added followed by stirring for 24 h to give 84% N-(4-benzyloxy-3-methoxybenzyl)-N-(2-pyridin-2-ylethyl)-2-chlorobenzamide. Title compds. showed IC50's of

L6 ANSWER 47 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
5-60 μM in secondary luciferase assays in NIH3T3, CHO, or HEK293 cells.
IT 521312-33-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyridinylethylamines and amides as anticancer drugs)
RN 521312-33-4 CAPLUS
CN Benzoic acid, 4-[[4-[[(2-chlorobenzoyl)[2-(2-pyridinyl)ethyl]amino]methyl]-2-methoxyphenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 48 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:352159 CAPLUS
DOCUMENT NUMBER: 138:354246
TITLE: Preparation of benzenes as bone resorption inhibitors for treatment of osteoporosis
INVENTOR(S): Fujimoto, Katsumi; Shibata, Tomoyuki; Nakamura, Yuji; Echigo, Yuki
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 179 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003128640	A	20030508	JP 2001-327592	20011025
PRIORITY APPLN. INFO.:			JP 2001-327592	20011025

OTHER SOURCE(S): MARPAT 136:354246
AB 4-R1R2COC6H4ACOR3 [I: R1 = (un)substituted Ph; R2 = H, CO2H, (C1-6 alkoxy)carbonyl, tetrazol-5-yl; R3 = Glu-Glu-Ile-Glu (the N-terminal is linked to the ACO), NHCHR4C6H3(3-CONH2)(4-OZ); R4 = H, (un)substituted C1-6 alkyl, aralkyl; Z = cyclohexylmethyl; A = bond, [(C1-6 alkanoyl)amino-substituted] C1-4 alkylene], their esters, or pharmacol. acceptable salts are prepared Thus, acetyl-4-[tert-butoxycarbonyl-(4-methoxymethoxy-3-nitrophenyl)methoxy]phenylalanine Me ester was hydrolyzed, coupled with H-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-OtBu, and deprotected to give I (R1 = 4-hydroxy-3-nitrophenyl, R2 = CO2H, A = CH2CHNHAc, R3 = Glu-Glu-Ile-Glu).
IT 518977-57-6P 518977-63-4P 518977-67-8P 518977-68-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenes as bone resorption inhibitors for treatment of osteoporosis)
RN 518977-57-6 CAPLUS
CN Benzeneacetic acid, α-[4-[(2S)-2-(acetylamino)-3-[[(1S)-1-[3-(aminocarbonyl)-4-(cyclohexylmethoxy)phenyl]ethyl]amino]-3-oxopropyl]phenoxy]-3-bromo-4-carboxy-2-hydroxy-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 48 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

RN 518977-63-4 CAPLUS
CN Benzenebutanoic acid, γ-[[(2S)-2-(acetylamino)-3-[4-[(S)-(3-bromo-4-carboxy-2-hydroxyphenyl)carboxymethoxy]phenyl]-1-oxopropyl]amino]-3-(aminocarbonyl)-4-(cyclohexylmethoxy)-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 518977-67-8 CAPLUS
CN Benzeneacetic acid, α-[4-[[[(1S)-1-[3-(aminocarbonyl)-4-(cyclohexylmethoxy)phenyl]ethyl]amino]carbonyl]phenoxy]-5-carboxy-2-hydroxy-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 48 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 518977-68-9 CAPLUS
CN Benzeneacetic acid, α-[4-[[[[3-(aminocarbonyl)-4-(cyclohexylmethoxy)phenyl]methyl]amino]carbonyl]phenoxy]-5-carboxy-2-hydroxy-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 49 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:302783 CAPLUS
DOCUMENT NUMBER: 138:321013
TITLE: Nitroso derivatives of diphenylamines having ether or thioether functions, with nitric oxide activity, diphenylamine intermediates with antioxidant activity, pharmaceutical compositions containing them, and their use for the preparation of drugs
INVENTOR(S): Lardy, Claude; Festal, Didier; Caputo, Lidia
PATENT ASSIGNEE(S): Lipha, Fr.
SOURCE: Fr. Demande, 46 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2830862	A1	20030418	FR 2001-13344	20011016
WO 2003033467	A1	20030424	WO 2002-EP10607	20020920
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002338747	A1	20030428	AU 2002-338747	20020920
PRIORITY APPLN. INFO.:			FR 2001-13344 A	20011016
			WO 2002-EP10607 W	20020920

OTHER SOURCE(S): MARPAT 138:321013
GI

L6 ANSWER 49 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





AB The invention relates to nitrosodiphenylamines I and diphenylamines II [in which: W = O or S; R1 = (un)saturated, (un)substituted, (non)aromatic carbo- or heterocyclic radical, -E-Q or -E-Ar, or aliphatic hydrocarbyl with optional substitution; E = (un)substituted alkylene or alkenylene; Q = amino optionally substituted by 1 or 2 (un)saturated aliphatic hydrocarbyl groups; Ar = (un)saturated, (un)substituted, (non)aromatic carbo- or heterocyclic radical; R2 = halo, (un)saturated aliphatic hydrocarbon (optionally interrupted by O or S and optionally halogenated), nitro, CO2H, or cyano; n = 0-5, preferably 0-2; with exclusion of case: I (n = 1, R1 = Me, R2 = 2-Me)] and their acid or base addition salts. I are useful for treatment of pathologies characterized by a deficiency of production of NO and/or a situation of oxidative stress. II are useful both as intermediates to I, and in their own right as antioxidants functioning as free radical traps. A table of 35 I and 35 II were prepared For example, etherification of 4-[(4-methoxyphenyl)amino]phenol with 3-(chloromethyl)pyridine HCl in the presence of Cs2CO3 in Me2CO gave 64.2% II [W = O, R1 = 3-pyridyl, R2 = 4-OMe, n = 1] (III). A solution of III in AcOH was treated with aqueous NaNO2 for 3 h at room temperature to give 95.6% I [W = O, R1 = 3-pyridyl, R2 = 4-OMe, n = 1] (IV). Solns. of I spontaneously released NO, with the measured concentration of nitrites and nitrates being as high as 92 μM in the case of IV. Both III and IV showed antioxidant activity in a human LDL oxidation assay in vitro, with IC50 values of 4.6 and 6.7 μM, resp. Preferred examples include the four compds. I [R1 = 3-pyridyl; W = O, (R2)n = 4-cyano, 3-cyano, or 4-chloro; W = S, (R2)n = 4-OMe].

IT 512834-18-3P, 4-[[4-(1-(4-Methoxyphenyl)-2-oxohydrazino]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of nitrosodiphenylamines and diphenylamines with ether or thioether functions as NO donor drugs and/or antioxidants)

RN 512834-18-3 CAPLUS
CN Benzoic acid, 4-[[4-[(4-methoxyphenyl)nitrosoamino]phenoxy]methyl]- (CA INDEX NAME)



IT 512834-53-6P, 4-[[4-[(4-Methoxyphenyl)amino]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate and drug candidate; preparation of nitrosodiphenylamines and diphenylamines with ether or thioether functions as NO donor drugs and/or antioxidants)

RN 512834-53-6 CAPLUS
CN Benzoic acid, 4-[[4-[(4-methoxyphenyl)amino]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 50 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:156728 CAPLUS
DOCUMENT NUMBER: 139:22516
TITLE: Mesogenic V-Like Triad on the Basis of 3,4-Dihydroxybenzophenone
AUTHOR(S): Demina, E. V.; Bol'shakov, M. N.; Klimova, N. V.; Rudaya, L. I.; Yurre, T. A.; Shamanin, V. V.; Skorokhodov, S. S.
CORPORATE SOURCE: St. Petersburg State Institute of Technology, St. Petersburg, 198013, Russia
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2002), 38(12), 1810-1811
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3,4-Bis(4-carboxybenzoyloxy)benzophenone, which can be regarded as a rigid mesogenic V-like triad having a photoactive and chemical reactive group, was prepared by reaction of 3,4-dihydroxybenzophenone with benzyl 4-chloroformylbenzoate in aqueous organic medium in the presence of phase transfer catalyst to give 3,4-bis(4-benzyloxycarbonylbenzoyloxy)benzopheno ne (I), followed by debenzylation of I.

IT 537712-38-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of bis(4-carboxybenzoyloxy)benzophenone mesogenic V-like triad on basis of 3,4-dihydroxybenzophenone)

RN 537712-38-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-benzoyl-1,2-phenylene ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 51 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:156363 CAPLUS
DOCUMENT NUMBER: 138:385118
TITLE: Mesogenic triad with a benzoyl group
AUTHOR(S): Bol'shakov, M. N.; Klimova, N. V.; Rudaya, L. I.; Yurre, T. A.; Shamanin, V. V.; Skorokhodov, S. S.
CORPORATE SOURCE: Institute of High-Molecular Compounds, Russian Academy of Sciences, St. Petersburg, 199004, Russia
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2002), 38(10), 1540-1541
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:385118

AB Reaction of 2,5-(HO)2C6H3COPh and BnO2CC6H4COCl-4 in presence of a phase-transfer catalyst led to formation of 2,5-bis(4-benzyloxycarbonylbenzoyloxy)benzophenone. Debenzylation of the ester gave 2,5-bis(4-carboxybenzoyloxy)benzophenone, a rigid mesogenic triad.

IT 524951-01-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of mesogenic triad with a benzoyl group)

RN 524951-01-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-benzoyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 52 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:111127 CAPLUS
DOCUMENT NUMBER: 138:138920
TITLE: Crosslinked polyimide varnish and its preparation by imidation of polyamic acid
INVENTOR(S): Kuroki, Takashi; Abe, Takaharu; Tamai, Masashi
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003041189	A	20030213	JP 2001-224288	20010725
PRIORITY APPLN. INFO.:			JP 2001-224288	20010725

GI



AB Polyimide varnish with good heat and chemical resistance and high decomposition temperature is prepared by heat treatment of linear amino-terminated polyamic acid with structure I, in which R1-2 = H, alkyl, and Ph, Z = trivalent or tetravalent aromatic group, n = 3 or 4. Thus, 4,4-bis(3-aminophenyloxy)biphenyl and bis(3,4-dicarboxyphenyl)ether dianhydride were reacted to obtain amino-terminated polyamic acid, and then crosslinked by a three-functional crosslinking agent prepared from a trimanhydride and methanol to receive crosslinked polyimide varnish with Tg of 212° and decomposition temperature of 546°.

IT 494770-98-8P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(crosslinking agent; preparation of crosslinked polyimide varnish from imidation of polyamic acid)

RN 494770-98-8 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 4,4',4''-(ethylidynetri-4,1-phenylene) ar,ar',ar''-trimethyl ester (9CI) (CA INDEX NAME)

CM 1

CRN 494770-97-7
CMF C47 H30 O18

L6 ANSWER 52 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 67-56-1
CMF C H4 O

IT 494770-99-9P
RL: IMF (Industrial manufacture); POF (Polymer in formulation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation of crosslinked polyimide varnish from imidation of polyamic acid)

RN 494770-99-9 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 4,4',4''-(ethylidynetri-4,1-phenylene) ar,ar',ar''-trimethyl ester, polymer with 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(oxy)]bis[benzenamine] and 5,5'-oxybis[1,3-isobenzofurandione] (9CI) (CA INDEX NAME)

CM 1

CRN 105112-76-3
CMF C24 H20 N2 O2



L6 ANSWER 52 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 2

CRN 1823-59-2
CMF C16 H6 O7



CM 3

CRN 494770-98-8
CMF C50 H36 O18
CCI IDS

CM 4

CRN 494770-97-7
CMF C47 H30 O18



CM 5

CRN 67-56-1

L6 ANSWER 52 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C H4 O

L6 ANSWER 53 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:89888 CAPLUS
DOCUMENT NUMBER: 138:265143
TITLE: Non-Peptide Angiotensin II Receptor Antagonists: Chemical Feature Based Pharmacophore Identification
AUTHOR(S): Krovat, Eva M.; Langer, Thierry
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Innsbruck, A-6020, Austria
SOURCE: Journal of Medicinal Chemistry (2003), 46(5), 716-726
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Chemical feature based pharmacophore models were elaborated for angiotensin II receptor subtype 1 (AT1) antagonists using both a quant. and a qual. approach (Catalyst HypoGen and HipHop algorithms, resp.). The training sets for quant. model generation consisted of 25 selective AT1 antagonists exhibiting IC50 values ranging from 1.3 nM to 150 μM. Addnl., a qual. pharmacophore hypothesis was derived from multiconformational structure models of two highly active AT1 antagonists. In the case of the quant. model, the best pharmacophore hypothesis consisted of a five-features model (Hypo1: seven points, one hydrophobic aromatic, one hydrophobic aliphatic, a hydrogen bond acceptor, a neg. ionizable function, and an aromatic plane function). The best qual. model consisted of seven features (Hypo2: 11 points, two aromatic rings, two hydrogen bond acceptors, a neg. ionizable function, and two hydrophobic functions). The obtained pharmacophore models were validated on a wide set of test mols. They were shown to be able to identify a range of highly potent AT1 antagonists, among those a number of recently launched drugs and some candidates presently undergoing clin. tests and/or development phases. The results of the authors study provide confidence for the utility of the selected chemical feature based pharmacophore models to retrieve structurally diverse compds. with desired biol. activity by virtual screening.

IT 114799-48-3
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(non-peptide angiotensin II receptor antagonists and chemical feature based pharmacophore identification)

RN 114799-48-3 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 53 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 54 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:34396 CAPLUS
DOCUMENT NUMBER: 138:229415
TITLE: Solid-state self-assembly of 1,4-bis(2-carboxybenzyloxy)benzene in the presence and absence of aromatic amines
AUTHOR(S): Liu, Rong; Valiyaveettil, Suresh; Mok, Kum-Fun; Vittal, Jagadese J.; Hoong, Angelia Kar Min
CORPORATE SOURCE: Department of Chemistry, National University of Singapore, 117 543, Singapore
SOURCE: CrystEngComm (2002), 4, 574-579
CODEN: CRECF4; ISSN: 1466-8033
URL: http://www.rsc.org/CFCart/displayarticleeonfree.cfm?article=8%2D9%223%24%5DVZB%214%2E%5FL5%286%2CO%5B4%5D%5C1P%25%24%3D29%23%3C%0A
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB Solid-state self-assembly of 1,4-bis(2-carboxybenzyloxy)benzene and its stoichiometric complexes with diamines such as 4,4'-bipyrydyl and 1,2-bis(4-pyridyl)ethylene are described with complete structural details. Carboxylic acid dimer formation and O-H···N-type H bonds were the major H bonding motifs in the crystal lattice. A wave-type topol. was observed for the H bonded chains.
IT 500904-56-3P, 1,4-Bis(2-carboxybenzyloxy)benzene
500904-57-4P, 1,4-Bis(2-carboxybenzyloxy)benzene compound with 4,4'-bipyrydyl (1:1) 500904-58-5P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation, crystal growth, crystal structure and solid-state self-assembly via hydrogen bonding of)
RN 500904-56-3 CAPLUS
CN Benzoic acid, 2,2'-[1,4-phenylenebis(oxymethylene)]bis- (9CI) (CA INDEX NAME)



RN 500904-57-4 CAPLUS
CN Benzoic acid, 2,2'-[1,4-phenylenebis(oxymethylene)]bis-, compd. with 4,4'-bipyridine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 500904-56-3

L6 ANSWER 54 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 54 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C22 H18 O6



CM 2

CRN 553-26-4
CMF C10 H8 N2



RN 500904-58-5 CAPLUS
CN Benzoic acid, 2,2'-[1,4-phenylenebis(oxymethylene)]bis-, compd. with 4,4'-(1E)-1,2-ethenediylbis[pyridine] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 500904-56-3
CMF C22 H18 O6



CM 2

CRN 13362-78-2
CMF C12 H10 N2

Double bond geometry as shown.

L6 ANSWER 55 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:810885 CAPLUS
DOCUMENT NUMBER: 138:32795
TITLE: Structure-Based Design of Selective Agonists for a Rickets-Associated Mutant of the Vitamin D Receptor
AUTHOR(S): Swann, Steve L.; Bergh, Joel; Farach-Carson, Mary C.; Ocasio, Cory A.; Koh, John T.
CORPORATE SOURCE: Department of Chemistry and Biochemistry and the Department of Biological Sciences, University of Delaware, Newark, DE, 19716, USA
SOURCE: Journal of the American Chemical Society (2002), 124(46), 13795-13805
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:32795
AB The nuclear and steroid hormone receptors function as ligand-dependent transcriptional regulators of diverse sets of genes associated with development and homeostasis. Mutations to the vitamin D receptor (VDR), a member of the nuclear and steroid hormone receptor family, have been linked to human vitamin D-resistant rickets (hVDRR) and result in high serum 1,25(OH)2D3 concns. and severe bone underdevelopment. Several hVDRR-associated mutants have been localized to the ligand binding domain of VDR and cause a reduction in or loss of ligand binding and ligand-dependent transactivation function. The missense mutation Arg 274 → Leu causes a >1000-fold reduction in 1,25(OH)2D3 responsiveness and is, therefore, no longer regulated by physiol. concns. of the hormone. In this study, computer-aided mol. design was used to generate a focused library of nonsteroidal analogs of the VDR agonist LG190155 that were uniquely designed to complement the Arg 274 → Leu associated with hVDRR. Half of the designed analogs exhibit substantial activity in the hVDRR-associated mutant, whereas none of the structurally similar control compds. exhibited significant activity. The seven most active designed analogs were more than 16 to 526 times more potent than 1,25(OH)2D3 in the mutant receptor (EC50 = 3.3-121 nM). Significantly, the analogs are selective for the nuclear VDR and did not stimulate cellular calcium influx, which is associated with activation of the membrane-associated vitamin D receptor.
IT 478537-04-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-based design of selective agonists for rickets-associated mutant of vitamin D receptor)
RN 478537-04-1 CAPLUS
CN Benzoic acid, 4-[[4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methylphenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 55 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 56 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:736254 CAPLUS
DOCUMENT NUMBER: 137:263064
TITLE: Preparation of triazaspiro[5.5]undecane derivatives as
the active ingredients useful in prevention or as remedy for HIV infection
INVENTOR(S): Mitsuya, Hiroaki; Maeda, Kenji; Shibayama, Shiro; Takaoka, Yoshikazu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 680 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074769	A1	20020926	WO 2002-JP2553	20020318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441162	A1	20020926	CA 2002-2441162	20020318
AU 2002238946	A1	20021003	AU 2002-238946	20020318
EP 1378509	A1	20040107	EP 2002-705300	20020318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008229	A	20040309	BR 2002-8229	20020318
HU 2004000241	A2	20040628	HU 2004-241	20020318
CN 1533390	A	20040929	CN 2002-809833	20020318
NZ 528270	A	20051028	NZ 2002-528270	20020318
NO 2003004149	A	20031119	NO 2003-4149	20030917
ZA 2003007318	A	20040729	ZA 2003-7318	20030918
MX 2003PA08528	A	20040630	MX 2003-PA8528	20030919
US 2004106619	A1	20040603	US 2003-472626	20030922
US 7285552	B2	20071023		

PRIORITY APPLN. INFO.: JP 2001-79611 A 20010319
WO 2002-JP2553 W 20020318

OTHER SOURCE(S): MARPAT 137:263064
GI

L6 ANSWER 56 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, COOH, SO2H, CONH2, CHO, heterocycle, aryl; R2 = alkyl, alkynyl; R3, R4 independently = H, alkyl, alkenyl, alkynyl, COOH, CONH2; R5 = H, alkyl, alkenyl, alkynyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts of the same optionally combined with at least one preventive and/or remedy for HIV infection are prepared as preventives and/or remedies for HIV infection or preventives and/or remedies for AIDS caused by the infection. Thus, the title compound II·2HCl was prepared from N-(tert-butyloxycarbonyl)leucine, N-allyloxycarbonyl-4-piperidine, n-propylamine, and 3,5-dimethyl-1-phenyl-4-formyl-pyrazole via cyclization, on resin prepared from aminomethylated polystyrene hydrochloride.
IT 343275-25-2P 343276-41-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazaspiro[5.5]undecane derivs. as the active ingredients in prevention or remedy of HIV infection)
RN 343275-25-2 CAPLUS
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(2-methylpropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 56 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 343276-41-5 CAPLUS
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 57 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:691399 CAPLUS
DOCUMENT NUMBER: 137:216748
TITLE: Substituted aminobenzoic acid derivatives for competitive inhibitors for VEGF receptors
INVENTOR(S): Wada, Hisaya; Asanuma, Hajime; Takayama, Tetsuo; Sato, Masakazu; Yamagishi, Takehiro; Shibuya, Masashi
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002255916	A	20020911	JP 2001-353074	20011119
PRIORITY APPLN. INFO.:			JP 2000-395412 A	20001226

OTHER SOURCE(S): MARPAT 137:216748
AB Compds. R2C6H3(CO2R1)NR3CO(CH2)nX-p-C6H4OR4 are prepared, where R1 = H, C1-6 alkyl or benzyl groups, R2 = H, halogens, Me, alkoxy, amines, R3 = H, C1-6 alkyl, R4 = C14-20 alkyl, X = a single bond or CO, and n = 1 or 2. Thus, Me 5-amino-2-fluorobenzoate reacted with 4-(octadecyloxy)phenylacetic acid in the presence of condensing agent to prepare the corresponding amide.
IT 457656-41-6P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted aminobenzoic acid derivs. for competitive inhibitors for VEGF receptors)
RN 457656-41-6 CAPLUS
CN Benzoic acid, 2-[[(4-carboxyphenyl)methoxy]-5-[[3-[4-(octadecyloxy)phenyl]-1-oxopropyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Me

L6 ANSWER 57 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 58 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:575041 CAPLUS
DOCUMENT NUMBER: 137:140338
TITLE: Preparation of aminoethanol derivatives as cholesteryl ester transfer protein inhibitors for treatment of hyperlipidemia, etc.
INVENTOR(S): Kori, Masakuni; Hamamura, Kazumasa; Fuse, Hiromitsu; Yamamoto, Toshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 748 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059077	A1	20020801	WO 2002-JP532	20020125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002228349	A1	20020806	AU 2002-228349	20020125
JP 2002293764	A	20021009	JP 2002-17487	20020125
EP 1362846	A1	20031119	EP 2002-710345	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004127574	A1	20040701	US 2003-470351	20030725
US 6982348	B2	20060103		
PRIORITY APPLN. INFO.:			JP 2001-19280 A	20010126
			WO 2002-JP532 W	20020125

OTHER SOURCE(S): MARPAT 137:140338
AB The title compds. Ar1CH(OR'')CH(CH2Ar2)NR'R [Ar1 represents an optionally substituted aromatic ring group; Ar2 represents a substituted aromatic ring group; OR'' represents optionally protected hydroxy; R represents acyl; and R' represents hydrogen or optionally substituted hydrocarbyl] are prepared. Compds. of this invention in vitro showed IC50 values of 0.0084 nM to 0.4 nM against cholesteryl ester transfer protein. A process for preparing the title compds. is claimed.
IT 444918-62-1P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoethanol derivs. as cholesteryl ester transfer protein inhibitors for treatment of hyperlipidemia)
RN 444918-62-1 CAPLUS
CN Benzoic acid, 4-[[4-[(1R,2S)-2-[[(6,7-dihydro-5H-benzocyclohepten-1-yl)carbonyl]amino]-1-hydroxy-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]propyl]phenoxy]methyl]-, rel- (CA INDEX NAME)

L6 ANSWER 58 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Relative stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 59 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:428637 CAPLUS
DOCUMENT NUMBER: 137:20220
TITLE: Preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II
INVENTOR(S): Pelcman, Benjamin; Gustafsson, Annika; Kym, Philip R.
PATENT ASSIGNEE(S): Karo Bio AB, Swed.; Abbott Laboratories
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043648	A2	20020606	WO 2001-IB2302	20011128
WO 2002043648	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430311	A1	20020606	CA 2001-2430311	20011128
AU 200223105	A	20020611	AU 2002-23105	20011128
TR 200300763	T2	20040921	TR 2003-763	20011128
JP 2004536025	T	20041202	JP 2002-545627	20011128
BR 2001015750	A	20041207	BR 2001-15750	20011128
EP 1509188	A2	20050302	EP 2001-998301	20011128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
CN 1630515	A	20050622	CN 2001-819567	20011128
HU 2006000304	A2	20060828	HU 2006-304	20011128
ZA 2003003453	A	20050526	ZA 2003-3453	20030506
NO 2003002415	A	20030527	NO 2003-2415	20030527
MX 2003PA04658	A	20030904	MX 2003-PA4658	20030527
BG 107871	A	20040227	BG 2003-107871	20030602
US 2004063781	A1	20040401	US 2003-433015	20031014
US 7220752	B2	20070522		

PRIORITY APPLN. INFO.: GB 2000-29102 A 20001129
WO 2001-IB2302 W 20011128

OTHER SOURCE(S): MARPAT 137:20220
GI

L6 ANSWER 59 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB The title compds. [I; X = CH2, CHYR7, CHYCOR7, CO, CS, C:NOR8; Y = O, S, NR8; R1 = CO2H, heteroaryl; R2, R3 = H, halo, alkyl, provided that one of R2 or R3 is other than hydrogen; R4 = alkyl, alkenyl, alkynyl, halo, etc.; R5 = alkyl which is substituted by A (provided that A is not halo), alkyl, alkenyl, etc.; R6 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R7 = H; R8 = H, alkyl, cycloalkyl, etc.; A = halo, cycloalkyl, alkenyl, etc.] that are liver selective glucocorticoid receptor antagonists, useful in therapy and in the regulation of metabolism, especially lowering blood glucose levels, were prepared E.g., a multi-step synthesis of I [R1 = CO2H; R2, R3 = Br; R4 = iso-Pr; R5 = (CH2)2C(:CH2)Me; X = CO; R6 = 3-MeC6H4] was given. The compds. I exhibit an affinity for the glucocorticoid receptor in the range between 0.1 and 5000 nM.

IT 434327-24-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II)

RN 434327-24-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(4-carboxyphenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (CA INDEX NAME)

L6 ANSWER 59 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L6 ANSWER 60 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:379646 CAPLUS
DOCUMENT NUMBER: 137:337744
TITLE: Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists
AUTHOR(S): Lima, Lidia M.; de Brito, Fernanda C. F.; de Souza, Simone D.; Miranda, Ana L. P.; Rodrigues, Carlos R.; Fraga, Carlos A. M.; Barreiro, Eliezer J.
CORPORATE SOURCE: Universidade Federal do Rio de Janeiro, Faculdade de Farmacia, LASSBio, Rio de Janeiro, RJ, 21944-970, Brazil
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(11), 1533-1535
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:337744
GI



I

AB A series of phthalimides I [R = HO2C(CH2)n, HO2CCHMe, 4-HO2CC6H4CH2, 3-(5-tetrazolyl)propyl; n = 1, 3, 4] was synthesized and evaluated as leukotriene D4 receptor antagonists. The tetrazole-bearing phthalimide LASSBio 552, I [R = 3-(5-tetrazolyl)propyl], was shown to be able to inhibit the contractile activity induced by 100 nM of LTD4 in guinea-pig tracheal strips with an IC50=31.2 μM and to present a better efficacy than zafirlukast used as standard

IT 473931-95-2P, LASSBio 551
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (arylethyl)phthalimides as leukotriene D4 receptor antagonists)

RN 473931-95-2 CAPLUS
CN Benzoic acid, 4-[[4-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 60 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 61 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:310525 CAPLUS
DOCUMENT NUMBER: 137:130031
TITLE: The study of electrochemical behavior of some oxepines
by cyclic voltammetry
AUTHOR(S): Tanase, I. Gh.; Muresceanu, Mihaela; Florea, I.; Buleandra, Mihaela
CORPORATE SOURCE: Department of Analytical Chemistry, University of Bucharest, Rom.
SOURCE: Scientific Bulletin - University "Politehnica" of Bucharest, Series B: Chemistry and Materials Science (2001), 63(3), 37-44
CODEN: SBUPBD; ISSN: 1454-2331
PUBLISHER: University "Politehnica" of Bucharest
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The voltammetric behavior of 6,11-dehydrobenzo (b, e) oxepin-11-one, 4-(4-tolylazo)-phenol, {[4-(4-tolylazo)]-phenoxymethyl}-benzoic acid and 2-(4-tolylazo)-dibenzo (b, e)oxepin-11(OH)-one was investigated using cyclic voltammetry and differential pulse voltammetry, in nonaq. medium of
N,N'-dimethylformamide and 0.2 M tetra-Bu ammonium bromide (TBABr). All these compds. are reducible and oxidizable on glassy carbon electrode, presenting one or two reduction waves and irreversible oxidation waves. Reduction
signals obtained for all four compds. could be used for quant. determination of
them by differential pulse voltammetry in the range of 10-6 - 10-3 M.
IT 341497-66-3
RL: ANT (Analyte); ANST (Analytical study)
(electrochem. behavior of oxepines by cyclic voltammetry)
RN 341497-66-3 CAPLUS
CN Benzoic acid, 2-[[4-[(4-methylphenyl)azo]phenoxy]methyl]- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:276292 CAPLUS
DOCUMENT NUMBER: 136:316685
TITLE: Polymers containing polyene-bridged second-order nonlinear optical chromophores and devices incorporating the same
INVENTOR(S): Zhang, Cheng; Fetterman, Harold R.; Steier, William; Michael, Joseph
PATENT ASSIGNEE(S): Pacific Wave Industries, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002029488	A1	20020411	WO 2001-US29239	20010918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6652779	B1	20031125	US 2000-679937	20001005
AU 200192779	A	20020415	AU 2001-92779	20010918
PRIORITY APPLN. INFO.:			US 2000-679937 A	20001005
			US 1998-122806 A2	19980727
			US 2000-488422 A2	20000120
			US 2000-546930 A2	20000411
			US 2000-551685 A2	20000418
			WO 2001-US29239 W	20010918

AB Second-order nonlinear optical device comprising an active element including a linear chain nonlinear optical polyester or poly(imide ester) formed by reacting a dihydroxy functionalized chromophore containing a π-conjugate polyene structure as the bridge or part of the bridge that connects an electron donor and electron acceptor with a monomer selected from an aromatic or aliphatic diacid or diacid dihalide and a monomer selected
from an aromatic or aliphatic diol. The polyesters may be crosslinked using
trifluoroether groups. Second-order nonlinear optical devices are also described which comprise an active element including a crosslinked nonlinear optical polymer material formed from dendritic or hyperbranched macromol. that carries ≥1 chromophores and thermally reactive groups at the periphery of the macromol. for crosslinking between the macromols. The dendrimers may each have a chromophore as the core and ≥1 dendrons that carry thermally reactive groups for crosslinking between the dendrimers. Tetrafluoroisophthaloyl dichloride.
IT 330982-78-0DP, reaction products with propanedinitrile

L6 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
furanylidene derivs. 410092-31-8DP, reaction products with propanedinitrile furanylidene derivs.
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(second-order nonlinear optical devices employing polymers contg. polyene-bridged second-order nonlinear optical chromophores)
RN 330982-78-0 CAPLUS
CN Benzoic acid, 4,4',4''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (CA INDEX NAME)



RN 410092-31-8 CAPLUS
CN Benzoic acid,
4-[[4-[1,1-bis[4-[[4-[(trifluoroethenyl)oxy]phenyl]methoxy]phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

IT 330982-78-0 410092-31-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(second-order nonlinear optical devices employing polymers containing polyene-bridged second-order nonlinear optical chromophores)
RN 330982-78-0 CAPLUS
CN Benzoic acid, 4,4',4''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (CA INDEX NAME)

L6 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 410092-31-8 CAPLUS
CN Benzoic acid, 4-[[4-[1,1-bis[4-[[4-[(trifluoroethenyl)oxy]phenyl]methoxy]phenyl]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 63 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:935594 CAPLUS
DOCUMENT NUMBER: 136:69730
TITLE: Preparation of 1,3-bis-(substituted-phenyl)-2-propen-1-ones as VCAM-1 inhibitors for treatment of inflammatory disorders
INVENTOR(S): Meng, Charles Q.; Ni, Liming; Sikorski, James A.; Hoong, Lee K.
PATENT ASSIGNEE(S): Atherogenics, Inc., USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098291	A2	20011227	WO 2001-US19720	20010620
WO 2001098291	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413878	A1	20011227	CA 2001-2413878	20010620
BR 2001011889	A	20030624	BR 2001-11889	20010620
EP 1330448	A2	20030730	EP 2001-946583	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 6608101	B1	20030819	US 2001-886348	20010620
JP 2004501147	T	20040115	JP 2002-504247	20010620
NZ 523443	A	20041126	NZ 2001-523443	20010620
MX 2002PA12660	A	20040514	MX 2002-PA12660	20021218
IN 2003DN00008	A	20060609	IN 2003-DN8	20030101
ZA 2003000134	A	20051006	ZA 2003-134	20030106
US 2003236298	A1	20031225	US 2003-443470	20030521
US 7078431	B2	20060718		
US 2006258735	A1	20061116	US 2006-485940	20060713

PRIORITY APPLN. INFO.:
US 2000-212769P P 20000620
US 2000-255934P P 20001215
US 2001-886348 A1 20010620
WO 2001-US19720 W 20010620
US 2003-443470 A1 20030521

OTHER SOURCE(S): MARPAT 136:69730
GI

L6 ANSWER 63 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R2a, R3a, R4a, R5a, R6a, R2b, R3b, R4b, R5b, and R6b = independently H, (cyclo)alkyl, (hetero)aryl, carbocyclyl, (halo)alkylthio, (un)substituted alkoxy or amino, (halo)acyl, amido, (halo)alkylsulfonyl, aminocarbonyl, alkenyl, alkynyl, halo, OH, SH, CN, NO2, SO3H, sulf(on)amido, PO3H2, alditol, carbohydrate, amino acid, etc.; R22 and R23 = independently H or alkyl; or R22 and R6a or R23 and R6a can join together to form a bridged carbocycle, (hetero)aryl, or heterocycle; R2a and R3a, R3a and R4a, R4a and R5a, R5a and R6a, R2b and R3b, R3b and R4b, R4b and R5b, or R5b and R6b and independently join to form a bridged (un)substituted carbocycle, cycloalkenyl, cycloalk(en)ylcarbonyl, (hetero)aryl, heterocycle, or alkylenedioxy; and the E or Z isomers thereof] were prepared to inhibit the expression of VCAM-1. For example, 3',5'-dimethoxy-4'-hydroxyacetophenone was treated with Et glycolate, PPh3, and di-Et azodicarboxylate in THF to give 4'-ethoxycarbonylmethoxy-3',5'-dimethoxyacetophenone (90%). Coupling the acetophenone and 5-(benzo[b]thien-2-yl)-2,4-dimethoxybenzaldehyde (preparation given) in the presence of NaOH in absolute EtOH afforded the 1,3-diphenyl-2-propen-1-one II (39%), which stimulated cultured human aortic smooth muscle cell activity with IC50 of 0.45 μM. I are useful for the treatment of inflammatory disorders that are mediated by VCAM-1, including arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

L6 ANSWER 63 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 383174-20-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bis(substituted phenyl)propenones as VCAM-1 inhibitors for treatment of inflammatory disorders)

RN 383174-20-7 CAPLUS

CN Benzoic acid, 4-[[2-methoxy-4-[3-[2-methoxy-5-(2-thienyl)phenyl]-1-oxo-2-propenyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 64 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:904082 CAPLUS

DOCUMENT NUMBER: 136:37405

TITLE: Preparation of substituted stilbenes as glucose uptake enhancers

INVENTOR(S): Patterson, John; Park, Jeong Weong; Lum, Robert T.; Spevak, Wayne R.

PATENT ASSIGNEE(S): Telik, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094295	A1	20011213	WO 2001-US17673	20010601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002032218	A1	20020314	US 2001-872763	20010531
US 6479548	B2	20021112		
CA 2411340	A1	20011213	CA 2001-2411340	20010601
EP 1289936	A1	20030312	EP 2001-941753	20010601
EP 1289936	B1	20041020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535840	T	20031202	JP 2002-501812	20010601
TW 579373	B	20040311	TW 2001-90113322	20010601
AT 280148	T	20041115	AT 2001-941753	20010601
ES 2231504	T3	20050516	ES 2001-1941753	20010601
PRIORITY APPLN. INFO.:			US 2000-208591P	P 20000602
			WO 2001-US17673	W 20010601

OTHER SOURCE(S): MARPAT 136:37405

GI

L6 ANSWER 64 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. [I; R1, R3, R4 = H, alkyl, halo, etc.; R2 = H, alkyl, OH, etc.; or R2 and R3, together with the carbon atoms to which they are attached, form a heterocyclic ring; R5 = H, alkyl, aryl; R6, R7 = H, alkyl, etc.; R8, R9 = H, alkyl, halo, etc.; R10 = H, alkyl, OH, etc.] which activate the insulin receptor kinase, which leads to increased sensitivity to insulin and an increase in glucose uptake, were prepared and formulated. E.g., a multi-step synthesis of II, starting with monomethyl terephthalate and benzyl 4-aminobenzoate, which produced an 50% increase in glucose transport at 109 μM, was given. The invention also specifically concerns methods for treating humans with hyperglycemia, especially for the treatment of type II diabetes.

IT 380365-14-0P 380365-16-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted stilbenes as glucose uptake enhancers)

RN 380365-14-0 CAPLUS

CN Benzoic acid, 2-[[3,4-bis[(4-carboxyphenyl)methoxy]benzoyl]amino]-5-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 64 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 380365-16-2 CAPLUS
CN Benzoic acid, 2-[[3,4-bis[(3-carboxyphenyl)methoxy]benzoyl]amino]-5-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 65 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:895648 CAPLUS
DOCUMENT NUMBER: 136:19729
TITLE: Hydrazone, hydrazine and thiosemicarbazone derivatives as antifungal agents
INVENTOR(S): Mei, Xiaodan; Wang, Peng; Caracoti, Andrei; Mingo, Pamela; Boyd, Vincent; Murray, Robert; Sisti, Nicholas J.; Xiang, Yi Bin; Zhu, Shuhao; Wobbe, C. Richard; Moore, Daniel
PATENT ASSIGNEE(S): Anadys Pharmaceuticals, Inc., USA
SOURCE: U.S., 14 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6329378	B1	20011211	US 2000-501758		20000210
PRIORITY APPLN. INFO.:			US 1999-119387P	P	19990210
			US 1999-141117P	P	19990625

OTHER SOURCE(S): MARPAT 136:19729
GI



I



II

AB Title compds. such as I and (E)-II were prepared as antifungal agents. Thus, I was prepared in 3 steps starting from 2,3-dichloropyrazine and proceeding via 2-chloro-3-methoxypyrazine and 2-hydrazinyl-3-methoxypyrazine, the latter then being reacted with 3,5-dichlorosalicylaldehyde. I showed min. inhibitory concns. of 1, 1, and 2 μg/mL against Candida albicans, Saccharomyces cerevisiae, and Aspergillus nidulans, resp.

L6 ANSWER 65 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 378780-98-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydrazone, hydrazine and thiosemicarbazone derivs. as antifungal agents)
RN 378780-98-4 CAPLUS
CN Benzoic acid, 4-[[4-[(E)-[[[(4-chlorophenyl)amino]thioxomethyl]hydrazono]methyl]-3-hydroxyphenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 66 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:822163 CAPLUS
DOCUMENT NUMBER: 136:130668
TITLE: Reactive immunization elicits catalytic antibodies for polyester hydrolysis
AUTHOR(S): Chen, Da-Wei; Kubiak, Robert J.; Ashley, Jon A.; Janda, Kim D.
CORPORATE SOURCE: Department of Chemistry, The Scripps Research Institute and the Skaggs Institute for Chemical Biology, La Jolla, CA, 92037, USA
SOURCE: Journal of the Chemical Society, Perkin Transactions 1
(2001), (21), 2796-2803
CODEN: JCSPCE; ISSN: 1472-7781
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:130668
AB In the search for biocatalysts for degradation of nonnatural polymers, reactive immunization with haptens and was used to prepare catalytic antibodies capable of cleaving short oligomeric esters, as well as the insol. polyester. These antibodies were found to be highly specific and efficient esterases for oligomers. Triester was preferentially hydrolyzed by an endo-cleavage pathway, however, with a higher mol. weight polymer no site specificity could be observed Catalytic efficiency of the antibodies towards the insol. polymer was limited due to phys. constraints.
IT 392743-70-3P 392743-71-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reactive immunization elicits catalytic antibodies for polyester hydrolysis)
RN 392743-70-3 CAPLUS
CN 1,3-Benzenedicarboxylic acid, mono[4-[(4-hydroxyphenyl)sulfonyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 392743-71-4 CAPLUS
CN 1,3-Benzenedicarboxylic acid, mono[4-(phenylsulfonyl)phenyl] ester (9CI) (CA INDEX NAME)

L6 ANSWER 66 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 67 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 67 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:760373 CAPLUS
DOCUMENT NUMBER: 135:325271
TITLE: Photopolymerizable compositions containing urethane compounds, presensitized lithographic printing plates therefrom, and platemaking method
INVENTOR(S): Okamoto, Hideaki; Urano, Toshiyoshi; Noguchi, Motoharu
PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001290267	A	20011019	JP 2001-16536	20010125
PRIORITY APPLN. INFO.:			JP 2000-23993 A	20000201

AB The compns. contain ethylenic monomers (including urethane compds. having ≥4 urethane bonds and ≥4 addition-polymerizable double bonds) and photopolymn. initiator systems. Thus, a composition containing a reaction product of NK Ester A 9530 (dipentaerythritol pentaacrylate-based compound) and ME 20-100 (polyisocyanate) 44, 2-(methacryloyloxy)ethyl phosphate 11, a titanocene radical generator 5, dipyrromethemeboron difluoride-based sensitizers 1.0, and Me methacrylate-methacrylic acid-Cyclomer A 200 (alicyclic epoxy acrylate) copolymer 45 parts was applied on an anodized Al plate, exposed to a laser beam, and developed with an alkali solution to give a test piece with good resolution and durability.
IT 367965-48-8
RL: CAT (Catalyst use); USES (Uses)
(photopolymn. initiator; photopolymerizable compns. containing urethane compds. for photosensitive lithog. plates with good resolution and durability)
RN 367965-48-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[2-[4,6-bis(trichloromethyl)-1,3,5-triazin-2-yl]ethenyl]phenyl] ester (9CI) (CA INDEX NAME)



L6 ANSWER 68 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:713284 CAPLUS
DOCUMENT NUMBER: 135:242458
TITLE: Preparation of amphipathic aldehyde glucuronides and their use as adjuvants and immunoeffectors
INVENTOR(S): Johnson, David
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070663	A2	20010927	WO 2001-US8548	20010316
WO 2001070663	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2403553	A1	20010927	CA 2001-2403553	20010316
US 2001053363	A1	20011220	US 2001-810915	20010316
US 6649172	B2	20031118		
EP 1265840	A2	20021218	EP 2001-918784	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528068	T	20030924	JP 2001-568876	20010316
US 2004063647	A1	20040401	US 2003-652797	20030828
PRIORITY APPLN. INFO.:			US 2000-190466P P	20000317
			US 2001-810915 A1	20010316
			WO 2001-US8548 W	20010316

OTHER SOURCE(S): MARPAT 135:242458
GI



I

AB This invention relates to the preparation of aromatic aldehyde containing compds. I

L6 ANSWER 68 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
wherein R is H, CHO; R1 is H, alkyl, saccharyl, acyl, CO2H; R2 is H, alkyl, substituted alkyl, and their uses as adjuvants and immunoeffectors.
Thus, 4-[(3-formyl-4-hydroxyphenoxy)methyl]benzoic acid was prepd. and tested in mice for its adjuvant activity.
IT 360078-79-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amphipathic aldehyde glucuronides and their use as adjuvants and immunoeffectors)
RN 360078-79-1 CAPLUS
CN β-D-Glucopyranosiduronic acid, 4-[(4-carboxyphenyl)methoxy]-2-formylphenyl (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 69 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:619582 CAPLUS
DOCUMENT NUMBER: 135:338737
TITLE: Comparative QSAR: Angiotensin II Antagonists
AUTHOR(S): Kurup, Alka; Garg, Rajni; Carini, D. J.; Hansch, Corwin
CORPORATE SOURCE: Department of Chemistry, Pomona College, Claremont, CA, 91711, USA
SOURCE: Chemical Reviews (Washington, D. C.) (2001), 101(9), 2727-2750
CODEN: CHREAY; ISSN: 0009-2665
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A QSAR study was carried out on nonpeptide angiotensin II antagonists which included a review of the literature on bioactivity and derivation of QSAR equations. The QSAR were divided into 4 groups according to the test system: rabbit, rat, guinea pig and human. Within each group, these are arranged according to potency (log 1/C). Also listed is the CMR (calculated molar refractivity) which is similar to molar volume but contains a small element for polarizability, and Clog P values which give an assessment of the hydrophobic effects. The authors also used π as a measure of local hydrophobic binding sites. All the QSAR reported in the study were derived by the authors. The physicochem. parameters were autoloaded from their C-QSAR databases and the QSAR regression anal. was executed with a C-QSAR program. The authors derived 39 QSAR equations which provide an overview of the structure-activity relationship for a variety of compds. To the authors knowledge, these are the first QSAR for angiotensin antagonists. The most important conclusion reached is the lack of importance of hydrophobic interactions with the receptors. The relevance of the biphenyl moiety for hydrophobicity is discussed and a model of the pharmacophore is presented.
IT 114799-46-1 114799-47-2 114799-48-3
114799-49-4 114799-61-0 125848-45-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(comparative QSAR of nonpeptide angiotensin II antagonists)
RN 114799-46-1 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 69 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-47-2 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-48-3 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 69 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-49-4 CAPLUS
CN Benzoic acid,
2-[[4-[[5-[(acetyloxy)methyl]-2-butyl-4-chloro-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-61-0 CAPLUS
CN Benzoic acid, 2-[[4-[[5-(hydroxymethyl)-2-(propylthio)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 69 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 125848-45-5 CAPLUS
CN Benzoic acid, 2-[[4-[[2-(ethylthio)-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 70 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:489371 CAPLUS
DOCUMENT NUMBER: 135:76805
TITLE: Preparation of tricyclic compounds as leukotriene antagonists
INVENTOR(S): Kuroki, Yoshiaki; Ueno, Hitoshi; Katsube, Tetsushi; Kawaguchi, Tetsuo; Okanari, Eiji; Ikuta, Takashi
PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047889	A1	20010705	WO 2000-JP9406	20001228
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395834	A1	20010705	CA 2000-2395834	20001228
AU 2001022301	A5	20010709	AU 2001-22301	20001228
EP 1254897	A1	20021106	EP 2000-985983	20001228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003216571	A1	20031120	US 2002-169199	20020731
PRIORITY APPLN. INFO.:			JP 1999-372455 A	19991228
			WO 2000-JP9406 W	20001228

OTHER SOURCE(S): MARPAT 135:76805
GI



AB Novel tricyclic compds. having dibenz[b,e]oxepine, dibenz[b,e]thiepine, and dibenz[a,d]cycloheptane rings of general formula (I) or pharmacol. acceptable salts thereof [wherein R1 is H, halo, OH, NO2, cyano, CONH2, CHO, CO2H, C1-4 alkoxycarbonyl, 1H-tetrazol-5-yl, C1-4 alkyl, fluoro-C1-4 alkyl, hydroxy-C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, etc.; R2 is H, halo, NO2, cyano, C1-4 alkyl, or C1-4 alkoxy; A is a group

L6 ANSWER 70 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
derived from an optionally substituted and/or optionally benzene ring-fused five- or six-membered arom. heterocycle contg. 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; B is OCH2, CH2CH2, SCH2, CH2O, or CH2S; X is S, O, CH2, or CH; Y is optionally substituted C1-10 alkylene, phenylene, or Q; wherein o, p or
p1 is an integer of 0-2; q is an integer of 1-4; Z is optionally protected
carboxyl, 1H-tetrazol-5-yl, SO3H, NHSO2R3, or CONHSO2R3; wherein R3 is C1-4 alkyl, fluoro-C1-4 alkyl, optionally substituted phenyl; a solid line
accompanied by a dotted line represents a single or double bond; m is an integer of 1 to 4; and n is an integer of 1 to 3) are prepd. These compds. exhibit potent antagonism against leukotriene D4, C4, and E4 and are useful as antiallergic agents and anti-inflammatory agents. Thus, 0.77 g 2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine was dissolved in CF3CO2H and CH2Cl2, treated with 0.18 mL 3-mercaptopropionic acid under ice-cooling, and stirred at room temp. for 30 min to give 0.22 g 3-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio]propionic acid (II) which was converted into the sodium salt. II.Na in vitro inhibited the binding of [3H]leukotriene D4 to leukotriene D4 receptor with pKi of 9.5.
IT 346603-51-8P 346604-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. as leukotriene antagonists, antiallergic,
and antiinflammatory agents)
RN 346603-51-8 CAPLUS
CN Benzoic acid, 3-cyano-2-[[4-[(1E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxy]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 346604-51-1 CAPLUS
CN Benzoic acid, 2-[[4-[2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxy]methyl]-4-fluoro- (CA INDEX NAME)

L6 ANSWER 70 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 71 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:416939 CAPLUS
DOCUMENT NUMBER: 135:46203
TITLE: Preparation and effect of triazaspiro[5.5]undecane derivatives as active ingredients in remedy for inflammatory diseases
INVENTOR(S): Habeshita, Hiromu; Hamano, Shinichi; Shibayam, Shiro; Takaoka, Yoshikazu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040227	A1	20010607	WO 2000-JP8517	20001201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2394679	A1	20010607	CA 2000-2394679	20001201
AU 200116506	A	20010612	AU 2001-16506	20001201
AU 780419	B2	20050317		
EP 1236726	A1	20020904	EP 2000-979050	20001201
EP 1236726	B1	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000016111	A	20030325	BR 2000-16111	20001201
HU 2003000641	A2	20030628	HU 2003-641	20001201
TW 224597	B	20041201	TW 2000-89125555	20001201
AT 283854	T	20041215	AT 2000-979050	20001201
NZ 519183	A	20050225	NZ 2000-519183	20001201
PT 1236726	T	20050429	PT 2000-979050	20001201
ES 2233479	T3	20050616	ES 2000-979050	20001201
RU 2265021	C2	20051127	RU 2002-117652	20001201
ZA 2002004203	A	20030627	ZA 2002-4203	20020527
NO 2002002609	A	20020726	NO 2002-2609	20020531
NO 323631	B1	20070618		
MX 2002PA05465	A	20031015	MX 2002-PA5465	20020531
US 2004097511	A1	20040520	US 2003-148382	20030508
US 7119091	B2	20061010		

PRIORITY APPLN. INFO.:
JP 1999-344967 A 19991203
JP 2000-18673 A 20000127
JP 2000-27968 A 20000204
JP 2000-147882 A 20000519

L6 ANSWER 71 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
WO 2000-JP8517 W 20001201

OTHER SOURCE(S): MARPAT 135:46203
GI



I



II

AB Title compds. [I: R1 = H, aryl, arylalkyloxycarbonyl, alkenyloxycarbonyl, heterocyclylalkyl, alkyl, alkenyl, alkynyl; R2 = alkyl, alkynyl; R3 = H; R4 = alkyl; R5 = H, alkyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts thereof, are prepared via solid
phase synthesis using divinylbenzene-polystyrene or divinylbenzene-Rink resin. Title compds. I, having controlling effects of chemokines/chemokine receptors, are useful in preventing and/or treating various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, etc. Thus, the title compound II·HCl was prepared and biol. tested.

IT 342913-02-4P 342913-92-2P 343275-25-2P
343276-41-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of triazaspiro[5.5]undecane derivs. as active ingredients in inflammatory disease therapy)

RN 342913-02-4 CAPLUS

L6 ANSWER 71 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(2-methylpropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 342913-92-2 CAPLUS
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 343275-25-2 CAPLUS
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(2-methylpropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L6 ANSWER 71 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 343276-41-5 CAPLUS
CN Benzoic acid, 3-[[4-[[(3S)-1-butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 72 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:255930 CAPLUS
DOCUMENT NUMBER: 134:280608
TITLE: Preparation of bi- and terphenylcarboxamides as protein tyrosine phosphatase inhibitors
INVENTOR(S): Butera, John A.; Caufield, Craig E.; Graceffa, Russell F.; Greenfield, Alexander; Gundersen, Eric G.; Havran, Lisa Marie; Katz, Alan H.; Lennox, Joseph R.; Mayer, Scott C.; McDevitt, Robert E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 75 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6214877	B1	20010410	US 1999-307850	19990510
US 2001018525	A1	20010830	US 2001-771469	20010126
US 6451827	B2	20020917		
US 2003083341	A1	20030501	US 2002-215438	20020809
US 6765021	B2	20040720		
US 2004214869	A1	20041028	US 2004-843026	20040511
US 7008636	B2	20060307		

PRIORITY APPLN. INFO.: US 1998-108154P P 19980512
US 1999-307850 A3 19990510
US 2001-771469 A3 20010126
US 2002-215438 A3 20020809

OTHER SOURCE(S): MARPAT 134:280608
GI



II

L6 ANSWER 72 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB R1OZR [1; R = OH, alkyl, alkoxy, (hetero)aryl(alkyl), ureido, etc.; R1 = H, (carboxy)alkyl, etc.; Z = (un)substituted 2-aryl-1,4-phenylene] were prepared Thus, 4-(HO)C6H4CO2Et was brominated and the iodinated product etherified by HOCH2CH2OH to give Et 3-bromo-4-(2-hydroxyethoxy)-5-iodobenzoate which was arylated by 3-ClC6H4B(OH)2 and the product amidated by dodecylamine to give, after saponification, title compound II [R = Bu(CH2)8NHCO]. Data for biol. activity of I were given.

IT 251476-32-1P 251476-95-6P 251476-96-7P
251477-00-6P 251477-04-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bi- and terphenylcarboxamides as protein tyrosine phosphatase inhibitors)

RN 251476-32-1 CAPLUS
CN Benzoic acid, 4-[[[5'-[[(7-phenylheptyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 251476-95-6 CAPLUS
CN Benzoic acid, 2-methoxy-4-[[[5'-[[(8-phenyloctyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 72 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 251476-96-7 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[[[5'-[[(8-phenyloctyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 251477-00-6 CAPLUS
CN Benzoic acid, 4-[[[3-bromo-5-[[(8-phenyloctyl)amino]carbonyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]methyl]-2-methoxy- (CA INDEX NAME)



L6 ANSWER 72 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 251477-04-0 CAPLUS
CN Benzoic acid, 4-[[[3-bromo-5-[[(8-phenyloctyl)amino]carbonyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]methyl]-2-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 73 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:190352 CAPLUS
DOCUMENT NUMBER: 135:5420
TITLE: Synthesis of 2-[4-(p-tolylazo)phenoxymethyl]benzoic acid and some potentially biologically active amides
AUTHOR(S): Florea, Stelian; Brujan, Loredana
CORPORATE SOURCE: Fac. Chim., Univ. Craiova, Rom.
SOURCE: Revista de Chimie (Bucharest, Romania) (2000), 51(12), 979-982
CODEN: RCBUAU; ISSN: 0034-7752
PUBLISHER: SYSCOM 18 SRL
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
OTHER SOURCE(S): CASREACT 135:5420

AB 2-[4-(P-Tolylazo)phenoxymethyl]benzoic acid (I) was synthesized from 4-(p-tolylazo)phenol and phthalide and its chloride was condensed with various primary and secondary amines. The visible spectrum of I in acid and alkaline solution shows that this compound exists in an azo-hydrazone tautomeric equilibrium The structures of the new compds. were characterized by elemental analyses, IR and mass-spectrometry.

IT 341497-66-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-[4-(p-tolylazo)phenoxymethyl]benzoic acid and some amides)

RN 341497-66-3 CAPLUS
CN Benzoic acid, 2-[[4-[(4-methylphenyl)azo]phenoxy]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:44861 CAPLUS
DOCUMENT NUMBER: 134:231514
TITLE: Correlation of anti-HIV activity with anion spacing in a series of cosalane analogs with extended polycarboxylate pharmacophores
AUTHOR(S): Santhosh, Kalpathy C.; Paul, Gitendra C.; De Clercq, Erik; Pannecouque, Christophe; Witvrouw, Myriam; Loftus, Tracy L.; Turpin, Jim A.; Buckheit, Robert W., Jr.; Cushman, Mark
CORPORATE SOURCE: Department of Medicinal Chemistry and Molecular Pharmacology School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, 47907, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 703-714
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:231514

AB Cosalane and its synthetic derivs. inhibit the binding of gp120 to CD4 as well as the fusion of the viral envelope with the cell membrane. The binding of the cosalanes to CD4 is proposed to involve ionic interactions of the neg. charged carboxylates of the ligands with pos. charged arginine and lysine amino acid side chains of the protein. To investigate the effect of anion spacing on anti-HIV activity in the cosalane system, a series of cosalane tetracarboxylates was synthesized in which the two proximal and two distal carboxylates are separated by 6-12 atoms. Maximum activity was observed when the proximal and distal carboxylates are separated by 8 atoms. In a series of cosalane amino acid derivs. containing glutamic acid, glycine, aspartic acid, β-alanine, leucine, and phenylalanine residues, maximum activity was displayed by the di(glutamic acid) analog. A hypothetical model has been devised for the binding of the cosalane di(glutamic acid) conjugate to CD4. In general, the compds. in this series are more potent against HIV-1RF in CEM-SS cells than they are vs HIV-1IIIB in MT-4 cells, and they are least potent vs HIV-2ROD in MT-4 cells.

IT 229948-50-9P 229948-51-0P 229948-52-1P
330582-63-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(correlation of anti-HIV activity with anion spacing in a series of cosalane analogs with extended polycarboxylate pharmacophores)

RN 229948-50-9 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 229948-51-0 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-52-1 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 330582-63-3 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-ylbutylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 75 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:32760 CAPLUS
DOCUMENT NUMBER: 134:252679
TITLE: Highly Efficient and Thermally Stable Nonlinear Optical Dendrimer for Electrooptics
AUTHOR(S): Ma, Hong; Chen, Baoquan; Sassa, Takafumi; Dalton, Larry R.; Jen, Alex K.-Y.
CORPORATE SOURCE: Department of Materials Science and Engineering Department of Chemistry, University of Washington, Seattle, WA, 98195-2120, USA
SOURCE: Journal of the American Chemical Society (2001), 123(5), 986-987
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis and characterization of a crosslinkable nonlinear optical (NLO) dendrimer is reported. The NLO dendrimer was constructed through a double-end functionalization of a 3-D shape phenyl-tetracyanobutadienyl thiophene-stilbene-based NLO chromophore as the center core and crosslinkable trifluorovinyl ether-containing dendrons as the exterior moieties. The resulting dendrimer exhibits a combination of large r33 value of 60 pm/V at 1.55 μm and good temporal stability at 85°.

IT 330982-78-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and crosslinking of nonlinear-optical dendritic monomer)

RN 330982-78-0 CAPLUS
CN Benzoic acid, 4,4',4''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:872661 CAPLUS
DOCUMENT NUMBER: 134:216802
TITLE: Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds
AUTHOR(S): Howard, O. M. Z.; Dong, H. F.; Oppenheim, J. J.; Insaf, S.; Santhosh, K. C.; Paul, G.; Cushman, M.
CORPORATE SOURCE: Laboratory of Molecular Immunoregulation, National Cancer Institute--Frederick Cancer Research and Development Center, Frederick, MD, 21702, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), Volume Date 2001, 11(1), 59-62
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The anti-HIV agent cosalane and several of its analogs inhibited RANTES-induced migration of human monocytes, but they did not inhibit migration induced by MIP1α or MIP1β. RANTES-induced migration of single receptor CCR1-HEK transfectants was also inhibited by the cosalanes. Acetylation of the reactive amino groups of RANTES abrogated the inhibitory activity of cosalane. The data suggest that cosalane and its structural analogs may interfere with the RANTES/CCR1 interaction by binding to RANTES.

IT 229948-56-5P 229948-57-6P 229948-58-7P
329328-09-8P 329328-14-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compds.)

RN 229948-56-5 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



4 Na

RN 229948-57-6 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



4 Na

RN 229948-58-7 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



●4 Na

RN 329328-09-8 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



●2 Na

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



●2 Na

RN 329328-14-5 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxy-2-methoxyphenyl)methoxy]-5-chloro-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 77 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:806430 CAPLUS
DOCUMENT NUMBER: 134:214835
TITLE: Dendrimer-based chemically amplified resists for sub-100-nm lithography
AUTHOR(S): Tully, David C.; Trimble, Alexander R.; Frechet, Jean M. J.
CORPORATE SOURCE: Dep. Chem., Univ. of California, Berkeley, CA, USA
SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (2000), 3999(Pt. 2, Advances in Resist Technology and Processing XVII), 1202-1206
CODEN: PSISDG; ISSN: 0277-786X
PUBLISHER: SPIE-The International Society for Optical Engineering
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several new poly(benzyl ether) and poly(benzyl ester) dendrimers that incorporate acid- and thermally-labile peripheral groups have been synthesized. tert-Bu ester terminated poly(benzyl ether) dendrimers were synthesized using α-bromo-tert-Bu acetate in the preliminary protection step to afford the first generation alc. A standard bromination of the focal point benzylic alc. was used for the activation step, while standard Williamson ether conditions were used for the coupling steps to afford higher generation poly(benzyl ether) dendrons. tert-Bu ester terminated dendrons were then coupled to a difunctional core to produce the [G-3] dendrimer. tert-Bu carbonate (t-Boc) terminated poly(benzyl ester) dendrimers were also synthesized. This class of dendrimers was synthesized by first protecting monomeric building block 3,5-dihydroxybenzaldehyde with di-t-Bu dicarbonate. A reductive activation step afforded the [G-1] alc. The growth steps were accomplished by either Mitsunobu etherification with 3,5-dihydroxybenzaldehyde or by esterification with 5-hydroxymethylisophthalic acid. Finally, coupling of the benzyl alc. dendrons to a polyfunctional core afforded second and third generation dendrimers. Chemical amplified resists formulated from both t-Bu ester and t-Boc terminated dendrimers show high sensitivity to DUV and e-beam irradiation Feature sizes well below 100 nm have been routinely patterned using e-beam lithog.

IT 305323-45-9
RL: PEP (Physical, engineering or chemical process); PROC (Process) (preparation of tert-Bu carbonate terminated dendrimer for resist application)

RN 305323-45-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5,5',5''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (9CI) (CA INDEX NAME)

L6 ANSWER 77 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 78 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:633845 CAPLUS
DOCUMENT NUMBER: 133:357149
TITLE: Dendrimers with thermally labile end groups: An alternative approach to chemically amplified resist materials designed for sub-100 nm lithography
AUTHOR(S): Tully, David C.; Trimble, Alexander R.; Frechet, Jean M. J.
CORPORATE SOURCE: Department of Chemistry, University of California at Berkeley, Berkeley, CA, 94720-1460, USA
SOURCE: Advanced Materials (Weinheim, Germany) (2000), 12(15), 1118-1122
CODEN: ADVMEW; ISSN: 0935-9648
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Chemical amplified resists are described which are based on tert-butoxycarbonyloxy-terminated dendrimers and photoacid generators. Resist formulations prepared from these dendrimers were highly sensitive to both deep-UV and electron-beam exposures, providing reproducible patterning <100 nm.
IT 305323-45-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of tert-butoxycarbonyloxy-terminated dendrimers for lithog. chemical amplified resists formulations)
RN 305323-45-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5,5',5''-[ethylidynetris(4,1-phenyleneoxymethylene)]tris- (9CI) (CA INDEX NAME)



L6 ANSWER 78 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:619262 CAPLUS
DOCUMENT NUMBER: 133:344174
TITLE: Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates
AUTHOR(S): Paul, G. C.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T. L.; Turpin, J. A.; Buckheit, R. W.; Cushman, M.
CORPORATE SOURCE: School of Pharmacy and Pharmacal Sciences, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2149-2152
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The binding of the anti-HIV agent cosalane to CD4 is thought to involve ionic interactions of neg. charged carboxylates of the ligand with pos. charged residues on the surface of the protein. An investigation of the optimal anion distances for anti-HIV activity in a series of cosalane tetracarboxylate analogs has been completed, and maximal activity results when the two proximal and the two distal carboxylates are separated by eight atoms.
IT 229948-50-9P 229948-51-0P 229948-52-1P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates)
RN 229948-50-9 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-51-0 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-52-1 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro- (CA INDEX NAME)

L6 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 80 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:323251 CAPLUS
DOCUMENT NUMBER: 132:334280
TITLE: Preparation of 4-aryloxysulfonyl-2-hydroxybenzoates and analogs as insulin receptor protein tyrosine phosphatase 1B inhibitors
INVENTOR(S): Dollings, Paul J.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6063815	A	20000516	US 1999-307920	19990510
PRIORITY APPLN. INFO.:			US 1998-100427P P	19980512

OTHER SOURCE(S): MARPAT 132:334280
GI



II

AB YXZCOR [I; R = (un)substituted Ph; X = O, NR6, CH2NR6; R6 = H or alkyl; Y = SO2R1, CH2R1, CH2CO2R7; R1 = (un)substituted (hetero)aryl; R7 = H or alkyl; Z = 2,6-(un)substituted 1,4-phenylene] were prepared were prepared for treatment of insulin resistance and hyperglycemia. Thus, 4-(HO)C6H4COPh was bisiodinated and the O-protected product condensed with PhB(OH)2 to give, after deprotection, [2'-hydroxy[1,1':3',1'']terphenyl-5'-yl]phenylmethanone which was O-acylated by 2,4-(HO)(ClO2S)C6H3CO2H to give title compound II. Data for biol. activity of I were given.

IT 267883-84-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryloxysulfonyl-2-hydroxybenzoates and analogs as insulin receptor protein tyrosine phosphatase 1B inhibitors)

RN 267883-84-1 CAPLUS
CN Benzoic acid, 4-[[(5'-benzoyl[1,1':3',1''-terphenyl]-2'-yl)oxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L6 ANSWER 80 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 81 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:152248 CAPLUS
DOCUMENT NUMBER: 133:120757
TITLE: Synthesis of oligomeric alkylhydroquinone terephthalates. II
AUTHOR(S): Majnusz, Jerzy; Biedrzycki, Zbigniew
CORPORATE SOURCE: Department of Physical Chemistry and Technology of Polymers, Faculty of Chemistry, Silesian Technical University, Gliwice, PL 44-100, Pol.
SOURCE: Polish Journal of Applied Chemistry (1999), 43(1-2), 125-133
CODEN: PJACE2; ISSN: 0867-8928
PUBLISHER: Polish Scientific Publishers PWN
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several preparation procedures of oligomeric alkylhydroquinone terephthalates containing four and more benzene rings, from 2-alkylhydroquinones, terephthaloyl chloride and monofunctional acid chlorides as well as 4-methoxyphenol are described. Oligoesters containing four to seven benzene rings were prepared in multi-step reactions of the defined compds., whereas oligoesters containing more than seven benzene rings were obtained by a two-step polycondensation of an excess of alkylhydroquinones with terephthaloyl chloride followed by the final reaction of the obtained polycondensation products terminated by hydroxyl groups with anisoyl chloride. The phase transition temps. and the chemical compns. of the compds. studied are given.

IT 285553-97-1P 285553-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of oligomeric alkylhydroquinone terephthalates)

RN 285553-97-1 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-octyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



RN 285553-98-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-decyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 81 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 82 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:100893 CAPLUS
DOCUMENT NUMBER: 132:250953
TITLE: Ethanol initiated reactions using microwaves. A technique for aromatic ester synthesis
AUTHOR(S): Bratulescu, G.; Le Bigot, Y.; Delmas, M.
CORPORATE SOURCE: Institut National Polytechnique de Toulouse, Ecole Nationale Superieure de Chimie de Toulouse, Laboratoire de Catalyse, Chimie Fine et Polymeres, Toulouse, 31077, Fr.
SOURCE: Synthetic Communications (2000), 30(1), 171-176
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:250953

AB Ortho-phthalic monoesters were synthesized through a reaction between phthalic anhydride and K phenoxides. Synthesis was performed by irradiating pastes containing organic reagents and a small quantity of EtOH.

IT 262606-80-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(ethanol initiated microwave mono-esterification of phthalic anhydride with phenoxide)

RN 262606-80-4 CAPLUS
CN 1,2-Benzenedicarboxylic acid, mono[4-(phenylazo)phenyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 83 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:764010 CAPLUS
DOCUMENT NUMBER: 132:12200
TITLE: Preparation of terphenyloxyalkanoic acids and analogs as protein-tyrosine phosphatase inhibitors
INVENTOR(S): Butera, John Anthony; Caufield, Craig Eugene; Graceffa, Russell Francis; Greenfield, Alexander; Gundersen, Eric Gould; Havran, Lisa Marie; Katz, Alan Howard; Lennox, Joseph Richard; Mayer, Scott Christian; McDevitt, Robert Emmett
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961410	A1	19991202	WO 1999-US10158	19990510
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331056	A1	19991202	CA 1999-2331056	19990510
AU 9940727	A	19991213	AU 1999-40727	19990510
EP 1077929	A1	20010228	EP 1999-924158	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002516305	T	20020604	JP 2000-550819	19990510
MX 2000PA11094	A	20010405	MX 2000-PA11094	20001110

PRIORITY APPLN. INFO.: US 1998-76709 A 19980512
WO 1999-US10158 W 19990510

OTHER SOURCE(S): MARPAT 132:12200
GI



AB Title compds. [I; R = H, alkyl, SO2ZCO2H, CH2CO2H, (hetero)arylmethyl,

L6 ANSWER 83 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
etc.; R1,R2 = H, halo, alkyl, (hetero)aryl, etc.; R3 = alkyl, (hetero)aryl(alkyl), alkoxy(methyl), (un)substituted CONH2, etc.; Z = hydroxyphenyl] were prepd. Thus, Et 2-bromo-4-(2-hydroxyethoxy)-5-iodobenzoate was condensed with 3-ClC6H4B(OH)2 and the product amidated by
dodecylamine to give, after oxidn., I (R = CH2CO2H, R1 = R2 = C6H4Cl-3, R3
= dodecylcarbamoyl). Data for biol. activity of I were given.

IT 251476-32-1P 251476-95-6P 251476-96-7P
251477-00-6P 251477-04-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted biphenyl-, aryl, and terphenyloxyalkanoic acids
as inhibitors for protein-tyrosine phosphatases in treatment of insulin
resistance and hyperglycemia)

RN 251476-32-1 CAPLUS
CN Benzoic acid, 4-[[[5'-[[(7-phenylheptyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 251476-95-6 CAPLUS
CN Benzoic acid, 2-methoxy-4-[[[5'-[[(8-phenyloctyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 83 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 251476-96-7 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[[[5'-[[(8-phenyloctyl)amino]carbonyl]-3,3''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 251477-00-6 CAPLUS
CN Benzoic acid, 4-[[[3-bromo-5-[[(8-phenyloctyl)amino]carbonyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]methyl]-2-methoxy- (CA INDEX NAME)



L6 ANSWER 83 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 251477-04-0 CAPLUS
CN Benzoic acid, 4-[[[3-bromo-5-[[(8-phenyloctyl)amino]carbonyl]-3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]methyl]-2-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 84 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
cationic photopolymn. initiator, a sensitizing group accelerating the photoinitiated cationic reaction, and a cationically polymerizable group in the same mol. Thus, di-Ph ether 12.8, iodosobenzene acetate 48.3, and potassium hexafluorophosphate 27.6 g were reacted to give 39.2 g 1,1'-diphenyl-1,1'-(4,4'-oxydiphenyl)diiodonium bishexafluorophosphate (I). A compn. comprising 100 parts UVR 6110 epoxy resin and 1 parts I was
irradiated with Hg lamp showing rapid curability.
IT 244770-33-0P 244770-35-2P
RL: CAT (Catalyst use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(preparation of iodonium salt compds. useful as photopolymn. initiators for
rapidly photocurable compns.)
RN 244770-33-0 CAPLUS
CN Iodonium, [4-[(2-carboxyphenyl)methoxy]phenyl](4-methylphenyl)-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 244770-32-9
CMF C21 H18 I O3



CM 2

CRN 16919-18-9
CMF F6 P
CCI CCS



RN 244770-35-2 CAPLUS
CN Iodonium, [4-[(2-carboxyphenyl)methoxy]phenyl](2,4,6-trimethylphenyl)-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 244770-34-1
CMF C23 H22 I O3

L6 ANSWER 84 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:626245 CAPLUS
DOCUMENT NUMBER: 131:258069
TITLE: Rapidly photocurable compositions containing iodonium salt compounds as photopolymerization initiators
INVENTOR(S): Takahashi, Eiji; Shirai, Akihiro; Takahashi, Hiroshi; Kimizuka, Shinichi
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9948945	A1	19990930	WO 1999-JP1351	19990318
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11269107	A	19991005	JP 1998-92187	19980323
JP 11279213	A	19991012	JP 1998-99961	19980330
EP 1106639	A1	20010613	EP 1999-909226	19990318
EP 1106639	B1	20070829		
R: DE, FR				
JP 2000119306	A	20000425	JP 1999-76916	19990319
US 6558871	B1	20030506	US 2000-646700	20000919

PRIORITY APPLN. INFO.:
JP 1998-90671 A 19980320
JP 1998-90672 A 19980320
JP 1998-92187 A 19980323
JP 1998-99961 A 19980330
JP 1998-226844 A 19980811
WO 1999-JP1351 W 19990318

OTHER SOURCE(S): MARPAT 131:258069
AB Title composition is a photocurable cationic composition which cures in a short time
upon irradiation with actinic energy rays. They are based on the following
findings: (1) a colorless lowly toxic iodonium salt compound can be easily
synthesized in high yield when a specific substrate is used as a starting material; (2) a photocurable composition curing in a short time to give a cured
article having excellent material properties is obtained by using the iodonium salt compound in combination with a sensitizer; and (3) a highly sensitive photocurable composition which upon irradiation with actinic energy rays
cures in a short time to give a cured article having excellent material properties is obtained by using a compound having a group functioning as a

L6 ANSWER 84 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 16919-18-9
CMF F6 P
CCI CCS



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 85 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:390409 CAPLUS
DOCUMENT NUMBER: 131:45048
TITLE: Preparation of disalicylate analog based sialyl Lewisx mimetics as antiinflammatory agents and selectin receptors
INVENTOR(S): Anderson, Mark B.; Levy, Daniel E.; Holme, Kevin R.
PATENT ASSIGNEE(S): Glycomed Incorporated, USA; Sankyo Co., Ltd.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929706	A2	19990617	WO 1998-US25788	19981204
WO 9929706	A3	19990812		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9919036	A	19990628	AU 1999-19036	19981204
PRIORITY APPLN. INFO.:			US 1997-67877P	P 19971208
			WO 1998-US25788	W 19981204

OTHER SOURCE(S): MARPAT 131:45048
GI

L6 ANSWER 85 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewisx (sLex), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compds. mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compds. are disalicylate, its analogs, and disalicylate-based C-glycoside compds. I wherein R1-R12 are independently alkoxy, H, OH, aryl, aryloxy, aralkoxy, alkoxyaryl, amino, alkyl, sialic acid, quinic acid, sulfone, sulfonamide, phosphate, NO2, carboxylic acid, heterocycle; R2R3 and R9R10 are S, O, amine; R5R12 is CH2, CO, O, S, imino; R6R7 is O, CH2, imino, were prepared as selectin receptors. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compds. disclosed. Thus, C-glycoside II was prepared as P-selectin receptor (IC50 = 1039 μM).

IT 227595-87-1P 227595-90-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 85 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of disalicylate analog based sialyl Lewisx mimetics as antiinflammatory agents and selectin receptors)

RN 227595-87-1 CAPLUS
CN Benzoic acid, 5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-[(4-carboxyphenyl)methoxy]- (CA INDEX NAME)



RN 227595-90-6 CAPLUS
CN Benzoic acid, 5-[(3-carboxy-2-hydroxyphenyl)methyl]-2-[(4-carboxyphenyl)methoxy]- (CA INDEX NAME)



L6 ANSWER 86 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:301132 CAPLUS
DOCUMENT NUMBER: 131:74053
TITLE: Synthesis of main-chain liquid crystalline polyesters containing flexible spacer of poly(ethylene oxide)
AUTHOR(S): Tan, Chibing; Zhang, Shufan; Xu, Mao
CORPORATE SOURCE: Polymer Phys. Lab., Inst. of Chem., Chinese Acad. of Sci., Beijing, 100080, Peop. Rep. China
SOURCE: Gaofenzi Xuebao (1999), (2), 240-243
CODEN: GAXUE9; ISSN: 1000-3304
PUBLISHER: Kexue Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB A series of polyesters based on triad aromatic ester mesogenic unit but different length of poly(ethylene oxide) flexible spacers in the main chain was prepared by solution polycondensation and its chemical structure and mesogenic behavior were examined The intermediates of each step and synthesized polymers and monomers containing mesogenic unit were characterized by elementary anal., IR, 1H-NMR and m.p. measurement.

IT 129255-93-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in synthesis of main-chain liquid crystalline polyesters containing flexible spacer of poly(ethylene oxide))

RN 129255-93-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-methyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 87 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:300373 CAPLUS
DOCUMENT NUMBER: 130:359303
TITLE: Color developer for heat-sensitive recording material and process for manufacture thereof
INVENTOR(S): Hayakawa, Kunio; Morita, Mitsunobu
PATENT ASSIGNEE(S): Ricoh Cy Ltd., Japan
SOURCE: Fr. Demandé, 204 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2767283	A1	19990219	FR 1998-10446	19980814
FR 2767283	B1	20011123		
JP 11058982	A	19990302	JP 1997-233381	19970814
JP 3651736	B2	20050525		
JP 11140036	A	19990525	JP 1997-323851	19971110
JP 3700895	B2	20050928		
JP 11151864	A	19990608	JP 1997-335141	19971119
JP 3611073	B2	20050119		
JP 11152265	A	19990608	JP 1997-335142	19971119
JP 3673983	B2	20050720		
JP 11158122	A	19990615	JP 1997-344162	19971127
JP 3673984	B2	20050720		
JP 11170707	A	19990629	JP 1997-356211	19971209
JP 3651741	B2	20050525		
JP 11180939	A	19990706	JP 1997-364686	19971218
JP 11180047	A	19990706	JP 1997-364687	19971218
JP 3611078	B2	20050119		
JP 11286179	A	19991019	JP 1998-153632	19980518
JP 3611080	B2	20050119		

PRIORITY APPLN. INFO.:

JP 1997-233381	A	19970814
JP 1997-323851	A	19971110
JP 1997-323852	A	19971110
JP 1997-335141	A	19971119
JP 1997-335142	A	19971119
JP 1997-344162	A	19971127
JP 1997-356211	A	19971209
JP 1997-364686	A	19971218
JP 1997-364687	A	19971218
JP 1998-42936	A	19980209

AB The invention relates to color developers for heat-sensitive recording material which comprises a heat-sensitive coloring layer contg. a leuco dye and a color developer on a support, wherein the recording material is used with a thermal head, a heat pen or a laser beam. The color developer comprises at least one compd. having at least two types of arom. rings which have at least one carboxyl group and an electron accepting group, arom. ring having a carboxylic group and an electron donating group, or arom. ring without an electron-accepting or -donating group.

L6 ANSWER 87 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 224642-05-1P 224642-06-2P 224642-07-3P
224642-11-9P 224642-21-1P 224642-22-2P
224642-23-3P
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(color developer for heat-sensitive recording material)

RN 224642-05-1 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 3-nitro-, 1,1'-(sulfonyldi-4,1-phenylene) ester (9CI) (CA INDEX NAME)



RN 224642-06-2 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 3-nitro-, 1,1'-(thiodi-4,1-phenylene) ester (9CI) (CA INDEX NAME)



RN 224642-07-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 3-nitro-, 1,1'-[(2-methoxy-1-methyl-2-oxoethylidene)di-4,1-phenylene] ester (9CI) (CA INDEX NAME)



L6 ANSWER 87 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 224642-11-9 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 3-nitro-, 1,1'-(1,4-naphthalenediyl) ester (9CI) (CA INDEX NAME)



RN 224642-21-1 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 4-methyl-, 2,2'-(thiodi-4,1-phenylene) ester (9CI) (CA INDEX NAME)



RN 224642-22-2 CAPLUS
CN [1,1'-Biphenyl]-3,4-dicarboxylic acid, 3,3'-[(2-methoxy-1-methyl-2-oxoethylidene)di-4,1-phenylene] ester (9CI) (CA INDEX NAME)

L6 ANSWER 87 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 224642-23-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 4-hydroxy-, 2,2'-[1,2-ethanediylbis(oxy-2,1-ethanediyl-4,1-phenylene)] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:261311 CAPLUS
DOCUMENT NUMBER: 131:88081
TITLE: Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency
AUTHOR(S): Cushman, Mark; Insaf, Shabana; Paul, Gitendra; Ruell, Jeffrey A.; De Clercq, Erik; Schols, Dominique; Pannecouque, Christophe; Witvrouw, Myriam; Schaeffer, Catherine A.; Turpin, Jim A.; Williamson, Karen; Rice, William G.
CORPORATE SOURCE: Department of Medicinal Chemistry and Molecular Pharmacology School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, 47907, USA
SOURCE: Journal of Medicinal Chemistry (1999), 42(10), 1767-1777
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The anti-HIV agent cosalane inhibits both the binding of gp120 to CD4 as well as an undefined postattachment event prior to reverse transcription. Several cosalane analogs having an extended polyanionic "pharmacophore" were designed based on a hypothetical model of the binding of cosalane to CD4. The analogs were synthesized, and a number of them displayed anti-HIV activity. One of the new analogs was found to possess enhanced potency as an anti-HIV agent relative to cosalane itself. Although the new analogs inhibited both HIV-1 and HIV-2, they were more potent as inhibitors of HIV-1 than HIV-2. Mechanism of action studies indicated that the most potent of the new analogs inhibited fusion of the viral envelope with the cell membrane at lower concns. than it inhibited attachment, suggesting inhibition of fusion as the primary mechanism of action.

IT 229948-50-9P 229948-51-0P 229948-52-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(extension of polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency)

RN 229948-50-9 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-51-0 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 229948-52-1 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



IT 229948-56-5P 229948-57-6P 229948-58-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(extension of polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency)

RN 229948-56-5 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(2-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



4 Na

RN 229948-58-7 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(4-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



4 Na

RN 229948-57-6 CAPLUS
CN Benzoic acid, 3,3'-[4-(3β,5α)-cholestan-3-yl-1-butenylidene]bis[6-[(3-carboxyphenyl)methoxy]-5-chloro-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



4 Na

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 89 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:113645 CAPLUS
DOCUMENT NUMBER: 130:139652
TITLE: Preparation of mercaptoacyl amino acids as metallo-β-lactamase inhibitors
INVENTOR(S): Bateson, John Hargreaves; Best, Desmond John
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906365	A1	19990211	WO 1998-EP4974	19980721
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2298682	A1	19990211	CA 1998-2298682	19980721
EP 1000024	A1	20000517	EP 1998-943877	19980721
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001512099	T	20010821	JP 2000-505124	19980721

PRIORITY APPLN. INFO.: GB 1997-16221 A 19970731
GB 1997-16224 A 19970731
WO 1998-EP4974 W 19980721

OTHER SOURCE(S): MARPAT 130:139652
AB Mercaptoacyl amino acids R4SCR5R6C(:CHR3)CONR2CHR1CO2R [R = H, salt-forming cation, or in vivo hydrolyzable ester-forming group; R1 = H, alkyl, haloalkyl, mercaptoalkyl, alkoxy, hydroxy, amino, nitro, carboxy, etc.; R2 = H, alkyl, arylalkyl; R3 = H, alkyl, haloalkyl, cycloalkyl, fused arylcycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R4 = H or in vivo hydrolyzable acyl; R5 and R6 are independently H and alkyl or together represent (CH2)r, where r is 2-5] were prepared as metallo-β-lactamase inhibitors. Thus, D N-(E-α-mercaptomethyl-3-phenyl-2-propenoyl)-D-phenylglycine was prepared and when combined with carbapenem antibiotic meropenem showed min. inhibitor concentration against Bacteroides fragilis of 8 μg/mL, vs. >256 μg/mL for the compound alone and > μg/mL for meropenem alone.
IT 220119-73-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mercaptoacyl amino acids as metallo-β-lactamase inhibitors)
RN 220119-73-3 CAPLUS
CN Benzeneacetic acid, 4-[(3-carboxyphenyl)methoxy]-α-[[(2E)-2-(mercaptomethyl)-1-oxo-3-phenyl-2-propenyl]amino]-, α-methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 90 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:6876 CAPLUS
DOCUMENT NUMBER: 130:213514
TITLE: Interaction of oligopeptides with heparin
AUTHOR(S): Zhao, Ruifeng; Haratake, Mamoru; Ottenbrite, Raphael M.
CORPORATE SOURCE: Department of Chemistry, Virginia Commonwealth University, Richmond, VA, 23284, USA
SOURCE: Science and Technology of Polymers and Advanced Materials: Emerging Technologies and Business Opportunities, [Proceedings of the International Conference on Frontiers of Polymers and Advanced Materials], 4th, Cairo, Jan. 4-9, 1997 (1998), Meeting Date 1997, 513-520. Editor(s): Prasad, Paras N. Plenum: New York, N. Y.
CODEN: 67CCA5
DOCUMENT TYPE: Conference
LANGUAGE: English
AB The interaction of oligopeptides with heparin was investigated by heparin-affinity chromatog. Aromatic ring-containing tetrapeptides are retained longer than tripeptides and the aliphatic chain-containing tetrapeptides on the heparin affinity column at a low pH. The aromatic ring appears to be an essential component in the retention of the oligopeptides on the heparin affinity column. The association of these oligopeptides with heparin is very weak, due to an interaction between the aromatic rings and heparin, such as a charge transfer, in addition to hydrophobic interactions and H-bonding. This result is supported by the low heparin encapsulation efficiency (29.1%) observed in the tetrapeptide pEE(α)F(γ)F aggregates. The tetrapeptide pEE(α)F(γ)F was submitted to collaborators for further in vivo tests with heparin.
IT 220890-57-3
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(interaction of oligopeptides with heparin)
RN 220890-57-3 CAPLUS
CN L-Tyrosine, 5-oxo-L-prolyl-L-α-glutamyl-O-(2-carboxybenzoyl)-L-tyrosyl-, hydrogen 1,2-benzenedicarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 91 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:621101 CAPLUS
DOCUMENT NUMBER: 129:239865
TITLE: Pyrrolidine and thiazole derivatives with metallo-β-lactamase inhibitory properties
INVENTOR(S): Bateson, John Hargreaves; Best, Desmond John
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840056	A2	19980917	WO 1998-EP1272	19980224
WO 9840056	A3	19990128		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2285446	A1	19980917	CA 1998-2285446	19980224
EP 970062	A2	20000112	EP 1998-910730	19980224
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001524074	T	20011127	JP 1998-539185	19980224
US 6211212	B1	20010403	US 1999-367610	19990817

PRIORITY APPLN. INFO.: GB 1997-5188 A 19970313
GB 1997-5194 A 19970313
WO 1998-EP1272 W 19980224

OTHER SOURCE(S): MARPAT 129:239865

AB A method for treatment of batterial infections in humans or animals comprises administering, in combination with a β-lactam antibiotic, a therapeutically effective amount of an amino acid derivative or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof. For example, ammonium N-[2-(R,S)-mercapto-1-(R,S)-cyclohexanecarbonyl]-D-phenylglycine was prepared and inhibitory activity of the compound against Bacillus fragilis CfiA metallo-β-lactamase was determined to be IC50 value of <1 μM.

IT 213027-45-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrrolidine and thiazole derivs. with β-lactamase inhibitory properties)

RN 213027-45-3 CAPLUS
CN Benzeneacetic acid, 4-[(4-carboxyphenyl)methoxy]-α-[[(2-mercaptocyclohexyl)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 91 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:604896 CAPLUS
DOCUMENT NUMBER: 129:189122
TITLE: Preparation of phenoxypropanolamines as β3-adrenoceptor agonists
INVENTOR(S): Rami, Harshad Kantilal; Dean, David Kenneth; Beeley, Lee James
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9837056	A1	19980827	WO 1998-GB514	19980218
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: GB 1997-3492 A 19970220

OTHER SOURCE(S): MARPAT 129:189122

GI



AB ROCH2CH(OH)CH2NHCR1R2CH2ZO(CH2)nZ1(CH2)mR5 [R = (un)substituted aryl; R1,R2 = H or alkyl; R1R2 = alkylene; R5 = acid group or hydrolizable derivative thereof; Z = (un)substatituted phenylene; Z1 = phenylene; m,n = 0-4] were prepared Thus, Me 2-(4-(2-aminoethyl)phenoxymethyl)benzoate was condensed with (S)-2,2-di-tert-butyl-6-(2-oxiranylmethyl)-4H-1,3,2-benzodioxasilinane (preparation each given) to give, after saponification and hydrolysis, title compound I. Data for biol. activity of I were given.

IT 211917-51-0P 211917-53-2P 211917-54-3P
211917-57-6P 211917-59-8P 211917-60-1P
211917-61-2P 211917-62-3P 211917-63-4P
211917-64-5P 211917-65-6P 211917-66-7P
211917-67-8P 211917-68-9P 211917-69-0P
211917-70-3P 211917-71-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of phenoxypropanolamines as β3-adrenoceptor agonists)

RN 211917-51-0 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 211917-53-2 CAPLUS
CN Benzoic acid, 3-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]ethyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 211917-54-3 CAPLUS
CN Benzoic acid, 4-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]ethyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Li

RN 211917-57-6 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 211917-59-8 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-[3-[(methylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 211917-62-3 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-[(phenylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211917-61-2
CMF C31 H32 N2 O8 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 211917-63-4 CAPLUS
CN Benzoic acid, 2-[[4-[[1-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]cyclopentyl]methyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Li

RN 211917-60-1 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-[4-[(methylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 211917-61-2 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-[(phenylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



● Li

RN 211917-64-5 CAPLUS
CN Benzoic acid, 2-[[2-bromo-4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-2-methylpropyl]phenoxy]methyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 211917-65-6 CAPLUS
CN Benzoic acid, 3-[[4-[2-[[(2S)-2-hydroxy-3-[4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 211917-66-7 CAPLUS
CN Benzoic acid, 4-[[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 211917-67-8 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 211917-68-9 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-[3-[(methylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 211917-69-0 CAPLUS
CN Benzoic acid,
2-[[4-[2-[[(2S)-2-hydroxy-3-[4-[(methylsulfonyl)amino]phenoxy]propyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 211917-70-3 CAPLUS
CN Benzoic acid, 2-[[4-[[1-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]cyclopentyl]methyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 211917-71-4 CAPLUS
CN Benzoic acid, 2-[[2-bromo-4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]-2-methylpropyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 211917-76-9P 211917-81-6P 211917-86-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenoxypropanolamines as β3-adrenoceptor agonists)

RN 211917-76-9 CAPLUS
CN Benzoic acid, 2-[[4-[2-[[(2S)-3-[[2,2-bis(1,1-dimethylethyl)-4H-1,3,2-benzodioxasilin-6-yl]oxy]-2-hydroxypropyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 211917-81-6 CAPLUS
CN Benzoic acid, 3-[[4-[2-[[(2S)-3-[[2,2-bis(1,1-dimethylethyl)-4H-1,3,2-benzodioxasilin-6-yl]oxy]-2-hydroxypropyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 211917-86-1 CAPLUS
CN Benzoic acid, 4-[[4-[2-[[(2S)-3-[[2,2-bis(1,1-dimethylethyl)-4H-1,3,2-benzodioxasilin-6-yl]oxy]-2-hydroxypropyl]amino]ethyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 93 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NaBH4 in presence of CF3CO2H given] at ambient temp. and refluxing for 1 h
gave 84.6% 1-(2,6-diisopropylphenyl)-3-[3-(4-nitrobenzyloxy)benzyl]urea which at 100 nM gave 89.29% inhibition of ACAT activity in J774 cells, vs.
36.94% for N-[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolinyl]-N'-(2,4-difluorophenyl)urea (TMP-153) as a ref.
IT 207274-37-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylurea derivs. as antiarteriosclerotic agents)
RN 207274-37-1 CAPLUS
CN Benzoic acid, 4-[[4-[[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]methyl]-2-methoxyphenoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 93 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:304130 CAPLUS
DOCUMENT NUMBER: 128:321464
TITLE: Preparation of benzylurea derivatives as antiarteriosclerotic agents
INVENTOR(S): Kanamaru, Yoshihiko; Hirota, Hiroyuki; Shibata, Akihiro; Komoto, Teruo; Naito, Hiroyuki; Tachibana, Koichi; Ohtsuka, Mari; Ishii, Fumio; Sato, Susumu
PATENT ASSIGNEE(S): SS Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 839803	A1	19980506	EP 1997-118069	19971017
EP 839803	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 10182588	A	19980707	JP 1997-266098	19970930
US 5922767	A	19990713	US 1997-946098	19971007
CA 2218300	A1	19980430	CA 1997-2218300	19971015
TW 438749	B	20010607	TW 1997-86115288	19971017
CN 1181377	A	19980513	CN 1997-121556	19971029
CN 1061646	B	20010207		

PRIORITY APPLN. INFO.: JP 1996-288216 A 19961030

OTHER SOURCE(S): MARPAT 128:321464
GI



I

AB Benzylureas [I; R1, R2 = H, halo, alkyl, alkoxy; R3 = Ph, (un)substituted heterocyclyl; R4 = (un)substituted Ph; n = 1-6] and their salts which selectively inhibit acyl CoA cholesterol acyltransferase (ACAT) in macrophages present in artery walls and are useful as prophylactic and therapeutic agents for arteriosclerosis, were prepared and claimed. The use of I as drugs and pharmaceutical compns. containing I are also claimed. For example, adding a solution of 2,6-diisopropylphenyl isocyanate in 10 mL PhMe dropwise to a suspension of 2.58 g 3-(4-nitrobenzyloxy)benzylamine [preparation in 82% yield by reduction of O-methyl-3-(4-nitrobenzyloxy)benzaldoxime with

L6 ANSWER 94 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:268482 CAPLUS
DOCUMENT NUMBER: 128:321930
TITLE: Preparation of β-thiopropionylamino acid derivatives as β-lactamase inhibitors
INVENTOR(S): Bateson, John Hargreaves; Best, Desmond John; Clarke, Brian Peter; Gilpin, Martin Leonard; Witty, David R.; et al.
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Bateson, John Hargreaves; Best, Desmond John; Clarke, Brian Peter; Gilpin, Martin Leonard
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817639	A1	19980430	WO 1997-EP5709	19971010
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268930	A1	19980430	CA 1997-2268930	19971010
AU 9850501	A	19980515	AU 1998-50501	19971010
EP 934262	A1	19990811	EP 1997-913147	19971010
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001502345	T	20010220	JP 1998-518931	19971010
IN 1997MA02341	A	20050304	IN 1997-MA2341	19971017
US 6156774	A	20001205	US 1999-284098	19990407

PRIORITY APPLN. INFO.: GB 1996-21692 A 19961017
GB 1997-4581 A 19970305
GB 1997-16212 A 19970731
WO 1997-EP5709 W 19971010

OTHER SOURCE(S): MARPAT 128:321930
GI

L6 ANSWER 94 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





II III

AB Title mercapto amino acid derivs. R4SCR5R6CHR3CONR2CHR1CO2R [I; R = H, salt-forming cation of in vivo hydrolyzable ester-forming group; R1 = Q, Q1; ring A = monocyclic aryl or heteroaryl ring; ring B = monocyclic aryl, alicyclic, or heterocyclic ring; C, D = Zp(CR8CR9)q. (CR8CR9)qZp; p = 0, 1, q = 0-3 provided that p + q ≠ 0 in C; R8, R9 = H, (C1-6)alkyl; CR8R9 = O; Z = O, NR10, S(O)x; R10 = H, (C1-6)alkyl, aryl(C1-6)alkyl; x = 0-2; wherein C and D are linked ortho to one another on each of the rings A and B in Q1; R2 = H, (C1-6)alkyl, aryl(C1-6)alkyl; R3 = H, (C1-6)alkyl substituted by 0-3 halo atoms, (C3-7)cycloalkyl, fused aryl(C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl-(CH2)m-X-(CH2)n, heterocyclyl, heterocyclyl-(CH2)m-X-(CH2)n; m = 0-3; n = 1-3; X = O, S(O)x, bond; R4 = H or in vivo hydrolyzable acyl; R5, R6 = H, (C1-6)alkyl; R5R6 = (CH2)2-5] for use in treatment of bacterial infections in humans or animals by administration in combination with a β-lactam antibiotic. Thus, lithiation of thiophene and alkylation with 3-(bromomethyl)tetrahydrofuran gave 2-(tetrahydrofuran-3-ylmethyl)thiophene, which underwent lithiation and acylation with Et oxalyl chloride to give oxoacetate II (X1 = O). II (X1 = O) was converted into hydroxyiminoacetate II (X1 = NOH), reduced in situ to the corresponding amine, acylated with 2-(acetylthio)4-phenylbutanoic acid (preparation given), and saponified to give desired title compound III. III and related mercaptopropionyl derivs. inhibited Bacteroides fragilis CfiA metallo-β-lactamase with IC50 <1 μM. Compound III inhibited Bacteroides fragilis 262 strain, which produces CfiA metallo-β-lactamase, alone with MIC >256 μg/mL, but with MIC 16 μg/mL in the presence of 8 μg/mL meropenem.

IT 206764-77-4P 206764-78-5P 206765-05-1P
206765-06-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L6 ANSWER 94 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206765-06-2 CAPLUS
CN Benzeneacetic acid, 4-[(3-carboxyphenyl)methoxy]-α-[[(2S)-2-(mercaptomethyl)-1-oxo-4-phenylbutyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 94 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-thiopropionylamino acid derivs. as β-lactamase inhibitors)

RN 206764-77-4 CAPLUS
CN Benzeneacetic acid, 4-[(4-carboxyphenyl)methoxy]-α-[[(2R)-2-(mercaptomethyl)-1-oxo-4-phenylbutyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 206764-78-5 CAPLUS
CN Benzeneacetic acid, 4-[(4-carboxyphenyl)methoxy]-α-[[(2S)-2-(mercaptomethyl)-1-oxo-4-phenylbutyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 206765-05-1 CAPLUS
CN Benzeneacetic acid, 4-[(3-carboxyphenyl)methoxy]-α-[[(2R)-2-(mercaptomethyl)-1-oxo-4-phenylbutyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 95 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:208517 CAPLUS
DOCUMENT NUMBER: 128:243826
TITLE: Preparation of 2-amino-1-(4-hydroxy-2-methylphenyl)propanol derivatives as β2 adrenaline receptor-stimulating agents
INVENTOR(S): Kitazawa, Makio; Okazaki, Kosuke; Tamai, Tetsuro; Saito, Masaru; Tanaka, Nobuyuki; Kobayashi, Hiroaki; Kikuchi, Ken; Muranaka, Hideyuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813333	A1	19980402	WO 1997-JP3399	19970925
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9743202	A	19980417	AU 1997-43202	19970925
PRIORITY APPLN. INFO.:			JP 1996-291028	A 19960926
			WO 1997-JP3399	W 19970925

OTHER SOURCE(S): MARPAT 128:243826
GI



I

AB The title compds. I [one of Y and Z represents ACOR [wherein A represents ODE (wherein D represents alkylene; and E represents a single bond or phenylene) or ethylene; and R represents hydroxy, alkyl, alkoxy, aralkoxy, amino, dialkylamino or alicyclic amino] while the other represents hydrogen; and the carbon atoms marked with R and S resp. represent those of R- and S-configurations], useful as β2 agonists (no data) are prepared I are selective β2 adrenaline receptor agonists and are useful as bronchodilators and as agents for the prevention of abortion and premature birth.

IT 204971-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L6 ANSWER 95 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-amino-1-(4-hydroxy-2-methylphenyl)propanol derivs. as β2 adrenaline receptor-stimulating agents)
RN 204971-14-2 CAPLUS
CN Benzoic acid, 4-[[4-[2-[[2-hydroxy-2-(4-hydroxy-2-methylphenyl)-1-methylethyl]amino]ethyl]phenoxy]methyl]-, disodium salt, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 Na

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 96 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:708565 CAPLUS
DOCUMENT NUMBER: 127:346202
TITLE: N-phenylglycinolphenylacetamides as antiatherosclerotic agents
INVENTOR(S): Goldmann, Siegfried; Mueller, Ulrich; Connell, Richard; Bischoff, Hilmar; Denzer, Dirk; Gruetzmann, Rudi; Beuck, Martin
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19615263	A1	19971023	DE 1996-19615263	19960418
EP 802186	A1	19971022	EP 1997-105721	19970407
EP 802186	B1	20001129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 197794	T	20001215	AT 1997-105721	19970407
ES 2153141	T3	20010216	ES 1997-105721	19970407
PT 802186	T	20010430	PT 1997-105721	19970407
JP 10059915	A	19980303	JP 1997-106822	19970410
US 5750783	A	19980512	US 1997-833824	19970410
CA 2202704	A1	19971018	CA 1997-2202704	19970415
GR 3035371	T3	20010531	GR 2001-400198	20010206

PRIORITY APPLN. INFO.: DE 1996-19615263 A 19960418

OTHER SOURCE(S): CASREACT 127:346202; MARPAT 127:346202
GI

L6 ANSWER 96 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [A= (un)substituted carbocyclic, Ph, heterocyclic; X = bond, CO; D, E = H, cycloalkyl, N3, OH, halogen, alkyl, alkoxy, alkenyl; R1 = cycloalkyl, alkyl; R2 = H, alkyl; R3 = H, CH2OH; R4 = (un)substituted Ph] were prepared for use as antiatherosclerotic agents (no data). Thus, tert-Bu 2-(4-hydroxyphenyl)-2-cyclopentylacetate was 3-chlorobenzylated, hydrolyzed, and amidated with (R)-HOCH2CHPhNH2 to give the amide II.
IT 198332-42-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylglycinolphenylacetamides as antiatherosclerotic agents)
RN 198332-42-2 CAPLUS
CN Benzoic acid, 2-[[4-[1-cyclopentyl-2-[(2-hydroxy-1-phenylethyl)amino]-2-oxoethyl]phenoxy]methyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 97 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:613831 CAPLUS
DOCUMENT NUMBER: 127:278203
TITLE: Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
INVENTOR(S): Bock, Mark G.; Evans, Ben E.; Williams, Peter D.; Freidinger, Roger M.; Pettibone, Douglas J.; Hobbs, Doug W.; Anderson, Paul S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 92,840, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5665719	A	19970909	US 1995-470693	19950606

PRIORITY APPLN. INFO.: US 1993-92840 B2 19930716

OTHER SOURCE(S): MARPAT 127:278203
GI



I



II

AB Compds. of formula I [X = O, NH, or NR8; Y = CH2, CHR8, or C(R8)2; R1 = camphor-10-yl, alkoxy, styryl, hydroxystyryl, furyl, (un)substituted thienyl, naphthyl, indolyl, tetrahydronaphthyl, (un)substituted pyridyl,

L6 ANSWER 97 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrazinyl, (un)substituted cyclohexyl or Ph; R2 = H, alkoxy, alkyl, amino,
alkylcarbonylamino, nitro, or halo; R3 = H, alkoxycarbonyl, cyano, or carbamoyl; and m = 0 or 1] and various analogs are disclosed. The compds.
as useful as oxytocin (OT) and vasopressin receptor antagonists. Over 275
synthetic examples are given. For instance, Me 2,4-dihydroxybenzoate underwent Mitsunobu etherification with N-(tert-butoxycarbonyl)-4-piperidinol (51%), followed by O-methylation of the remaining hydroxyl (88%), sapon. of the Me ester (95%), and coupling of the resultant acid with 1-(4-piperidinyl)-1,2-dihydro-4H-3,1-benzoxazin-2-one (HCl salt) using EDC and HOBt (88%), to give title compd. II [R = CO2Bu-tert]. The latter was deprotected with HCl in dioxane (93%) and acetylated with Ac2O (89%) to give title compd. II [R = Ac]. The latter inhibited binding of [3H]-OT to rat uterine OT receptors in vitro with an IC50 of 47 nM.
IT 196794-52-2P 196794-59-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone and benzopyrimidinone derivs. as oxytocin and
vasopressin receptor antagonists)
RN 196794-52-2 CAPLUS
CN Benzoic acid, 3-[[3-methoxy-4-[[4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-1-piperidinyl]carbonyl]phenoxy]methyl]- (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 97 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L6 ANSWER 97 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 196794-59-9 CAPLUS
CN Benzoic acid, 3-[[3-methoxy-4-[[4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-1-piperidinyl]carbonyl]phenoxy]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 196794-52-2
CMF C29 H28 N2 O7

PAGE 1-A



L6 ANSWER 98 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:644709 CAPLUS
DOCUMENT NUMBER: 125:328229
TITLE: Use of 19F NMR spectroscopy to evaluate reactions in solid phase organic synthesis
AUTHOR(S): Svensson, Anette; Fex, Tomas; Kihlberg, Jan
CORPORATE SOURCE: Center for Chemistry, The Lund Inst. Technol., Lund Univ., Lund, S-221 00, Swed.
SOURCE: Tetrahedron Letters (1996), 37(42), 7649-7652
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Gel-phase 19F NMR spectroscopy has been used to characterize products from
a variety of reactions of fluorinated aroms. linked to a TentaGel resin. High quality spectra were obtained in a few minutes using an ordinary NMR spectrometer, and the 19F chemical shifts of the support-bound compds. closely matched those of soluble refs. In addition, substantial chemical shift
differences were obtained for almost all of the synthetic transformations, illustrating the potential of 19F NMR for rapid monitoring of reactions in
solid-phase organic synthesis.
IT 183664-20-2DP, polymer bound
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(evaluation of reactions in solid phase organic synthesis by 19F NMR)
RN 183664-20-2 CAPLUS
CN Benzoic acid, 4-[(4-carboxyphenyl)methoxy]-3-fluoro-, 1-(pentafluorophenyl) ester (9CI) (CA INDEX NAME)



IT 183664-26-8DP, polymer bound
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(evaluation of reactions in solid phase organic synthesis by 19F NMR)
RN 183664-26-8 CAPLUS
CN Benzoic acid, 4-[[2-fluoro-4-(1-piperidinylcarbonyl)phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 98 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 99 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:170684 CAPLUS
DOCUMENT NUMBER: 124:289234
TITLE: Synthesis of some substituted dibenz[b,e]oxepin-11(6H)-ones
AUTHOR(S): Nicolae, Anca; Maior, Ovidiu; Florea, Stelian; Wolff, Adolf D.
CORPORATE SOURCE: Facultatea de Chimie, Universitatea Bucuresti, Bucharest, Rom.
SOURCE: Revista de Chimie (Bucharest) (1996), 47(1), 5-9
CODEN: RCBUAU; ISSN: 0034-7752
PUBLISHER: CHIMINFORM DATA
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI



I

AB New dibenz[b,e]oxepin-11(6H)-ones I [R = H, Me, CMe3, CMe2Ph, R1-R3 = H; R = H, Cl, R1, R3 = Me, R2 = H; R = R1 = H, R2 = R3 = Me] were synthesized by cyclodehydration in presence of polyphosphoric ester of the acids obtained by reaction of phthalide with the substituted phenols.

IT 175794-62-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted dibenzoxepinones)

RN 175794-62-4 CAPLUS
CN Benzoic acid, 2-[[4-(1-methyl-1-phenylethyl)phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 100 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:1004271 CAPLUS
DOCUMENT NUMBER: 124:57515
TITLE: Synthesis of mesogenic polyesters with 2-dichloromethylhydroquinone moieties
AUTHOR(S): Zhou, Qifeng; Guo, Ailan
CORPORATE SOURCE: Department Chemistry, Peking University, Beijing, 100871, Peop. Rep. China
SOURCE: Chinese Journal of Polymer Science (1995), 13(3), 285-8
CODEN: CJPSEG; ISSN: 0256-7679
PUBLISHER: Science Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of novel mesogenic polyesters with 2-dichloromethylhydroquinone moieties were synthesized by polycondensation of the novel diacyl chloride monomer 2-dichloromethyl-1,4-bis(4'-chloroformylbenzoyl)oxybenzene (I) with α, ω-polymethylenediols including ethylene glycol, 1,4-butanediol, 1,6-hexanediol and 1,10-decanediol. The diacyl chloride monomer was synthesized by simultaneous transformations of both the carboxy and formaldehyde groups of 2-formyl-1, 4-bis (4'-carboxybenzoyl) oxybenzene into acyl chloride and dichloromethyl groups resp. The syntheses of the monomer (I) and the polymers were reported.

IT 172272-78-5P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis of mesogenic polyesters with dichloromethylhydroquinone moieties)

RN 172272-78-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-formyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 101 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:997533 CAPLUS
DOCUMENT NUMBER: 124:175842
TITLE: Preparation of substituted pyridine leukotriene B4 antagonists
INVENTOR(S): Cohen, Noal; Lee, Ferdinand Kwo-Chen; Yagaloff, Keith Alan
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9528386	A1	19951026	WO 1995-EP1262	19950406
W: AU, BR, CA, CN, JP, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186252	A1	19951026	CA 1995-2186252	19950406
AU 9522569	A	19951110	AU 1995-22569	19950406
AU 690258	B2	19980423		
ZA 9502859	A	19960104	ZA 1995-2859	19950406
EP 755381	A1	19970129	EP 1995-915853	19950406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1145619	A	19970319	CN 1995-192521	19950406
JP 09505605	T	19970603	JP 1995-526671	19950406
JP 2866202	B2	19990308		
BR 9507459	A	19971111	BR 1995-7459	19950406
PRIORITY APPLN. INFO.:			US 1994-228246 A	19940413
			US 1995-395092 A	19950306
			WO 1995-EP1262 W	19950406

OTHER SOURCE(S): MARPAT 124:175842
GI



I

AB The title compds. [I; X = O, CO; Y = CH, S(O)uR8, NR5SO2R8, OR9, R10, etc.; Z = (O)y(CR5R6)sR10, (O)y(CR5R6)vOR9, R10; R1, R3 = (un)substituted aryl, heteroaryl, alkyl, aralkyl; R2 = H, lower alkyl, halogen, lower alkoxy; R4 = H, lower alkyl; R5, R6 = H, lower alkyl; R7 = hydroxy, lower alkoxy, NR5R6; R8 = lower alkyl, (un)substituted aryl or aralkyl; R9 = H, lower alkyl, (un)substituted aryl, aralkyl, lower alkanoyl or aroyl; R10 = COR7, CONHSO2R8, 1H-tetrazol-5-yl; m = 3-8; n, s = 1-12; t = 0, 1; u = 0-2; v = 2-12; yr = 0, 1; z = 0, 1; etc.], which are leukotriene B4

L6 ANSWER 101 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
antagonists useful in the treatment of inflammatory diseases (no data), asthma (no data), allergies (no data), arthritis (no data), etc. (no data), are prepd. and I-contg. formulations presented. Thus,

2-(3-carboxypropoxy)-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzeneprop anoic acid was prepd. and demonstrated, in guinea pigs at 0.1 mg/kg, an 86% remission of leukotriene B4-induced bronchoconstriction.

IT 173839-32-2P 173839-36-6P 173839-40-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridine leukotriene B4 antagonists)

RN 173839-32-2 CAPLUS
CN Benzenepropanoic acid, 5-[(4-carboxyphenyl)methoxy]-2-[6-[(3,5-diphenyl-2-pyridinyl)oxy]hexyl]- (CA INDEX NAME)



RN 173839-36-6 CAPLUS
CN Benzenepropanoic acid, 5-[(2-carboxyphenyl)methoxy]-2-[6-[(3,5-diphenyl-2-pyridinyl)oxy]hexyl]- (CA INDEX NAME)



RN 173839-40-2 CAPLUS
CN Benzenepropanoic acid, 5-[(3-carboxyphenyl)methoxy]-2-[6-[(3,5-diphenyl-2-pyridinyl)oxy]hexyl]- (CA INDEX NAME)



L6 ANSWER 102 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:573696 CAPLUS
DOCUMENT NUMBER: 122:314549
TITLE: Preparation of [(imidazopyridinomethyl)phenoxy]phenyla cetates and analogs as endothelin receptor antagonists
INVENTOR(S): Dhanoa, Daljit S.; Fitch, Kenneth J.; Veber, Daniel F.; Walsh, Thomas F.; Williams, David L., Jr.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Brit. UK Pat. Appl., 198 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2276383	A	19940928	GB 1994-5312	19940317
US 5374638	A	19941220	US 1993-34456	19930319
PRIORITY APPLN. INFO.:			US 1993-34456 A	19930319

OTHER SOURCE(S): MARPAT 122:314549
GI



I



II

AB Title compds. [I; E = bond, SO0-2(CH2)0-5, O; R = CO2H, 5-tetrazolyl(carbamoyl), P(O)(OH)2, etc.; R1 = alk(en)yl, Ph, heteroaryl, etc.; R9,R10 = H, alk(en)yl, halo, alkoxy, etc.; R11,R12 = H, alkyl, Ph, etc.; X = bond, O, CH2O, NH, etc.; Y = bond, O, NH, etc.; Z = CR4:CR4CR4:CR4, CR4:CR4CR4:N, CR4:NCR4:N, etc.; R4 = H, alkyl, halo, OH, etc.] were prepared Thus, 3,4-Cl(Me3CMe2SiO)C6H3CH2Br (preparation given) was condensed with 5,7-dimethyl-2-ethylimidazo[4,5-b]pyridine and the deprotected product etherified by 2-MeOC6H4CHBrCO2Me to give, after saponification,

L6 ANSWER 101 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 102 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
title compd. II. I had IC50 of <50nM against endothelin binding at cloned human endothelin receptors in vitro.

IT 163338-61-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(imidazopyridinomethyl)phenoxy]phenylacetates and analogs as endothelin receptor antagonists)

RN 163338-61-2 CAPLUS
CN Benzeneacetic acid, 2-carboxy-α-[2-chloro-4-[(7-methyl-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-propylphenoxy]- (CA INDEX NAME)



L6 ANSWER 103 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:551028 CAPLUS
DOCUMENT NUMBER: 122:302892
TITLE: Silver halide photographic material with decreased residual color
INVENTOR(S): Yamada, Taketoshi; Oonishi, Akira; Usagawa, Yasushi
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06347948	A	19941222	JP 1993-133470	19930603
PRIORITY APPLN. INFO.:			JP 1993-133470	19930603

AB The title material comprises ≥1 photog. layers containing ≥1 kinds of cyanine dyes selected from claimed cyanine dyes. The above material is developed in ≤45, ≤30 or ≤15 s.
IT 163074-53-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(silver halide photog. material with decreased residual color)
RN 163074-53-1 CAPLUS
CN Benzoic acid, 4-[[4-[[4,5-dihydro-4-[3-(4-methoxyphenyl)-2-propenylidene]-5-oxo-3-isoxazolyl]amino]phenoxy]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 104 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:395938 CAPLUS
DOCUMENT NUMBER: 122:188323
TITLE: Two-carrier liquid-phase synthesis of main-chain liquid crystalline oligomers and characterization of the products
AUTHOR(S): Seliger, H.; Goeldner, E.; Kittel, I.; Plage, B.; Schulten, H.-R.
CORPORATE SOURCE: Sektion Polymere, Univ. Ulm, Ulm, D-89081, Germany
SOURCE: Fresenius' Journal of Analytical Chemistry (1995), 351(2-3), 260-70
CODEN: FJACES; ISSN: 0937-0633
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Monodisperse oligomers were synthesized from terephthalic acid and α-hydrogen-ω-hydroxy[oxy-1,4-phenyloxy-1,10-decamethyleneoxy-1,4-phenylene] using a polyethylene glycol support. Isolation of the target oligomers was achieved by use of a second soluble carrier which could be introduced and cleaved selectively, thus allowing to characterize the product chain in solution The structures of the oligomers were assigned and identified using a combination of anal. methods such as electron impact mass spectrometry, IR- and 1H-NMR spectroscopy and temperature-resolved pyrolysis-field ionization mass spectrometry (Py-FIMS).
IT 143389-22-4P 161927-29-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(in two-carrier liquid-phase preparation of liquid-crystalline polyester oligomers)
RN 143389-22-4 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,10-decanediylbis(oxy-4,1-phenylene) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 161927-29-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[4-[[4-[[4-[[10-[4-[(4-

L6 ANSWER 104 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
carboxybenzoyl)oxy]phenoxy]decyl]oxy]phenoxy]carbonyl]benzoyl]oxy]-4-methylpentyl]-ω-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 161927-30-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; in two-carrier liquid-phase preparation of liquid-crystalline polyester oligomers)
RN 161927-30-6 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[2-[[4-[[[4-[[4-[[10-[4-[(4-carboxybenzoyl)oxy]phenoxy]decyl]oxy]phenoxy]carbonyl]benzoyl]oxy]methyl]phenyl]methoxy]-2-oxoethyl]-ω-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 104 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L6 ANSWER 105 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:392300 CAPLUS
DOCUMENT NUMBER: 124:57870
TITLE: Polyether-polyketone molding compositions with excellent processability and mechanical properties
INVENTOR(S): Saito, Yasuhiro; Shiobara, Tomoo
PATENT ASSIGNEE(S): Sekisui Chemical Co. Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06322254	A	19941122	JP 1993-113306	19930514
PRIORITY APPLN. INFO.:			JP 1993-113306	19930514

OTHER SOURCE(S): MARPAT 124:57870
GI



I

AB The compns. contain 0.2-15 phr ≥1 compound selected from I (R1, R2 = H, Me, Et; ≥1 of R1 and R2 being Me or Et), and alkali metal or alkaline earth metal salts of I acid derivs. Thus, 100 parts VICTREX 450G and 0.3 part I (R1, R2 = Me) were blended, pelletized, and injection molded to give a test piece showing flow temperature 348°, Tg 140°, and tensile strength 8.6 kg/mm2.
IT 163917-78-0 172175-17-6D, alkali metal or alkaline earth metal salts
RL: MOA (Modifier or additive use); USES (Uses)
(polyether-polyketone molding compns. with excellent processability and mech. properties)
RN 163917-78-0 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 4,4'-[(1-methylethylidene)di-4,1-phenylene] ester, calcium salt (1:2) (9CI) (CA INDEX NAME)

L6 ANSWER 105 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 Ca

RN 172175-17-6 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 4,4'-[(1-methylethylidene)di-4,1-phenylene] ester (9CI) (CA INDEX NAME)



L6 ANSWER 106 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:348141 CAPLUS
DOCUMENT NUMBER: 122:177682
TITLE: AT1-selective angiotensin II antagonists with phenoxyphenylacetic acid as a biphenyl replacement. Part I
AUTHOR(S): Fitch, K. J.; Walsh, T. F.; Patchett, A. A.; Chang, R.
S. L.; Siegl, P. K. S.; Faust, K. A.; Chen, T.-B.; Lotti, V. J.; Kivlighn, S. D.; et al.
CORPORATE SOURCE: Exploratory Chem., Merck Res. Labs., Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(2), 155-8
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of nonpeptidic angiotensin II (AII) antagonists selective for the AII AT1 receptor is described which contain a phenoxyphenylacetic acid element instead of the previously reported biphenyltetrazole moiety. This series yielded a compound (I) which exhibited binding affinities of AT1 = 16 nM and AT2 = 22 μM and demonstrated modest in vivo duration of blockade of AII-induced pressor responses in conscious rats after either i.v. or oral administration.
IT 137445-46-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(phenoxyphenylacetic acid deriv. as AT1-selective angiotensin II antagonists)
RN 137445-46-6 CAPLUS
CN Benzeneacetic acid, 2-carboxy-α-[4-[(7-methyl-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenoxy]- (CA INDEX NAME)

L6 ANSWER 106 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 107 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:484289 CAPLUS
DOCUMENT NUMBER: 121:84289
TITLE: Polyimide liquid crystals and their manufacture
INVENTOR(S): Yamashita, Wataru; Koga, Nobushi; Ookawa, Juichi; Oikawa, Hideaki; Asanuma, Tadashi; Yamaguchi, Teruhiro
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05331282	A	19931214	JP 1992-138962	19920529
JP 3201826	B2	20010827		
PRIORITY APPLN. INFO.:			JP 1992-138962	19920529

GI



I

AB A polyimide having structural repeating units I (R = C2-27 aliphatic or alicyclic or aromatic tetravalent group) is synthesized by condensing the fluoromethylated aromatic diamine with an appropriate tetracarboxylic acid dianhydride in the presence of an aromatic dicarboxylic acid anhydride or an aromatic monoamine, which terminates the polymer chain. The polyimide has liquid-crystalline properties upon heating, low dielec. constant, good heat resistance, and good processability. A polyimide was prepared from 1,3-bis[4-[4-amino-2-(trifluoromethyl)phenoxy]-α,α-dimethylbenzyl]benzene, pyromellitic dianhydride, and phthalic anhydride, and had dielec. constant 3.02, 2.99, and 2.96 at 60 Hz, 3 KHz and 1 MHz, resp.
IT 155621-73-1P

L6 ANSWER 107 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PREP (Preparation)
(prepn. of, with liq.-cryst. properties and low dielec. const.)
RN 155621-73-1 CAPLUS
CN Poly[(5,7-dihydro-1,3,5,7-tetraoxobenzo[1,2-c:4,5-c']dipyrrole-2,6(1H,3H)-diyl)[3-(trifluoromethyl)-1,4-phenylene]oxy-1,4-phenylene(1-methylethylidene)-1,3-phenylene(1-methylethylidene)-1,4-phenyleneoxy[2-(trifluoromethyl)-1,4-phenylene]], α-(2-carboxybenzoyl)-ω-[(2-carboxybenzoyl)oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 108 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:436153 CAPLUS
DOCUMENT NUMBER: 121:36153
TITLE: Enkephalin Analogs as Systemically Active Antinociceptive Agents: O- and N-Alkylated Derivatives of the Dipeptide Amide L-2,6-Dimethyltyrosyl-N-(3-phenylpropyl)-D-alaninamide
AUTHOR(S): Pitzele, Barnett S.; Hamilton, Robert W.; Kudla, Kathleen D.; Tsymbalov, Sofya; Stapelfeld, Awilda; Savage, Michael A.; Clare, Michael; Hammond, Donna L.; Hansen, Donald W., Jr.
CORPORATE SOURCE: Department of Chemistry and Neurological Diseases Research, Searle, Skokie, IL, 60077, USA
SOURCE: Journal of Medicinal Chemistry (1994), 37(7), 888-96
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A number of O- and N-alkylated derivs. of the antinociceptive, orally active, μ-opioid-selective truncated enkephalin analog L-2,6-dimethyltyrosyl-N-(3-phenylpropyl)-D-alaninamide (SC-39566) were synthesized to explore the structure-activity relationships of the series. The parent mol. is quite forgiving of substitution on the tyrosyl phenolic moiety and on the alanyl nitrogen. The tyrosyl and (phenylpropyl)amide NH sites, however, appear to be critical to interactions with the receptor, for even modest changes at these sites cause great loss of binding potency.
IT 155920-96-0P 155920-97-1P 155921-12-3P
155921-13-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antinociceptive activity of)
RN 155920-96-0 CAPLUS
CN D-Alaninamide, O-[(4-carboxyphenyl)methyl]-2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 155920-97-1 CAPLUS
CN D-Alaninamide, O-[(4-carboxyphenyl)methyl]-2,6-dimethyl-D-tyrosyl-N-(3-phenylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 108 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



● HCl

RN 155921-12-3 CAPLUS
CN D-Alaninamide, O-[(4-carboxyphenyl)methyl]-2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155921-13-4 CAPLUS
CN D-Alaninamide, O-[(4-carboxyphenyl)methyl]-2,6-dimethyl-D-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 109 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:245977 CAPLUS
DOCUMENT NUMBER: 120:245977
TITLE: Novel phototransformation of o-nitrobenzylic polymers to azopolymers
AUTHOR(S): Ajayaghosh, A.; George, Soney C.; George, M. V.
CORPORATE SOURCE: Photochem. Res. Unit, Reg. Res. Lab., Trivandrum, 695 019, India
SOURCE: Journal of the Chemical Society, Chemical Communications (1994), (4), 423-4
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Synthesis and phototransformations of a polyamide-polyester bearing two o-nitrobenzylic chromophores at sym. positions per repeating unit to a polar photochromic azopolymer are described.

IT 154522-60-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by phototransformation of nitrobenzylic polyester)

RN 154522-60-8 CAPLUS

CN Poly[oxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxycarbonyl(4-carboxy-1,3-phenylene)azo(6-carboxy-1,3-phenylene)carbonyl] (9CI) (CA INDEX NAME)



L6 ANSWER 110 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:216992 CAPLUS
DOCUMENT NUMBER: 120:216992
TITLE: Process for preparing antiviral polyurea oligomers
INVENTOR(S): Cardin, Alan D.; Jackson, Richard L.; Mullins, Michael J.
PATENT ASSIGNEE(S): Dow Chemical Co., USA; Merrell Dow Pharmaceuticals Inc.
SOURCE: U.S., 19 pp, Cont.-in-part of U.S. Ser. No. 549,782, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5276182	A	19940104	US 1991-710370	19910610
AU 9180242	A	19920109	AU 1991-80242	19910708
AU 635850	B2	19930401		
CA 2046491	A1	19920110	CA 1991-2046491	19910708
FI 9103298	A	19920110	FI 1991-3298	19910708
FI 108041	B1	20011115		
NO 9102672	A	19920110	NO 1991-2672	19910708
NO 302827	B1	19980427		
EP 467185	A2	19920122	EP 1991-111315	19910708
EP 467185	A3	19920909		
EP 467185	B1	19981021		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9200749	A1	19920123	WO 1991-US4804	19910708
W: AU, CA, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9182867	A	19920204	AU 1991-82867	19910708
AU 650281	B2	19940616		
CN 1058959	A	19920226	CN 1991-105595	19910708
CN 1051096	B	20000405		
ZA 9105280	A	19930331	ZA 1991-5280	19910708
EP 538373	A1	19930428	EP 1991-913441	19910708
EP 538373	B1	19980513		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 62621	A2	19930528	HU 1991-2299	19910708
HU 219229	B	20010328		
HU 63561	A2	19930929	HU 1993-38	19910708
HU 214876	B	19980728		
JP 06500535	T	19940120	JP 1991-512671	19910708
JP 3442072	B2	20030902		
IL 98761	A	19950330	IL 1991-98761	19910708
HU 72414	A2	19960429	HU 1995-533	19910708
RU 2099360	C1	19971220	RU 1991-5001066	19910708
AT 165974	T	19980515	AT 1991-913441	19910708
ES 2116295	T3	19980716	ES 1991-913441	19910708
AT 172477	T	19981115	AT 1991-111315	19910708
ES 2124695	T3	19990216	ES 1991-111315	19910708
KR 212336	B1	19990802	KR 1991-11531	19910708

L6 ANSWER 110 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CA 2086438	C	20020312	CA 1991-2086438	19910708
MX 9405969	A	20020314	MX 1994-5969	19910708
JP 04226521	A	19920817	JP 1991-168126	19910709
JP 3187455	B2	20010711		
CZ 288574	B6	20010711	CZ 1991-2120	19910709
SK 283655	B6	20031104	SK 1991-2120	19910709
RU 2070554	C1	19961220	RU 1992-5052506	19920909
RU 2102406	C1	19980120	RU 1992-5052865	19920909
RU 2108345	C1	19980410	RU 1992-5052497	19920909
US 6232349	B1	20010515	US 1993-965248	19930107
NO 9300052	A	19930309	NO 1993-52	19930108
US 5606108	A	19970225	US 1993-132551	19931006
US 5728874	A	19980317	US 1993-174597	19931227
US 5547992	A	19960820	US 1995-407832	19950321
US 5571505	A	19961105	US 1995-445158	19950519
US 5670143	A	19970923	US 1995-445192	19950519
US 5670144	A	19970923	US 1995-469390	19950606
US 5728731	A	19980317	US 1995-469386	19950606
NO 9601910	A	19920110	NO 1996-1910	19960510
NO 306512	B1	19991115		
US 5707615	A	19980113	US 1997-834697	19970401

PRIORITY APPLN. INFO.:

US 1990-549782	B2	19900709
US 1991-710370	A	19910610
HU 1991-2299	A	19910708
NO 1991-2672	A	19910708
WO 1991-US4804	A	19910708
CS 1991-2120	A	19910709
US 1993-965248	A3	19930107
US 1993-132551	A3	19931006
US 1995-444461	B1	19950519

AB Polyurea oligomers R(NHCO)m(NHXNHCO)nNHR3 [R = H, C1-4 alkyl, (un)substituted Ph; R3 = R, XNH2; X = (un)substituted phenylene, (un)substituted biphenyl, (un)substituted naphthylene, etc.; m = 0, 1; n = 3-50; such that when m = 0, then R = H], which demonstrate antiviral activity and are useful in the treatment of AIDS and ARC, are prepared by condensing an aromatic diamine with a difunctional electrophile in the presence of an acid acceptor in water or water with >1 mol of water-immiscible cosolvent at 0-100° and pH 7-9. Careful adjustment of the reactant stoichiometry or using a monofunctional end-capping agent produces a water-soluble polyurea oligomer having number-average mol. weight >10,000. Biol. testing data is presented.

IT 141291-61-4P 154064-71-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of virucidal, for treatment of AIDS)

RN 141291-61-4 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 4-[(4-carboxybenzoyl)oxy]-2,5-disulfophenyl 4-[[4-[(4-hydroxy-2,5-disulfophenoxy)carbonyl]benzoyl]oxy]-2,5-disulfophenyl ester, hexasodium salt (9CI) (CA INDEX NAME)

L6 ANSWER 110 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



●6 Na

PAGE 1-B



RN 154064-71-8 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 4-[(4-carboxybenzoyl)oxy]-2,5-disulfophenyl 4-[[4-[(4-hydroxy-2,5-disulfophenoxy)carbonyl]benzoyl]oxy]-2,5-disulfophenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 110 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L6 ANSWER 111 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:533431 CAPLUS
DOCUMENT NUMBER: 119:133431
TITLE: Preparation of diphenylheteroalkyl derivatives as fungicides.
INVENTOR(S): Mueller, Thomas; Janssen, Bernd; Zierke, Thomas; Eicken, Karl; Ammermann, Eberhard; Lorenz, Gisela
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4142514	A1	19930624	DE 1991-4142514	19911221
EP 548711	A1	19930630	EP 1992-121143	19921211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
PRIORITY APPLN. INFO.:			DE 1991-4142514 A	19911221

OTHER SOURCE(S): MARPAT 119:133431
GI



I

AB The diphenylheteroalkyl derivs. I (A = CH2, O, S; R1-5 = H, halo, alkyl, Ph, etc.; R2R3 = CH:CHCH:CH, R4R5 = CH2CH2CH2CH2, CH2CH2CH2, OCH2O, etc.; R6 = CO2H, alkoxycarbonyl) are prepared as fungicides (no biol. data). A suspension of NaH in DMF was treated with a solution of 2-methyl-4-tert-butylphenol in DMF, followed by the addition of 4-carbethoxybenzyl bromide, to give 4-carboxybenzyl 2-methyl-4-tert-butylphenyl ether.

IT 149288-76-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as fungicide)

RN 149288-76-6 CAPLUS
CN Benzoic acid, 4-[[4-(2,4-dichlorophenoxy)phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 111 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 112 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:213083 CAPLUS
DOCUMENT NUMBER: 118:213083
TITLE: Preparation of naphthyridine derivatives as angiotensin II inhibitors
INVENTOR(S): Ratcliffe, Arnold Harry; Pearce, Robert James; Gibson,
Keith Hopkinson; Wood, Robin; Masek, Brian Bernard
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK
SOURCE: Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 516392	A2	19921202	EP 1992-304791	19920527
EP 516392	A3	19930127		
EP 516392	B1	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
ZA 9203478	A	19930224	ZA 1992-3478	19920513
AU 9216251	A	19921203	AU 1992-16251	19920514
HU 61303	A2	19921228	HU 1992-1608	19920515
CA 2068946	A1	19921201	CA 1992-2068946	19920519
GB 2256196	A	19921202	GB 1992-11211	19920527
GB 2256196	B	19950510		
AT 204873	T	20010915	AT 1992-304791	19920527
NO 9202147	A	19921201	NO 1992-2147	19920529
US 5217976	A	19930608	US 1992-890453	19920529
CN 1073174	A	19930616	CN 1992-104257	19920529
BR 9202099	A	19930119	BR 1992-2099	19920601
JP 05163271	A	19930629	JP 1992-140731	19920601
US 5294620	A	19940315	US 1993-42321	19930402
PRIORITY APPLN. INFO.:			GB 1991-11759 A	19910531
			GB 1991-16309 A	19910729
			GB 1992-11211	19920527
			US 1992-890453 A3	19920529

OTHER SOURCE(S): MARPAT 118:213083
GI

L6 ANSWER 112 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I (R1 = H, C1-8 alkyl, C3-8 cycloalkyl, Ph, substituted C1-4 alkyl; R2 = H, C1-4 alkyl, C1-4 alkoxy, halo, F3C, HO2C, C1-3 alkoxycarbonyl, cyano, O2N, etc.; R3 = halo, C1-4 alkoxy, HO, (alkyl)amino, etc.; R4 = H, C1-4 alkyl, C1-4 alkoxy, halo, F3C, cyano, O2N; Ra, Rb = substituent on linking group A; A = CH:CHCO, COCH:CH, COCH2CH2, CH2CH2CO, CH2CO, COCH2; X = (substituted) phenylene, bond; Z = (substituted) 1H-tetrazol-5-yl, NHSO2CF3, etc.), N-oxides, salts thereof, are prepared 5,7-Dimethyl-1,6-naphthyridin-2(1H)-one was added to NaH in DMF followed by 5-(2-(4-bromomethylbiphenylyl))-2-triphenylmethyl-2H-tetrazole to give 5,7-dimethyl-1-[[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,6-naphthyridin-2(1H)-one which in CH2Cl2/MeOH was stirred for 30 min to give the title compound II. In an in vivo test assessed against angiotensin II-induced pressor response the ED50 of II was 0.048 mg/kg, i.v. Pharmaceutical formulations comprising I are given.

IT 146720-10-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 146720-10-7 CAPLUS

CN Benzoic acid, 2-[[4-[(5,7-diethyl-2-oxo-1,6-naphthyridin-1(2H)-yl)methyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 113 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:148191 CAPLUS
DOCUMENT NUMBER: 118:148191
TITLE: Transesterification reactions between a polyarylate and poly(1,4-butylene terephthalate): identification of interchange units via model compounds
AUTHOR(S): Espinosa, Eli; Fernandez-Berridi, Maria J.; Maiza, Inaki; Valero, Miguel
CORPORATE SOURCE: Dep. Cienc. Tecnol. Polimeros, Univ. Pais Vasco, San Sebastian, 20080, Spain
SOURCE: Polymer (1993), 34(2), 382-8
CODEN: POLMAG; ISSN: 0032-3861
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The reactions taking place during melt mixing of bisphenol A-isophthalic acid-terephthalic acid copolymer with poly(butylene terephthalate) were studied by 1H and 13C NMR. Model compds. whose structures match those of the polymers and possible interchange units were prepared and characterized by 1H and 13C NMR. By means of this characterization, assignments of the absorptions appearing in the spectra of the soluble fraction were possible.

IT 146556-57-2P 146556-58-3P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and NMR of, as model for transesterification products from polyarylate and poly(butylene terephthalate))

RN 146556-57-2 CAPLUS

CN 1,4-Benzenedicarboxylic acid, mono[4-(1-methyl-1-phenylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 146556-58-3 CAPLUS

CN 1,3-Benzenedicarboxylic acid, mono[4-(1-methyl-1-phenylethyl)phenyl] ester (9CI) (CA INDEX NAME)



L6 ANSWER 114 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:103130 CAPLUS
DOCUMENT NUMBER: 118:103130
TITLE: Studies on main-chain liquid-crystalline model oligomers of defined length and structure
AUTHOR(S): Seliger, H.; Eppel, M.; Goeldner, E.; Kittel, I.; Ludwig, A.; Schorr, Ludwig
CORPORATE SOURCE: Sekt. Polym., Univ. Ulm, Ulm, D 7900, Germany
SOURCE: Makromolekulare Chemie, Macromolecular Symposia (1992), 58(Solution Prop. Modif. Polym.), 215-20
CODEN: MCMSES; ISSN: 0258-0322
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Oligomers of defined sequence and structure-modeling main-chain liquid crystalline (LC) polymers were prepared (a) by solution synthesis; (b) by a novel liquid phase synthesis using 2 monomethoxy-poly(ethylene glycol) supports.
Benzyl and tertbutyl groups were used as an orthogonal pair of protecting groups for route a, and also as compatible anchor groups for carriers in route b. Depending on chain structure and end groups, at least ca. 3 mesogenic elements were required to allow for LC phase transitions. The phase behavior of oligomers with free carboxylic ends could be explained by their association tendency.

IT 143389-18-8 143389-19-9 143389-22-4
143389-24-6
RL: PROC (Process)
(phase behavior of, as models for liquid-crystalline polyester-polyethers)

RN 143389-18-8 CAPLUS

CN 1,4-Benzenedicarboxylic acid, mono[4-[[10-[4-[[(phenylmethoxy)carbonyl]oxy]phenoxy]decyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)



RN 143389-19-9 CAPLUS

CN 1,4-Benzenedicarboxylic acid, mono[4-[[10-(4-hydroxyphenoxy)decyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)



RN 143389-22-4 CAPLUS

L6 ANSWER 114 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,4-Benzenedicarboxylic acid, 1,10-decanediylbis(oxy-4,1-phenylene) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 143389-24-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, bis[4-[[10-[4-[(4-carboxybenzoyl)oxy]phenoxy]decyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:614252 CAPLUS
DOCUMENT NUMBER: 117:214252
TITLE: Preparation and properties of oligomers of defined chain length and structure as models for technical copolymers
AUTHOR(S): Seliger, H.; Bitar, M. B.; Goeldner, E.; Kittel, I.; Kilian, H. G.
CORPORATE SOURCE: Sekt. Polym., Univ. Ulm, Ulm, D-7900, Germany
SOURCE: Revue Roumaine de Chimie (1991), 36(1-3), 171-85
CODEN: RRCHAX; ISSN: 0035-3930
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Oligomeric segments of the macromols. with defined structure were prepared in an attempt to answer the question whether the thermal and mech. properties of the polyester elastomers were mainly influenced by the segregation or by the structural heterogeneity. Monobenzylated bisphenol A and terephthalic acid mono-tert-Bu ester were used as starting compds. for the preparation of oligomeric arylates.
IT 92002-18-1P 92002-19-2P 92002-20-5P
92002-21-6P 92002-22-7P 92002-23-8P
92002-24-9P 92002-25-0P 92002-49-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model for block polyester elastomers)
RN 92002-18-1 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 92002-19-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 114 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 92002-20-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-21-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 92002-22-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-D

RN 92002-23-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 92002-24-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 92002-25-0 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-[4-[[4-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-49-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-[4-[[4-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT 143389-18-8P 143389-19-9P 143389-22-4P
143389-24-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model for liquid-crystalline polymers)
RN 143389-18-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid,
mono[4-[[10-[4-[[(phenylmethoxy)carbonyl]oxy
]phenoxy]decyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 143389-19-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid,
mono[4-[[10-(4-hydroxyphenoxy)decyl]oxy]phen
yl] ester (9CI) (CA INDEX NAME)



RN 143389-22-4 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,10-decanediylbis(oxy-4,1-phenylene) ester
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 143389-24-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, bis[4-[[10-[4-[(4-
carboxybenzoyl)oxy]phenoxy]decyl]oxy]phenyl] ester (9CI) (CA INDEX NAME)

L6 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 116 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	1992:572322 CAPLUS
DOCUMENT NUMBER:	117:172322
TITLE:	Manufacture of terminal carboxylic acid-modified polyoxyphenylenes
INVENTOR(S):	Omura, Haruo; Aritomi, Mitsutoshi
PATENT ASSIGNEE(S):	Mitsubishi Petrochemical Co., Ltd., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 6 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04145125	A	19920519	JP 1990-266277	19901005
PRIORITY APPLN. INFO.:			JP 1990-266277	19901005

GI



I

AB The title polymers I [Q1, Q2 = halo, alkyl, Ph, aminoalkyl (for Q1), haloalkyl (for Q2), (halo)hydrocarbyloxy; R1-2 = H, C1-6 hydrocarbyl; R3 = direct bond, C1-32 hydrocarbon; Y = OH, reactive residue of CO2H; m = 1-5; n ≥10], showing high reactivity with other polymers, are prepared by treating (substituted) polyoxyphenylenes with benzyl halides XCR1R2C6H4(R3COY)m (X = halo). Thus, a solution of 20.0 g poly(phenylene ether) in PhMe was stirred with NaOMe at 90° for 30 min and treated with 5.1 g p-bromomethylphenylacetic acid for 7 h to give 100% modified polymer at terminal OH reactivity 30.3%.

IT 143673-06-7P
RL: PREP (Preparation)
(preparation of, with good reactivity)
RN 143673-06-7 CAPLUS
CN Poly[oxy(2,6-dimethyl-1,4-phenylene)], α-[(4-carboxyphenyl)methyl]-
ω-(2,6-dimethylphenoxy)- (9CI) (CA INDEX NAME)

L6 ANSWER 116 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 117 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:228231 CAPLUS
DOCUMENT NUMBER: 116:228231
TITLE: Synthetic oligomers for diagnosis and treatment of AIDS and AIDS-related complex
INVENTOR(S): Cardin, Alan D.; Jackson, Richard L.; Mullins, Michael J.
PATENT ASSIGNEE(S): Dow Chemical Co., USA; Merrell Dow Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 467185	A2	19920122	EP 1991-111315	19910708
EP 467185	A3	19920909		
EP 467185	B1	19981021		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5276182	A	19940104	US 1991-710370	19910610
CZ 288574	B6	20010711	CZ 1991-2120	19910709

PRIORITY APPLN. INFO.:

US 1990-549782	A	19900709
US 1991-710370	A	19910610
CS 1991-2120	A	19910709

AB The title oligomers (Markush included) are preferably polyureas, polycarbonates, polyesters, or polyamides having an average mol. weight <10,000.

The oligomers are water soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically acceptable. Preparation of reactants and oligomers is described, as is their activity against human immunodeficiency virus (syncytium formation and expression of P24 viral core antigen).

IT 141291-61-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for AIDS and AIDS-related complex diagnosis and treatment)
RN 141291-61-4 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[(4-carboxybenzoyl)oxy]-2,5-disulfophenyl 4-[[4-[(4-hydroxy-2,5-disulfophenoxy)carbonyl]benzoyl]oxy]-2,5-disulfophenyl ester, hexasodium salt (9CI) (CA INDEX NAME)

L6 ANSWER 117 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



●6 Na

PAGE 1-B



L6 ANSWER 118 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:656165 CAPLUS
DOCUMENT NUMBER: 115:256165
TITLE: Preparation of N-benzylated imidazopyridines and benzimidazoles as angiotensin II antagonists
INVENTOR(S): Greenlee, William J.; Patchett, Arthur A.; Hangauer, David; Walsh, Thomas; Fitch, Kenneth J.; Rivero, Ralph A.; Dhanoa, Daljit S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9111999	A1	19910822	WO 1991-US957	19910211
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2075627	A1	19910814	CA 1991-2075627	19910211
CA 2075637	A1	19910814	CA 1991-2075637	19910211
EP 517812	A1	19921216	EP 1991-905733	19910211
R: CH, DE, FR, GB, IT, LI, NL				
JP 05504969	T	19930729	JP 1991-505964	19910211
US 5240938	A	19930831	US 1991-744557	19910813
US 5264439	A	19931123	US 1991-744138	19910813
US 5449682	A	19950912	US 1993-61975	19930517

PRIORITY APPLN. INFO.:

US 1990-479786	A	19900213
WO 1991-US957	W	19910211
US 1991-671551	B2	19910319
US 1991-671552	B2	19910319
US 1991-744557	A3	19910813

OTHER SOURCE(S): MARPAT 115:256165
GI



I II

L6 ANSWER 118 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. [I; R1 = (substituted) alkyl, alkenyl, alkynyl, (hetero)aryl, perfluoroalkyl; R9, R10 = H, (cycloalkyl)alkyl, alkenyl, alkynyl, halo, alkoxy, perfluoroalkyl, (alkyl)cycloalkyl, aryl; adjacent R9R10 = CH:CHCH:CH; R11, R12 = H, (substituted) alkyl, aryl, arylalkyl, cycloalkyl; B = bond, SOn(CH2)s, O; n = 0-2; s = 0-5; X = O, SOn, imino, CH2O, CH2, CH2CH2, bond SOnCH2, etc.; Y = bond, SOn imino, CH2; Z = CO2H, alkoxycarbonyl, tetrazol-5-yl, arylsulfonylcarbamoyl, P(O)(OH)2, etc.; A1-A2-A3-A4-A5 = moieties to complete (substituted) benzene or heterocyclic (e.g., pyridine) rings], were prepared as antihypertensives, nootropics, anxiolytics, and antidepressants (no data). Thus, 2-butylbenzimidazole and 4-(PhCH2O)C6H4Cl were condensed to give 96% N-benzylated product, which was hydrogenolyzed (83%) followed by condensation with BrCHPhCO2Me (17%) and saponification (30%) to give title compound II.

IT 137445-46-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 137445-46-6 CAPLUS

CN Benzeneacetic acid, 2-carboxy-α-[4-[(7-methyl-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenoxy]- (CA INDEX NAME)



L6 ANSWER 119 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Benzoic acid, 4-[(4-carboxyphenyl)methoxy]-, 1-(6-hexyltetrahydro-2-oxo-2H-pyran-3-yl) ester, (3S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 119 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:438766 CAPLUS
DOCUMENT NUMBER: 115:38766
TITLE: Optically active compound and liquid crystal composition
INVENTOR(S): Ikemoto, Tetsuya; Sakashita, Keiichi; Hayashi, Seiji
PATENT ASSIGNEE(S): Mitsubishi Rayon Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 396410	A2	19901107	EP 1990-304804	19900502
EP 396410	A3	19910626		
R: DE, FR, GB				
US 5164113	A	19921117	US 1990-515754	19900430
JP 03072473	A	19910327	JP 1990-115518	19900501
JP 03072479	A	19910327	JP 1990-123556	19900514
PRIORITY APPLN. INFO.:			JP 1989-112935	A 19890502
			JP 1989-127482	A 19890519

OTHER SOURCE(S): MARPAT 115:38766
GI



AB An optically active compound is described having a δ-valerolactone ring (I) [Z1 = CO2, CH2O, O; when A1, A2 = unsubstituted or F-, Cl-, or CN-substituted p-phenylene, R1 = Me(CH2)qCHMe(CH2)p (p + q ≤12), II, CnH2n+1X1-p-CHMe, X1 = direct bond or O; when A1, A2 = one of their same as above and other one unsubstituted a F-or Cl- or CN-substituted 2,5-pyridinediyl or 3,6-pyridazinediyl or 2,5-pyrazinediyl or 2,5-pyrimidinediyle; n = 1-14; X = O, O2C, OCH2; Y = direct bond, O2C, CO2, CH2O, OCH2; some other restrictions of combinations apply]. Ferroelec. liquid crystal compns. containing the above compds. are chemical stable and not colored, and have good light stability and short response time.

IT 134538-04-8P
RL: PREP (Preparation)
(preparation and phase transition temperature and use of, as optically active compound in liquid crystal composition)

RN 134538-04-8 CAPLUS

L6 ANSWER 120 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:185568 CAPLUS
DOCUMENT NUMBER: 114:185568
TITLE: Preparation of anti-inflammatory 4-(heterocyclylamino)phenol derivatives
INVENTOR(S): Bantick, John Raymond; Hardern, David Norman; Appleton, Richard Anthony; Dixon, John; Wilkinson, David John
PATENT ASSIGNEE(S): Fisons PLC, UK
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English.
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9014338	A1	19901129	WO 1990-GB762	19900517
W: AU, FI, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9056682	A	19901218	AU 1990-56682	19900517
AU 630196	B2	19921022		
ZA 9003802	A	19910130	ZA 1990-3802	19900517
EP 425650	A1	19910508	EP 1990-908298	19900517
EP 425650	B1	19950809		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 06502384	T	19940317	JP 1990-507734	19900517
JP 07116155	B	19951213		
ES 2077066	T3	19951116	ES 1990-908298	19900517
RU 2049779	C1	19951210	RU 1990-4894663	19900517
CA 2017169	A1	19901120	CA 1990-2017169	19900518
HU 54119	A2	19910128	HU 1990-3094	19900518
HU 206323	B	19921028		
DD 300544	A5	19920617	DD 1990-340830	19900518
PL 164432	B1	19940729	PL 1990-285248	19900518
PL 164480	B1	19940831	PL 1990-289487	19900518
IL 94433	A	19950315	IL 1990-94433	19900518
CZ 280637	B6	19960313	CZ 1990-2444	19900518
CN 1047497	A	19901205	CN 1990-103739	19900519
RO 105958	B1	19930130	RO 1990-145922	19900912
NO 9100198	A	19910312	NO 1991-198	19910117
US 5428044	A	19950627	US 1993-138375	19931015
PRIORITY APPLN. INFO.:			GB 1989-11654	A 19890520
			GB 1989-11655	A 19890520
			GB 1990-3044	A 19900210
			WO 1990-GB762	A 19900517
			US 1991-634182	B1 19910301
			US 1992-978041	B1 19921118

OTHER SOURCE(S): MARPAT 114:185568
GI

L6 ANSWER 120 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB The title compds. [I; R1 = C(O)YZ, SO2R10; Y = single bond, O, NH, alkylimino, CO; Z = H, alkyl, alkyl substituted by ≤1 substituents selected from OH, alkoxy, acyloxy, CO2H, alkoxycarbonyl, (un)substituted CONH2 or NH2, heterocyclyl, (un)substituted aryl, etc.; R10 = alkyl; R2, R3, R5, R6 = H, alkyl, alkoxy, halo; R4 = H, alkyl; X = (un)substituted heterocyclyl] are prepared as antiinflammatories (no data). Thus, acetylation of 2,6-dimethyl-4-nitrophenol with AcCl in CH2Cl2 containing Et3N followed by hydrogenation over PtO2 in EtOH gave 4-amino-2,6-dimethylphenyl acetate which was refluxed with 3-amino-4,5-dihydro-1-phenyl-1H-pyrazole in PhMe containing 4-MeC6H4SO3H for 8 h to give 4-(4,5-dihydro-1-phenyl-1H-pyrazol-3-yl)amino-2,6-dimethylphenyl acetate. A total of 117 I containing heterocycles, i.e., pyrazole, benzimidazole, quinoline, pyrimidine, pyrazine, oxazole, 1,2,3-triazole, pyridazine, imidazole, 1,2,4-thiadiazole, thiophene, isoxazole, 1,2,4-triazine, and 1,3,4-thiadiazole, were prepared

IT 133356-63-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)

RN 133356-63-5 CAPLUS

CN 1,4-Benzenedicarboxylic acid, mono[2,6-dimethyl-4-[(1-phenyl-1H-pyrazol-3-yl)amino]phenyl] ester (9CI) (CA INDEX NAME)



L6 ANSWER 121 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:515982 CAPLUS
DOCUMENT NUMBER: 113:115982
TITLE: Synthesis of a mesogenic condensation monomer and the sequential block copolymers thereof
AUTHOR(S): Li, Zifa; Zhang, Ziyong; Zhou, Qifeng; Li, Zhe
CORPORATE SOURCE: Chem. Dep., Zhengzhou Univ., Zhengzhou, Peop. Rep. China
SOURCE: Gaofenzi Xuebao (1989), (2), 193-9
CODEN: GAXUE9; ISSN: 1000-3304
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB 2-Methyl-1,4-phenylenebis[(4-chloroformyl) benzoate] was prepared and polymerized with 1,10-decanediol and polypropylene glycol liquid crystal- and non-liquid crystal-containing sequential block copolymer. In the DSC thermograms of the samples with higher inherent viscosity, a marked exothermic peak existed after melting of the samples. This unusual phenomenon suggested an addnl. organization of the mols. in the liquid crystalline state.

IT 129255-93-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with thionyl chloride)

RN 129255-93-2 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-methyl-1,4-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 122 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:191374 CAPLUS
DOCUMENT NUMBER: 112:191374
TITLE: Part VI. Nonpeptide angiotensin II receptor antagonists: N-[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives
AUTHOR(S): Carini, David J.; Duncia, John V.; Johnson, Alexander L.; Chiu, Andrew T.; Price, William A.; Wong, Pancras C.; Timmermans, Pieter B. M. W.
CORPORATE SOURCE: Med. Prod. Dep., E. I. du Pont de Nemours and Co., Inc., Wilmington, DE, 19880, USA
SOURCE: Journal of Medicinal Chemistry (1990), 33(5), 1330-6
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of title compds. (I, R1 = Bu, SEt, SPr; R2 = H, Cl, CH2OH, CH2OAc; R3 = CH2OH, Cl, CH2OAc, CH2NHCO2Me; R4 = CO2H, NHSO2CF3; X = NHCO, CO, O, S, OCH2 etc.; n = 0-1) was synthesized and demonstrated to be antagonists of the angiotensin II (AII) receptor. I are structurally related to the N-(benzamidobenzyl)imidazoles and extend the scope of this new class of nonpeptide AII antagonists. The amide linkage (X = NHCO) in the N-(benzamidobenzyl)imidazoles can be replaced successfully by a variety of groups (X = O, S, CO, OCH2, CH:CH, NHCONH; n = 0-1); linkers of 0-1 atoms in length are most effective. When administered i.v. to awake renal hypertensive rats, these compds. exhibited potent antihypertensive activity.

IT 114799-46-1P 114799-47-2P 114799-48-3P
114799-49-4P 114799-61-0P 125848-45-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and angiotensin II antagonist activity of)

RN 114799-46-1 CAPLUS

CN Benzoic acid, 2-[[4-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 122 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-47-2 CAPLUS

CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-48-3 CAPLUS

CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 122 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-49-4 CAPLUS
CN Benzoic acid,
2-[[4-[[5-[(acetyloxy)methyl]-2-butyl-4-chloro-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-61-0 CAPLUS
CN Benzoic acid, 2-[[4-[[5-(hydroxymethyl)-2-(propylthio)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 122 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 125848-45-5 CAPLUS
CN Benzoic acid, 2-[[4-[[2-(ethylthio)-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 123 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:149114 CAPLUS
DOCUMENT NUMBER: 112:149114
TITLE: Recording materials containing electron-donating dye and salicylic acid derivatives
INVENTOR(S): Iwakura, Ken; Sano, Masajiro
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 01168487	A	19890703	JP 1987-329268		19871225
US 4920091	A	19900424	US 1988-290669		19881227
PRIORITY APPLN. INFO.:			JP 1987-329268	A	19871225
			JP 1988-59919	A	19880314
			JP 1988-59920	A	19880314
			JP 1988-170546	A	19880708

GI



I



II

AB The title recording materials use electron-donating dye precursors and salicylic acid derivs. or their metal salts (as electron-acceptors) of the formula I (Z = bivalent groups; R = R1 = H, alkyl, Ph, alkoxy, halo). The materials show excellent developability and good image stability. Thus, a color former sheet prepared by coating on a paper a dispersion of microcapsules containing Crystal Violet lactone and a developer sheet

L6 ANSWER 123 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
by coating a dispersion of II, a clay, CaCO3, ZnO, and Na hexametaphosphate in poly(vinyl alc.) and COOH-modified SBR latex were contacted with each other to give a high-quality recording sheet.
IT 125941-04-0
RL: USES (Uses)
(electron acceptor, recording material containing, for developability and
image stability)
RN 125941-04-0 CAPLUS
CN Zinc, [[3,3'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis[6-hydroxy-5-methylbenzoato]](2-)-O1,O6]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 124 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:118817 CAPLUS
DOCUMENT NUMBER: 112:118817
TITLE: Preparation of (biphenylylmethyl)imidazoles and analogs as antihypertensive agents
INVENTOR(S): Carini, David John; Wong, Pancras Chor Bun; Duncia, John Jonas Vytautas
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 271 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 324377	A2	19890719	EP 1989-100144	19890105
EP 324377	A3	19910206		
EP 324377	B1	19970416		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5138069	A	19920811	US 1988-279194	19881206
CA 1338238	C	19960409	CA 1988-586904	19881222
WO 8906233	A1	19890713	WO 1989-US52	19890105
W: JP				
JP 03501020	T	19910307	JP 1989-501656	19890105
JP 07025738	B	19950322		
EP 733366	A2	19960925	EP 1996-107930	19890105
EP 733366	A3	19961009		
EP 733366	B1	19980401		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 151755	T	19970515	AT 1989-100144	19890105
ES 2100150	T3	19970616	ES 1989-100144	19890105
AT 164520	T	19980415	AT 1996-107930	19890105
ES 2117463	T3	19980801	ES 1996-107930	19890105
DK 8900051	A	19890708	DK 1989-51	19890106
DK 174948	B1	20040315		
FI 8900070	A	19890708	FI 1989-70	19890106
FI 99012	B	19970613		
FI 99012	C	19970925		
NO 8900075	A	19890710	NO 1989-75	19890106
NO 177265	B	19950508		
NO 177265	C	19950816		
AU 8927771	A	19890713	AU 1989-27771	19890106
AU 617736	B2	19911205		
ZA 8900127	A	19900926	ZA 1989-127	19890106
SU 1814646	A3	19930507	SU 1989-4613475	19890106
HU 64038	A2	19931129	HU 1989-50	19890106
HU 218201	B	20000628		
US 5128355	A	19920707	US 1989-435869	19891113
US 5153197	A	19921006	US 1989-436165	19891113
US 5155118	A	19921013	US 1989-436281	19891113
RU 2017733	C1	19940815	RU 1992-5010637	19920127
US 5210079	A	19930511	US 1992-832638	19920207
US 5354867	A	19941011	US 1993-47883	19930415
PRIORITY APPLN. INFO.:			US 1988-142580 A	19880107
			US 1988-279194 A	19881206
			US 1986-884920 B2	19860711
			US 1987-50341 B2	19870522
			EP 1989-100144 A3	19890105
			WO 1989-US52 W	19890105
			US 1989-373755 B2	19890630
			US 1990-542351 B1	19900622
			US 1990-545240 B1	19900627

OTHER SOURCE(S): MARPAT 112:118817
GI



AB The title compds. [I; R1 = acyl, tetrazolyl, aminoacyl, acylamino, biphenylyl, etc.; R2 = H, halo, NO2, cyano, C1-4 alkyl, etc.; R3 = H, halo, C1-4 alkyl, alkoxy; R6 = C2-10 alkyl, C3-10 alkenyl, alkynyl, C3-8 cycloalkyl, (un)substituted Ph, PhCH2, etc.; R7 = H, halo, NO2, cyano, pentafluorophenyl, etc.; R8 = H, cyano, C1-10 (fluoro)alkyl, etc.; r = 0-2] were prepared Thus, 2-butyl-4-chloro-5-hydroxymethylimidazole was stirred 0.5 h with NaOMe in MeOH and the product stirred overnight with 4'-bromomethyl-2-cyanobiphenyl (preparation given) in DMF to give title compound
II (R = cyano, R4 = H) which was converted in 2 steps to II (R = cyano, R4 = Me). The latter was stirred 2 days at 100° and 11 days at 120° with NaN3 in DMF containing NH4Cl to give II (R = 1H-tetrazol-5-yl, R4 = Me) the Na salt of which had IC50 of 0.020 uM for inhibition of angiotensin II receptor binding and showed significant decreases in blood pressure in rats at ≤10 and ≤100 mg/kg i.v. and orally, resp.
IT 114799-45-0P 114799-47-2P 114799-48-3P
114799-49-4P 114799-61-0P 124750-06-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antihypertensive agent)
RN 114799-45-0 CAPLUS
CN 1H-Imidazole-5-acetic acid, 2-butyl-1-[[4-[(2-carboxyphenyl)methoxy]phenyl]methyl]-4-chloro- (CA INDEX NAME)

L6 ANSWER 124 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-47-2 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-48-3 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 124 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-49-4 CAPLUS
CN Benzoic acid, 2-[[4-[[5-[(acetyloxy)methyl]-2-butyl-4-chloro-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-61-0 CAPLUS
CN Benzoic acid, 2-[[4-[[5-(hydroxymethyl)-2-(propylthio)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 124 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 124750-06-7 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 125 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 3

CRN 95-70-5
CMF C7 H10 N2



L6 ANSWER 125 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:634389 CAPLUS
DOCUMENT NUMBER: 111:234389
TITLE: Manufacture of hard moldings from ionene polymers containing diacetylene groups
INVENTOR(S): Matsuda, Hiroo; Nakanishi, Hachiro; Tanaka, Yoshio; Nakayama, Kazuo; Kato, Masao
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01092230	A	19890411	JP 1987-56150	19870311
JP 06015621	B	19940302		

PRIORITY APPLN. INFO.: JP 1987-56150 19870311

AB Moldings having high modulus and strength are prepared by solid-phase polymerization of the diacetylene groups of polymers containing units (O2CR1C.tplbond.CC.tplbond.CR1CO2)2- (H3NR2NH3)2+ (I; R1, R2 = alkylene, cycloalkylene, arylene, etc.) and polycondensation of the products in a mold at 100-400°/5000-150,000 atmospheric Irradiation of a polymer containing units I [R1 = (CH2)8; R2 = (CH2)5] with gamma rays (50 MRad) in vacuo and press molding at 230°/50,000 atm for 20 min gave a molding having Vickers hardness 190 kg/mm2.

IT 116075-83-3P
RL: PREP (Preparation)
(preparation of radiochem. cured, as hard moldings)

RN 116075-83-3 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, compd. with 2-methyl-1,4-benzenediamine (1:1), homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 116075-82-2
CMF C32 H16 N2 O12 . C7 H10 N2

CM 2

CRN 116075-81-1
CMF C32 H16 N2 O12



L6 ANSWER 126 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:632596 CAPLUS
DOCUMENT NUMBER: 111:232596
TITLE: Quinoline derivatives, their use in the treatment of hypersensitive ailments, and pharmaceutical compositions containing them
INVENTOR(S): Huang, Fu Chi; Galemmo, Robert Anthony, Jr.; Campbell, Henry Flud
PATENT ASSIGNEE(S): Rorer International (Overseas), Inc., USA
SOURCE: Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 315399	A2	19890510	EP 1988-310241	19881101
EP 315399	A3	19901128		
EP 315399	B1	19960110		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4920132	A	19900424	US 1987-116420	19871103
WO 8904305	A1	19890519	WO 1988-US3897	19881101
W: AU, JP, US				
AU 8927946	A	19890601	AU 1989-27946	19881101
AU 633475	B2	19930204		
JP 03500889	T	19910228	JP 1989-500520	19881101
JP 07107053	B	19951115		
AT 132856	T	19960115	AT 1988-310241	19881101
US 5059610	A	19911022	US 1990-477896	19900420
PRIORITY APPLN. INFO.:			US 1987-116420 A	19871103
			WO 1988-US3897 A	19881101

OTHER SOURCE(S): CASREACT 111:232596; MARPAT 111:232596
GI

L6 ANSWER 126 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Quinolines I [A = O, S; B = O, S, SO, SO2, NR1, CO, NR1CO, CONR1; D = O, S, NR, CR1:CR1, bond; E = bond, CR1:CR1; a, n = 0-2; b = 0-1; c, e = 0-4; d, f = 0-5; R = H, alkyl, OH, alkoxy, CO2H, carbalkoxy, halo, NO2, haloalkyl, cyano, acyl; R' = H, alkyl, OH, alkoxy, halo, haloalkyl; R1 = H, alkyl, aralkyl; R2 = (CH2)xX; x = 0-3; X = H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, OH, alkoxy, aralkoxy, (di)(alkyl)amino, aralkylamino, acylamino, carbamyl, CO2H, carbalkoxy, tetrazolyl, acylsulfonamido; vicinal (R2)2 = (CH2)y; y = 1-4; geminal (R2)2 = (CH2)z; z = 2-5; geminal (R1)2, R1R2 = :CHR1; Z = CO2R1, cyano, CONHSO2R3, CON(R1)2, OR, tetrazolyl (may be substituted by alkyl, carboxyalkyl, or carbalkoxyalkyl); R3 = H, alkyl, haloalkyl, Ph, PhCH2] are prepared as lipoxygenase inhibitors and/or leukotriene antagonists (no data). Alkylation of Na 3-(2-quinolinylmethoxy)phenoxide by p-NCC6H4CH2Br in DMF gave 4-[3-(2-quinolinylmethoxy)phenoxymethyl]benzonitrile, which underwent cycloaddn. with HN3 (from NaN3 and pyridine-HCl) in DMF to give title [[(quinolinylmethoxy)phenoxymethyl]phenyl]tetrazole II.

IT 123226-32-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiallergic quinoline derivs.)

RN 123226-32-4 CAPLUS

CN Benzoic acid, 4-[[4-[(2-quinolinylmethyl)sulfinyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 126 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 123247-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as allergy inhibitor)

RN 123247-26-7 CAPLUS

CN Benzoic acid, 4-[[4-[(2-quinolinylmethyl)sulfonyl]phenoxy]methyl]- (CA INDEX NAME)



IT 123226-42-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiallergic quinoline derivs.)

RN 123226-42-6 CAPLUS

CN Benzoic acid, 4-[[4-[(2-quinolinylmethyl)thio]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 127 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:526455 CAPLUS

DOCUMENT NUMBER: 111:126455

TITLE: Q-model information cluster analysis-assisted design of dauricine derivatives

AUTHOR(S): Cai, Huiming; Huang, Zhenya; Yang, Zhenxiang; Wang, Erhua; Peng, Sixun

CORPORATE SOURCE: Div. Med. Chem., China Pharm. Univ., Nanjing, Peop. Rep. China

SOURCE: Zhongguo Yaoke Daxue Xuebao (1989), 20(1), 1-4
CODEN: ZHYXE9; ISSN: 1000-5048

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



I

AB Dauricine (I; R = H) was taken as a lead compound and the Q-model information-cluster anal. was employed for the computer-aided mol. design; 59 substituents were clustered into 3 categories, 5-cluster, 10-cluster and 16-cluster, according to 3 kinds of chemical structure parameter, R, Vw' and SIC (structural information content). On the basis of the results of the anal. of 5-cluster, 12 derivs. of dauricine were designed and then prepared Their calmodulin-antagonistic activities were examined The results showed that the derivs. of different clusters have more varied activities and the derivs. of the same cluster have less varied activities except one compound The results also showed that the first group of 5-cluster is an active group.

IT 122559-79-9 122560-06-9
RL: BIOL (Biological study)
(Q-model information cluster anal. of structure in relation to)

RN 122559-79-9 CAPLUS

CN 1,2-Benzenedicarboxylic acid, mono[4-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]-2-[4-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]phenyl] ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 127 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 122560-06-9 CAPLUS

CN Benzoic acid, 4-[[4-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]-2-[4-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]phenoxy]methyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L6 ANSWER 127 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

L6 ANSWER 128 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:497993 CAPLUS
DOCUMENT NUMBER: 111:97993
TITLE: Diamine alkadiynedioate salts for production of two-dimensional macromolecular crystals and shaped articles
INVENTOR(S): Matsuda, Hiro; Nakanishi, Hachiro; Kato, Masao; Tanaka, Yoshio; Nakayama, Kazuo
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan; Japan, Ministry of International Trade and Industry
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4814404	A	19890321	US 1987-90099	19870827
JP 63063635	A	19880322	JP 1986-208714	19860904
JP 02038579	B	19900831		
JP 63063713	A	19880322	JP 1986-208715	19860904
JP 63033486	B	19880705		
JP 63221115	A	19880914	JP 1987-53432	19870309
JP 04012885	B	19920306		
PRIORITY APPLN. INFO.:			JP 1986-208714	19860904
			JP 1987-53432	19870309
			JP 1986-208715	19860904

AB The title polymers, giving rigid moldings, are prepared by solid-state addition polymerization of HOCOZC.tplbond.C-C.tplbond.C2CO2H.H2N2lNH2 [2, Z' = (substituted) alkylene, arylene, or cycloalkylene] followed by solid-state polycondensation. The salt HOCO(CH2)8C.tplbond.C-C.tplbond.C(CH2)8CO2H.H2N(CH2)5NH2 was irradiated with 50 Mrad γ-rays to form blackish-blue polydiacetylene crystals and heated 24 h at 120° in vacuo to give red polyamide-polydiacetylene 2-dimensional crystals.

IT 116075-82-2P
RL: PREP (Preparation)
(preparation of)

RN 116075-82-2 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, compd. with 2-methyl-1,4-benzenediamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 116075-81-1
CMF C32 H16 N2 O12

L6 ANSWER 128 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 95-70-5
CMF C7 H10 N2



IT 122186-24-7P
RL: PREP (Preparation)
(preparation of, with 2-dimensional crystallization, by radiochem.-thermal polymerization)

RN 122186-24-7 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, polymer with 2-methyl-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1

CRN 116075-81-1
CMF C32 H16 N2 O12



CM 2

CRN 95-70-5
CMF C7 H10 N2

L6 ANSWER 128 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 129 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:407850 CAPLUS
DOCUMENT NUMBER: 111:7850
TITLE: Thermally stable polymers based on bismaleimides containing amide, imide, and ester linkages
AUTHOR(S): Melissaris, Anastasios P.; Mikroyannidis, John A.
CORPORATE SOURCE: Dep. Chem., Univ. Patras, Patras, 260 01, Greece
SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry
(1989), 27(1), 245-62
CODEN: JPACEC; ISSN: 0887-624X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Seven structurally different bismaleimides were synthesized and characterized by IR and proton NMR spectroscopy. The chains of these polymer precursors were extended by incorporating amidized, imidized, and esterified 4-chloroformyl phthalic anhydride. The bismaleimides containing amide and imide linkages were prepared by a simple synthetic route based on the reaction of the monomaleamic acid derived from various aromatic diamines with 4-chloroformyl phthalic anhydride and subsequent cyclodehydration of the intermediate triamic acid. The DTA scans of bismaleimides showed exotherms at 221-304° associated with their polymerization reactions. The thermogravimetric anal. traces of the polymers did not show a weight loss up to 351-393 and 344-372° in N and air atmospheres, resp. The anaerobic char yield of polymers at 800° was 44-61%.

IT 121069-74-7P 121069-76-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 121069-74-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-[[[4-[(3-carboxy-1-oxo-2-propenyl)amino]phenyl]amino]carbonyl]-, 1,1'-(1,4-phenylene) ester, (Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 129 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 129 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 121069-76-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-[[[4-[(3-carboxy-1-oxo-2-propenyl)amino]phenyl]amino]carbonyl]-, 1,1'-[(1-methylethylidene)di-4,1-phenylene] ester, (Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



L6 ANSWER 129 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L6 ANSWER 130 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:172814 CAPLUS
DOCUMENT NUMBER: 110:172814
TITLE: Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes
AUTHOR(S): Brown, Frederick J.; Bernstein, Peter R.; Cronk, Laura A.; Dosset, David L.; Hebbel, Kevin C.; Maduskuie, Thomas P., Jr.; Shapiro, Howard S.; Vacek, Edward P.; Yee, Ying K.; et al.
CORPORATE SOURCE: Dep. Med. Chem., ICI Pharm. Group, Wilmington, DE, 19897, USA
SOURCE: Journal of Medicinal Chemistry (1989), 32(4), 807-26
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:172814
GI



I

AB Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group. Although considerable attention has focused on FPL 55712-derived analogs, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid I (R = Ac,R1 = CO2H) was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-Pr group ,e.g., I (R = Ac, R1 = PhCH2, CH2CMe:CH2) and the 4-acetyl functionality ,e.g., I (R = CO2Me, CO2Et, R1 = Pr) yielded potent antagonists. A number of compds. exhibited longer duration of action in vivo than FPL 55712.
IT 118683-26-4P 118683-29-7P 118683-34-4P
118683-35-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and peptidoleukotriene antagonist activity of)
RN 118683-26-4 CAPLUS
CN Benzoic acid, 4-[(4-benzoyl-3-hydroxy-2-propylphenoxy)methyl]-3-methoxy- (CA INDEX NAME)

L6 ANSWER 130 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 130 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118683-29-7 CAPLUS
CN Benzoic acid, 4-[(4-carboxy-2-methoxyphenyl)methoxy]-2-hydroxy-3-propyl-, 1-phenyl ester (CA INDEX NAME)



RN 118683-34-4 CAPLUS
CN Benzoic acid, 4-[[3-hydroxy-4-[(phenylamino)carbonyl]-2-propylphenoxy]methyl]-3-methoxy- (CA INDEX NAME)



RN 118683-35-5 CAPLUS
CN Benzoic acid, 4-[[3-hydroxy-2-propyl-4-(1-pyrrolidinylcarbonyl)phenoxy]methyl]-3-methoxy- (CA INDEX NAME)

L6 ANSWER 131 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:136554 CAPLUS
DOCUMENT NUMBER: 110:136554
TITLE: Manufacture for hard polyamide-polydiacetylene moldings
INVENTOR(S): Matsuda, Hiroo; Nakanishi, Hachiro; Tanaka, Yoshio; Nakayama, Kazuo; Kato, Masao
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO:	KIND	DATE	APPLICATION NO.	DATE
JP 63221115	A	19880914	JP 1987-53432	19870309
JP 04012885	B	19920306		
US 4814404	A	19890321	US 1987-90099	19870827
PRIORITY APPLN. INFO.:			JP 1986-208714	19860904
			JP 1986-208715	19860904
			JP 1987-53432	19870309

OTHER SOURCE(S): MARPAT 110:136554
AB Title moldings are prepared by heat polymerizing HO2CR1C.tplbond.CC.tplbond.CR1CO 2H.H2NR2NH2 salt [I; R1-2 = (substituted) alkylene, cycloalkylene, arylene] in a mold of at 100-400° and (0.5-15) × 104 atmospheric. Thus, I [R1 = (CH2)8; R2 = (CH2)5] was filled in a mold and treated at 230° and 50,000 atm for 20 min to give a test piece with Vickers hardness 100.
IT 116075-83-3P
RL: PREP (Preparation)
(preparation of, by solid-state high-pressure polymerization, for hard moldings)
RN 116075-83-3 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, compd. with 2-methyl-1,4-benzenediamine (1:1), homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 116075-82-2
CMF C32 H16 N2 O12 . C7 H10 N2

CM 2

CRN 116075-81-1
CMF C32 H16 N2 O12

L6 ANSWER 131 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 3

CRN 95-70-5
CMF C7 H10 N2



L6 ANSWER 132 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 132 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:101867 CAPLUS
DOCUMENT NUMBER: 110:101867
TITLE: Manufacture of contact lenses using synthetic resins
INVENTOR(S): Sano, Yoshio; Mogami, Takao; Koinuma, Yasuyoshi; Murata, Takashige
PATENT ASSIGNEE(S): Seiko Epson Corp., Japan; Nippon Oils & Fats Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63092901	A	19880423	JP 1986-238283	19861007
JP 2759321	B2	19980528		
PRIORITY APPLN. INFO.:			JP 1986-238283	19861007

GI



I

AB Synthetic resin lens compns. contain CH2:CR1CH2O2CC6H4-o-CO2R2O2CC6H4-o-CO2CH2CR1:CH2 (R1 = H or Me; R2 = (CH2)n, (CH2CH2O)mCH2CH2, etc.; 2 ≤ n ≤ 10; 1 ≤ m ≤ 10) as the major components.
Anhydrous phthalate was added to diethylene glycol to give diethylene glycol
diphthalate half ester, which was then treated with allyl alc. and mixed with toluene to give diethylene glycol bis(allyl-o-phthalate). This product was mixed with diallyl isophthalate, 2-hydroxy-4-octoxybenzophenone, and diisopropyl peroxycarbonate, was poured into a mold and made into a copolymer lens.

IT 119214-44-7P
RL: PREP (Preparation)
(preparation and condensation with allyl chloride)

RN 119214-44-7 CAPLUS
CN 1,2-Benzenedicarboxylic acid, (1-methylethylidene)di-4,1-phenylene ester (9CI) (CA INDEX NAME)

L6 ANSWER 133 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:24427 CAPLUS
DOCUMENT NUMBER: 110:24427
TITLE: Diacetylenedicarboxylic acid amine salts
INVENTOR(S): Matsuda, Hiroo; Nakanishi, Hachiro; Kato, Masao
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63063635	A	19880322	JP 1986-208714	19860904
JP 02038579	B	19900831		
US 4814404	A	19890321	US 1987-90099	19870827
PRIORITY APPLN. INFO.:			JP 1986-208714	19860904
			JP 1986-208715	19860904
			JP 1987-53432	19870309

AB The title salts [O2CR1C.tplbond.CC.tplbond.CR1CO2]2-[H3NR2NH3]2+ (I; R1, R2 = alkylene, arylene; R1 and R2 may be substituted with ≥1 of halo, cyano, alkyl, aryl, NO2, ether, ester, amide, OH, CO, and sulfonyl groups) are useful as raw materials for crystalline two-dimensional high-strength, high-modulus polymers. Thus, a solution of 3.62 g HO2C(CH2)8C.tplbond.CC.tplbond.C(CH2)8CO2H in 30 mL EtOH and a solution of
1.02 g pentamethylenediamine in 30 mL EtOH were mixed and left for .apprx.3 h to precipitate 4.5 g I [R1 = (CH2)8, R2 = (CH5)] with m.p. 112-113°.

IT 116075-82-2P
RL: PREP (Preparation)
(preparation of, as raw material for two-dimensional high-strength polymers)

RN 116075-82-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, compd. with 2-methyl-1,4-benzenediamine (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 116075-81-1
CMF C32 H16 N2 O12



CM 2

L6 ANSWER 133 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 95-70-5
CMF C7 H10 N2



L6 ANSWER 134 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:612513 CAPLUS
DOCUMENT NUMBER: 109:212513
TITLE: Fluorine-containing polyamic acids and polyimides for coatings
INVENTOR(S): Numata, Shunichi; Fujisaki, Koji; Kinjo, Noriyuki
PATENT ASSIGNEE(S): Hitachi, Ltd., Japan; Hitachi Chemical Co., Ltd.
SOURCE: U.S., 15 pp. Division of U.S. Ser. No. 670,977, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4760126	A	19880726	US 1986-904203	19860908
PRIORITY APPLN. INFO.:			US 1984-670977	A3 19841113

AB The title polymers, heat- and moisture-resistant, are prepared from dianhydrides containing perfluoroalkylidene groups and diamines. Stirring 12.95 g bisphenol AF trimellitic anhydride ester (1:2), 2.05 g p-phenylenediamine (I), and 85 g N-methylpyrrolidone at room temperature for 5 h (viscosity 250 P at 25°) gave a polyamic acid solution which was coated on glass and heated at 150° for 1 h, 250° for 30 min, and 400° for 1 h to give a polyimide with good heat resistance and moisture absorption (25°, relative humidity 75%) 0.75%; vs. good and 4.8, resp., for pyromellitic dianhydride -I polyimide.

IT 117579-21-2P 117579-23-4P
RL: TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(coatings, heat- and moisture-resistant, manufacture of)

RN 117579-21-2 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 6-(trifluoromethyl)-, 4,4'-[[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]di-4,1-phenylene] ester, polymer with 4,4'-[[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis(4,1-phenyleneoxy)]bis[benzenamine] (9CI) (CA INDEX NAME)

CM 1

CRN 117579-20-1
CMF C35 H16 F12 O12

L6 ANSWER 134 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 69563-88-8
CMF C27 H20 F6 N2 O2



RN 117579-23-4 CAPLUS
CN 1,2,4-Benzenetricarboxylic acid, 4,4'-[(1,1,2,2,3,3,4,4,5,5-decafluoro-1,5-pentanediyl)di-4,1-phenylene] ester, polymer with 4,4'-[[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis(4,1-phenyleneoxy)]bis[benzenamine] (9CI) (CA INDEX NAME)

CM 1

CRN 117579-22-3
CMF C35 H18 F10 O12



CM 2

CRN 69563-88-8
CMF C27 H20 F6 N2 O2

L6 ANSWER 134 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:529008 CAPLUS
DOCUMENT NUMBER: 109:129008
TITLE: Preparation of angiotensin II receptor-blocking (phenylalkyl)imidazoles
INVENTOR(S): Carini, David John; Duncia, John Jonas Vytautas
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 314 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 253310	A2	19880120	EP 1987-109919	19870709
EP 253310	A3	19900829		
EP 253310	B1	19941026		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1334092	C	19950124	CA 1987-540399	19870623
NO 8702863	A	19880112	NO 1987-2863	19870709
NO 176049	B	19941017		
NO 176049	C	19950125		
ES 2063734	T3	19950116	ES 1987-109919	19870709
DK 8703596	A	19880112	DK 1987-3596	19870710
DK 174700	B1	20030922		
FI 8703071	A	19880112	FI 1987-3071	19870710
FI 96025	B	19960115		
FI 96025	C	19960425		
AU 8775596	A	19880121	AU 1987-75596	19870710
AU 599396	B2	19900719		
JP 63023868	A	19880201	JP 1987-171328	19870710
JP 05029351	B	19930430		
HU 45976	A2	19880928	HU 1987-3174	19870710
ZA 8705052	A	19890329	ZA 1987-5052	19870710
SU 1694062	A3	19911123	SU 1987-4203085	19870710
IL 83153	A	19911215	IL 1987-83153	19870710
HU 218461	B	20000828	HU 1975-99020	19870710
US 5128355	A	19920707	US 1989-435869	19891113
US 5153197	A	19921006	US 1989-436165	19891113
US 5155118	A	19921013	US 1989-436281	19891113
PRIORITY APPLN. INFO.:			US 1986-884920 A	19860711
			US 1987-50341 A	19870522
			HU 1987-3174 A	19870710
			US 1988-142580 B2	19880107
			US 1988-279194 A3	19881206

OTHER SOURCE(S): MARPAT 109:129008
GI

L6 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB The title compound [I; R1 = tetrazol-5-yl, 1,2,3-triazol-4-yl, (HO)2S(O)O, (HO)2P(O)O, HPO3, substituted NH2, alkyl, PhCH2, (un)substituted PhCH2CH2, PhCH:CH, (un)modified CO2H, SO3H, etc.; R2 = H, C1-4 alkyl, C1-4 alkoxy, C1-4 acyloxy, MeSO2NH, CF3SO2NH, aryl, furyl, tetrazol-5-yl, Br, Cl, F, iodo, NO2, (un)modified CO2H; R3 = H, C1-4 alkyl, C1-4 alkoxy, Br, Cl, F, iodo; R4 = H, CF3, cyano, Br, Cl, F, iodo; R5 = H, cyano, (un)substituted alkyl, alkenyl; n = 0-2] and their pharmaceutically acceptable salts were prepared as angiotensin II receptor-blocking agents, useful as antihypertensives. 2-Butyl-5-chloro-1H-imidazole-4-methanol was treated with NaOMe in MeOH, and N-alkylated with 4-BrCH2C6H4CN to give benzylimidazolemethanol II (R7 = OH, R8 = cyano). This was chlorinated with SOCl2 and treated with NaCN to give II (R7 = R8 = cyano). The latter was refluxed 6 h in 1:1 12N HCl/HOAc to give II (R7 = R8 = CO2H) (III). III inhibited angiotensin II binding in rat adrenal cortical microsomes with an IC50 of 1.80 μM and was active in reducing blood pressure in rats at 10 mg/kg i.v.

IT 114799-45-0P 114799-46-1P 114799-47-2P
114799-48-3P 114799-49-4P 114799-61-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihypertensive)

RN 114799-45-0 CAPLUS
CN 1H-Imidazole-5-acetic acid, 2-butyl-1-[[4-[(2-carboxyphenyl)methoxy]phenyl]methyl]-4-chloro- (CA INDEX NAME)

L6 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-46-1 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-47-2 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(methoxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-48-3 CAPLUS
CN Benzoic acid, 2-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



RN 114799-49-4 CAPLUS
CN Benzoic acid,
2-[[4-[[5-[(acetyloxy)methyl]-2-butyl-4-chloro-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 114799-61-0 CAPLUS
CN Benzoic acid, 2-[[4-[[5-(hydroxymethyl)-2-(propylthio)-1H-imidazol-1-yl]methyl]phenoxy]methyl]- (CA INDEX NAME)



L6 ANSWER 136 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 3

CRN 95-70-5
CMF C7 H10 N2



L6 ANSWER 136 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:493876 CAPLUS
DOCUMENT NUMBER: 109:93876
TITLE: Manufacture of two-dimensional crystalline polymers from nylon salts of diacetylenedicarboxylic acids
INVENTOR(S): Matsuda, Hiroo; Nakanishi, Hachiro; Kato, Masao
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63063713	A	19880322	JP 1986-208715	19860904
JP 63033486	B	19880705		
US 4814404	A	19890321	US 1987-90099	19870827
PRIORITY APPLN. INFO.:			JP 1986-208714	19860904
			JP 1986-208715	19860904
			JP 1987-53432	19870309

OTHER SOURCE(S): MARPAT 109:93876
AB Nylon salts [O2CR1C.tplbond.CC.tplbond.CR1CO2]2-[H3NR2NH3]2+ (I; R1, R2 = alkylene, arylene; R1 and R2 may be substituted with ≥1 of halo, cyano, alkyl, aryl, NO2, ether, ester, amide, OH, CO, and sulfonyl groups) are polymerized to two-dimensional crystalline polymers by first polymerizing the diacetylene portion in the solid state and then polycondensing the nylon salt portion in the solid state. I [R1 = (CH2)8, R2 = (CH2)5] in a vacuum-sealed tube was irradiated with γ-ray (60Co; 50 MRad), then heated at 120° for 24 h in vacuum to give a two-dimensional crystalline polymer.
IT 116075-83-3P
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of, by polymerization of dialkynedicarboxylic acid amine salts)
RN 116075-83-3 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,3-butadiyne-1,4-diylbis(2-nitro-4,1-phenylene) ester, compd. with 2-methyl-1,4-benzenediamine (1:1), homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 116075-82-2
CMF C32 H16 N2 O12 . C7 H10 N2

CM 2

CRN 116075-81-1
CMF C32 H16 N2 O12

L6 ANSWER 137 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1987:478251 CAPLUS
DOCUMENT NUMBER: 107:78251
TITLE: Preparation of phenylalanine derivatives as proteinase inhibitors
INVENTOR(S): Okamoto, Shosuke; Okada, Yoshio; Okunomiya, Akiko; Naito, Taketoshi; Kimura, Yoshio; Yamada, Morihiko; Ohno, Nori; Katsuura, Yasuhiro; Seki, Yumi
PATENT ASSIGNEE(S): Showa Denko K. K., Japan
SOURCE: Eur. Pat. Appl., 169 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 217286	A1	19870408	EP 1986-113166	19860924
EP 217286	B1	19900523		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
AU 8663051	A	19870402	AU 1986-63051	19860923
AU 598750	B2	19900705		
CA 1297633	C	19920317	CA 1986-518905	19860923
JP 63022061	A	19880129	JP 1986-224995	19860925
JP 07053705	B	19950607		
US 4895842	A	19900123	US 1986-912480	19860929
AU 587691	B2	19890824	AU 1987-70773	19870330
AU 8770773	A	19880929		
PRIORITY APPLN. INFO.:			JP 1985-212240 A	19850927
			JP 1986-45348 A	19860304

OTHER SOURCE(S): MARPAT 107:78251
GI



I

AB The title peptides [I; n = 4-10; R1, R2 = H, (un)substituted C1-C8 alkyl, (un)substituted C6-C8 cycloalkyl, (un)substituted Ph, (un)substituted pyridyl, pyrimidyl, N-benzylazacyclohexyl or NR1R2 = (thio)morpholino, (un)substituted piperidinyl, (un)substituted pyrrolidinyl; X = H, NO2, NH2, OR3; R3 = H, alkyl, alkenyl, (un)substituted CH2Ph, PhCOCH2,

L6 ANSWER 137 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyridylmethyl, (nitro)pyridyl, (nitro)pyrimidyl, (alkyl)PhSO2, (halo)PhCH2O2C] and pharmaceutically acceptable salts, useful as proteinase inhibitors and thereby useful as hemostatic, antiinflammatory and antiallergic agents, were prepd. Et3N, EtO2CCl and L-phenylalanine 4-acetylanilide-HCl were successively added to a soln. of trans-4-[N-(tert-butyloxycarbonyl)aminomethyl]cyclohexanecarboxylic acid and the mixt. was allowed to react at room temp. for 3 h to give, after acid hydrolysis, N-[trans-4-(aminomethyl)cyclohexylcarbonyl]-L-phenylalanine 4-acetylanilide. I in vitro inhibited plasmin, thrombin, trypsin, plasma and urokinase.

IT 109377-91-5P 109431-45-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as proteinase inhibitor and hemostatic, antiallergic, and antiinflammatory agent)

RN 109377-91-5 CAPLUS

CN Benzoic acid, 4-[[4-[3-[(4-acetylphenyl)amino]-2-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-3-oxopropyl]phenoxy]methyl]-, [1(S)-trans]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109431-45-0 CAPLUS

CN Benzoic acid, 4-[[4-[3-[(4-acetylphenyl)amino]-2-[[[4-(aminomethyl)cyclohexyl]carbonyl]amino]-3-oxopropyl]phenoxy]methyl]-, monohydrochloride, [1(S)-trans]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 137 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

L6 ANSWER 138 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:408052 CAPLUS
DOCUMENT NUMBER: 105:8052
TITLE: High-temperature-resistant electrically insulating coating powder
INVENTOR(S): Guilbert, Curtis R.; Fialla, Peter
PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8505627	A1	19851219	WO 1985-US882	19850513
W: AU, BR, JP, KP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4621122	A	19861104	US 1985-708701	19850306
AU 8544066	A	19851231	AU 1985-44066	19850513
AU 567819	B2	19871203		
EP 183779	A1	19860611	EP 1985-902797	19850513
EP 183779	B1	19890719		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
BR 8506765	A	19860923	BR 1985-6765	19850513
JP 61502336	T	19861016	JP 1985-502460	19850513
AT 44754	T	19890815	AT 1985-902797	19850513
ZA 8503856	A	19861230	ZA 1985-3856	19850521
CA 1244993	A1	19881115	CA 1985-483087	19850604

PRIORITY APPLN. INFO.: US 1984-617324 A 19840605
US 1985-708701 A 19850306
EP 1985-902797 A 19850513
WO 1985-US882 A 19850513

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Heat-resistant elec. insulating coating powder for wires comprises a blend of (a) epoxy-terminated adduct of hydantoin diepoxide (I) and aromatic dicarboxylic acid imide dissolved in I; (b) acid-terminated polyester; (c) ethylenically unsatd. aromatic fluxing agent; and an (d) unsatd. dicarboxylic acid. Thus, an epoxy-terminated adduct (comprising 80 weight parts II and 20 weight parts III) 10, acid-terminated polyester (IV) 30, Bismaleimid-M 10, fumaric acid 1, and a fluorocarbon flow control agent 0.004 g were melt-mixed, cooled, ground, and blended with 0.08 g pretreated fumed silica. The powder was coated on several clean Al panels and cured at 230° for 10 min. The cured coatings had dielec. breakdown 1100

L6 ANSWER 138 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
V/25 μ, dissipation factor 11% at 150°, and oxidative thermal stability 200°.

IT 102729-35-1
RL: PRP (Properties)
(elec. insulating coatings containing, for wires, heat-resistant)

RN 102729-35-1 CAPLUS

CN Poly[oxycarbonyl-1,3-phenylenecarbonyloxy-1,4-phenylene(1-phenylethylidene)-1,4-phenylene], α-hydro-ω-[(4-carboxybenzoyl)oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:531455 CAPLUS
DOCUMENT NUMBER: 101:131455
TITLE: Segmented block copolymers of uniform chain length and defined structure, 2. Investigation of some physical properties
AUTHOR(S): Krueger, J. K.; Marx, A.; Roberts, R.; Unruh, H. G.; Bitar, M. B.; Nguyen Trong Hao; Seliger, H.
CORPORATE SOURCE: Univ. Saarlandes, Saarbruecken, D-6600, Fed. Rep. Ger.
SOURCE: Makromolekulare Chemie (1984), 185(7), 1469-91
CODEN: MACEAK; ISSN: 0025-116X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Phys. investigations of models for segmented block copolyesters of uniform chain length and defined structure and their constituents are described. The thermal behavior of these compds. (phase transformations in the solid and liquid state and thermal stability) are discussed. Several oligomers show phase transitions in the solid state. The morphol. of some of the solids depends strongly on sample history. The effect of crystallization conditions is discussed. Glass-forming processes in bisphenol A isophthalates were studied by dielec. and Brillouin spectroscopy.
IT 92002-18-1 92002-19-2 92002-20-5
92002-21-6 92002-22-7 92002-23-8
92002-24-9 92002-25-0 92002-49-8
RL: PRP (Properties)
(properties of, as model compds. for block polyesters)
RN 92002-18-1 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[1-methyl-1-[4-[phenylmethoxy)phenyl]ethyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 92002-19-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 92002-20-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 92002-21-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-C



RN 92002-22-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 92002-23-8 CAPLUS

L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 92002-49-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-[4-[[4-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,4-Benzenedicarboxylic acid, mono[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 92002-24-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-25-0 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-[4-[[4-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



L6 ANSWER 140 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:531204 CAPLUS
DOCUMENT NUMBER: 101:131204
TITLE: Segmented block copolymer models of uniform chain length and defined structure, 1. Synthesis and characterization
AUTHOR(S): Seliger, Hartmut; Bitar, Mohammed Bassam; Nguyen Trong
Hao; Marx, Alexander; Roberts, Rolf; Krueger, Jan Kristian; Unruh, Hans Guenther
CORPORATE SOURCE: Sekt. Polym., Univ. Ulm, Ulm, D-7900, Fed. Rep. Ger.
SOURCE: Makromolekulare Chemie (1984), 185(7), 1335-60
CODEN: MACEAK; ISSN: 0025-116X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Segmented block polymer models of polyester thermoplastic elastomers of defined structure with mol. wts. >4000 were synthesized by condensing monofunctional derivs. of oligomers from bisphenol A, terephthalic acid, and oligomethylenes of uniform chain length. The aromatic oligoester blocks were prepared by stepwise addition of oxyterephthaloyloxy-1,4-phenyleneisopropylidene-1,4-phenylene units using suitable protection and activation. Oligoesters containing isophthaloyl and phthaloyl units were prepared similarly. Telechelic oligomethylene segments were prepared analogously from functional derivs. of decane. All compds. were characterized by chemical, spectroscopic, and chromatog. methods.

IT 92002-18-1P 92002-19-2P 92002-20-5P
92002-21-6P 92002-22-7P 92002-23-8P
92002-24-9P 92002-46-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 92002-18-1 CAPLUS
CN 1,4-Benzenedicarboxylic acid, mono[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl] ester (9CI) (CA INDEX NAME)



RN 92002-19-2 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-20-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-21-6 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 92002-22-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[[4-[[4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl 4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-[[4-[[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]ethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 140 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D

RN 92002-23-8 CAPLUS

L6 ANSWER 140 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 92002-25-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as model compound for segmented polyester thermoplastic
elastomers)
RN 92002-25-0 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-[4-[(4-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]carbonyl]benzoyl]oxy]phenyl]-1-methylethyl]phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L6 ANSWER 140 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1,4-Benzenedicarboxylic acid, mono[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl] ester (9CI)* (CA INDEX NAME)



RN 92002-24-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 4-[1-[4-[(4-carboxybenzoyl)oxy]phenyl]-1-methylethyl]phenyl 4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 92002-46-5 CAPLUS
CN 1,3-Benzenedicarboxylic acid, mono[4-[1-methyl-1-[4-(phenylmethoxy)phenyl]ethyl]phenyl] ester (9CI) (CA INDEX NAME)



L6 ANSWER 141 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1984:192658 CAPLUS
DOCUMENT NUMBER: 100:192658
TITLE: Liquid crystalline behavior of polymeric glycols terminated with aromatic diester and diacid mesogenic groups
AUTHOR(S): Hoshino, H.; Jin, J. I.; Lenz, R. W.
CORPORATE SOURCE: Chem. Eng. Dep., Univ. Massachusetts, Amherst, MA, 01003, USA
SOURCE: Journal of Applied Polymer Science (1984), 29(2), 547-54
CODEN: JAPNAB; ISSN: 0021-8995
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The thermotropic liquid crystalline behavior of bis(p-PhCH2OCOC6H4CO2-p-C6H4CO2H) esters (mesogen II) and bis(p-HOCOC6H4CO2-p-C6H4CO2H) esters (mesogen I) of polymeric glycols was studied by DSC and polarized hot-stage microscopy. The polymeric glycols were polyethylene, polytetramethylene, polybutadiene, and the hydrogenated polybutadiene glycols with mol. weight 650-6000. The mesogen I derivs. were not thermotropic (with 1 exception), but the mesogen II derivs. were; the model compound decamethylene p-[(p-carboxybenzoyl)oxy]benzoate [89367-67-9] was also liquid crystalline The nature of the mesophases formed by the mesogen II derivs. could not be clearly identified by their optical textures. Several mesogen II derivs. formed elastomeric films, although of low mol. weight, presumably because of chain extension by dimerization and association of terminal mesogenic groups.

IT 89360-28-1 89370-34-3
RL: PRP (Properties)
(liquid crystalline properties of)
RN 89360-28-1 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[4-[(4-carboxybenzoyl)oxy]benzoyl]-ω-[[4-[(4-carboxybenzoyl)oxy]benzoyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



L6 ANSWER 141 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 89370-34-3 CAPLUS
CN Poly(oxy-1,4-butanediyl), α-[4-[(4-carboxybenzoyl)oxy]benzoyl]-ω-[[4-[(4-carboxybenzoyl)oxy]benzoyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 89367-67-9
RL: PRP (Properties)
(liquid crystal properties of)
RN 89367-67-9 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,12-dodecanediylbis(oxycarbonyl-4,1-phenylene) ester (9CI) (CA INDEX NAME)

L6 ANSWER 141 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L6 ANSWER 142 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:216435 CAPLUS
DOCUMENT NUMBER: 92:216435
ORIGINAL REFERENCE NO.: 92:35073a,35076a
TITLE: Adhesives
INVENTOR(S): Matsubara, Takashi; Uramoto, Yoshito; Ishibashi, Sukeyuki
PATENT ASSIGNEE(S): Toa Gosei Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54161649	A	19791221	JP 1978-69800	19780612
JP 56027547	B	19810625		
PRIORITY APPLN. INFO.:			JP 1978-69800 A	19780612

AB The reaction products of polyhydric phenols or their derivs. with aromatic polybasic acids or anhydrides, such as 1:2 bisphenol A-trimellitic anhydride adduct (I) [73649-46-4], were used as hardening agents for adhesives containing epoxy resins and thermoplastic resins. Thus, galvanized sheet iron was bonded with an adhesive containing Epikote 1009 [25068-38-6] 100, I 15.2, and polyethylene [9002-88-4] 5 g with T-peeling strength 17.6 kg/25 mm.
IT 73590-10-0
RL: MOA (Modifier or additive use); USES (Uses)
(crosslinking agents, for epoxy resin-thermoplastic resin mixts., for adhesives)
RN 73590-10-0 CAPLUS
CN 1,2,4,5-Benzenetetracarboxylic acid, (1-methylethylidene)di-4,1-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 143 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:22236 CAPLUS
DOCUMENT NUMBER: 92:22236
ORIGINAL REFERENCE NO.: 92:3777a,3780a
TITLE: 1-(Aralkoxyphenyl)-2-(bisarylalkylamino)-alkanes
INVENTOR(S): Francis, John Elsworth
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: S. African, 42 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 7802420	A	19790425	ZA 1978-2420	19780427
PRIORITY APPLN. INFO.:			ZA 1978-2420 A	19780427

AB 4-[RC6H4(CH2)mO]C6H4CH2CHR1NH(CH2)nCPh2R2 (I; R = H, alkyl, alkoxy, halo, CF3; R1 = Me or Et; R2 = H or OH; m, n = 1 or 2) and their pharmaceutically-acceptable salts, useful as antihypertensives and for relief of angina pectoris (no data), were prepared Thus, 4-[(3-chlorobenzyl)oxy]benzaldehyde was condensed with EtNO2 (AcONH4) to give 1-[4-[3-chlorobenzyl)oxy]phenyl]-2-nitropropane, which was reduced by LiAlH4 to the amine, which condensed with Ph2C:CHCHO and the resulting product was reduced by LiAlH4 to give I (R = 3-Cl, R1 = Me, R2 = H, m = 1, n = 2).
IT 59067-84-4P 71488-38-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 59067-84-4 CAPLUS
CN Benzoic acid, 4-[[4-[2-[(3,3-diphenylpropyl)amino]propyl]phenoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 71488-38-5 CAPLUS
CN Benzoic acid, 3-[[4-[2-[(3,3-diphenylpropyl)amino]propyl]phenoxy]methyl]- (CA INDEX NAME)

L6 ANSWER 143 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 144 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1976:164383 CAPLUS
DOCUMENT NUMBER: 84:164383
ORIGINAL REFERENCE NO.: 84:26679a,26682a
TITLE: 1-(Aralkoxyphenyl)-2-(or -3)-.(bisarylalkylamino)alkanes
INVENTOR(S): Francis, John E.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Ger. Offen., 61 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2534339	A1	19760219	DE 1975-2534339	19750801
ZA 7504192	A	19760630	ZA 1975-4192	19750701
DK 7503171	A	19760206	DK 1975-3171	19750711
SE 7508181	A	19760206	SE 1975-8181	19750717
FI 7502095	A	19760206	FI 1975-2095	19750721
NO 7502621	A	19760206	NO 1975-2621	19750723
IL 47813	A	19790725	IL 1975-47813	19750725
CH 612909	A5	19790831	CH 1975-9935	19750730
CH 612910	A5	19790831	CH 1979-252	19750730
CH 612911	A5	19790831	CH 1979-253	19750730
CH 612912	A5	19790831	CH 1979-254	19750730
CH 612913	A5	19790831	CH 1979-255	19750730
FR 2281105	A1	19760305	FR 1975-24088	19750801
FR 2281105	B1	19800208		
CA 1069923	A1	19800115	CA 1975-232735	19750801
HU 175581	B	19800928	HU 1975-CI1597	19750801
BE 832082	A1	19760204	BE 1975-158907	19750804
NL 7509270	A	19760209	NL 1975-9270	19750804
ZA 7505018	A	19760728	ZA 1975-5018	19750804
AU 7583626	A	19770210	AU 1975-83626	19750804
AT 7506042	A	19770415	AT 1975-6042	19750804
AT 340388	B	19771212		
ES 439997	A1	19770616	ES 1975-439997	19750804
JP 51041345	A	19760407	JP 1975-94800	19750805
AT 7607832	A	19770415	AT 1976-7832	19761021
AT 340390	B	19771212		
AT 7607833	A	19770415	AT 1976-7833	19761021
AT 340391	B	19771212		
AT 7607835	A	19770415	AT 1976-7835	19761021
AT 340392	B	19771212		
AT 7607836	A	19770415	AT 1976-7836	19761021
AT 340393	B	19771212		
US 4329367	A	19820511	US 1980-219808	19801224

PRIORITY APPLN. INFO.: US 1974-494948 A 19740805
US 1975-590221 A2 19750630
AT 1975-6042 A 19750804

L6 ANSWER 144 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 1976-699016	A2	19760623
US 1977-790508	A2	19770425
US 1978-882004	A2	19780228
US 1979-74441	A1	19790910

OTHER SOURCE(S): CASREACT 84:164383; MARPAT 84:164383

GI



I



III

AB The amines I [R = F, Cl, Br, CF3, CN, etc.; R1 = H, Me; n = 1-5; m = 1, 2), useful as antihypertensives, were prepared Thus, 4-(3-ClC6H4CH2O)C6H4CHCHMeNH2 (II) was refluxed with Ph2C:CHCHO, with separation of H2O, followed by treatment with LiAlH4 to give III.HCl. II was prepared by the reaction of 3-ClC6H4OCH2OC6H4CHO-4 with EtNO2 and NH4OAc to give 3-ClC6H4CH2OC6H4CH:CMeNO2, which was reduced to II by LiAlH4. I are useful as antihypertensives; pharmaceutical formulations were given.

IT 59067-84-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59067-84-4 CAPLUS

CN Benzoic acid, 4-[[4-[2-[(3,3-diphenylpropyl)amino]propyl]phenoxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 145 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:515857 CAPLUS
DOCUMENT NUMBER: 77:115857
ORIGINAL REFERENCE NO.: 77:19095a,19098a
TITLE: Aromatic polyester imide products
INVENTOR(S): Adrova, N. A.; Bessonov, M. I.; Korzhavin, L. N.; Koton, M. M.; Maricheva, T. A.; Mirzaev, A.; Pushkina, T. P.; Rudakov, A. P.; Frenkel, S. Ya.
PATENT ASSIGNEE(S): Institute of High-Molecular-Weight Compounds, Academy of Sciences, U.S.S.R.
SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1972, 49(10), 107.
CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 332147		19720314	SU	19700710

AB P-phenylenebistrimellitate-4,4'-diaminodiphenyl ether copolymer [36485-23-1] was converted to fibers having improved mech. properties by spinning the copolymer into a coagulating bath containing castor oil-Me2CO mixture

IT 36485-23-1
RL: USES (Uses)
(fibers)

RN 36485-23-1 CAPLUS

CN 1,2,4-Benzenetricarboxylic acid, 4,4'-(1,4-phenylene) ester, polymer with 4,4'-oxybis[benzenamine] (9CI) (CA INDEX NAME)

CM 1

CRN 53624-86-5
CMF C24 H14 O12



CM 2

CRN 101-80-4
CMF C12 H12 N2 O

L6 ANSWER 145 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 146 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1968:59322 CAPLUS
DOCUMENT NUMBER: 68:59322
ORIGINAL REFERENCE NO.: 68:11451a,11454a
TITLE: Trihydroxy- or tetrahydroxybenzophenone esters of dicarboxylic acids as ultraviolet absorbers for polymers
INVENTOR(S): Strobel, Albert F.; Catino, Sigmund C.
PATENT ASSIGNEE(S): General Aniline and Film Corp.
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3366668	A	19680130	US 1965-504154	19651023
PRIORITY APPLN. INFO.:			US 1965-504154 A	19651023

GI For diagram(s), see printed CA Issue.

AB Compds. such as 2,2',4-trihydroxy-4'-methoxybenzophenone (I) are esterified with compds. such as succinic anhydride or phthalic anhydride, and the esters are used as uv light absorbers for polyesters and other resins. Thus, 52.8 g. I in 150 ml. dry picoline was treated slowly at <60° with 16.0 g. succinic anhydride and the mixture heated at 60° for 1 hr. to give 44 g. (crude) 4'-methoxy-2,2',4-trihydroxybenzophenone 4-(hydrogen succinate) (II, R = CH2CH2CO2H, R1 = R2 = R4 = H, R3 = OMe) (III). III (0.214%) was reacted with phthalic anhydride 1, succinic anhydride 1, and diethylene glycol 2 moles and then diluted to 60% solids with styrene to give a styrene-polyester resin which was cured in a mold and then exposed in a fadeometer for 100 hrs. The material was distinctly better than a product prepared by 1st forming the polymer and later milling it with the ester until homogeneous. Similarly prepared were the following II (R, R1, R2, R3, and R4 given): o-carboxyphenyl, H, H, H, H; CO2H, H, H, H, H; CH2CH2COCl, H, H, H, H; β-(4,6-diaminotriazin-2-yl)carbamoyl]-ethyl, H, H, H, H; CH2CH2CO2H, H, H, CH2CH2CO2H, H; CH2CH2CO2H, H, H, H, H; o-carboxyphenyl, H, H, o-carboxyphenyl, H; CH2CH2CO2H, H, H, H, vinyl; o-carboxyphenyl, H, H, Cl, H; CH2CH2CO2H, H, SO2CH2Ph, H, H; CH2CH2CO2H, H, CH2CH2OH, O2CCH2CH2CO2H, H; o-carboxyphenyl, (CH2)3Cl, H, o-carboxyphenyl, H; CH:CHCO2H (cis isomer), H, H, OMe, H; CH:CHCO2H (cis isomer), H, H, H, H.

IT 16262-82-1P 16328-57-7P 18614-83-0P
18614-87-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16262-82-1 CAPLUS

CN Phthalic acid, 4-ester with 2,2',4-trihydroxybenzophenone (8CI) (CA INDEX NAME)

L6 ANSWER 146 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 16328-57-7 CAPLUS

CN Phthalic acid, 4'-ester with 4-chloro-2,2',4'-trihydroxybenzophenone (8CI) (CA INDEX NAME)



RN 18614-83-0 CAPLUS

CN Phthalic acid, ester with 3'-hydroxy-4'-β-resorcyloyl-2-biphenylcarboxylic acid (1:1) (8CI) (CA INDEX NAME)



RN 18614-87-4 CAPLUS

CN Phthalic acid, ester with 3'-(3-chloropropyl)-5'-hydroxy-4'-β-resorcyloyl-2-biphenylcarboxylic acid (1:1) (8CI) (CA INDEX NAME)



L6 ANSWER 147 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1965:36646 CAPLUS
DOCUMENT NUMBER: 62:36646
ORIGINAL REFERENCE NO.: 62:6437a-c
TITLE: Bis(carboxybenzoates) of diols
INVENTOR(S): McIntyre, James E.
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 978660		19641223	GB 1962-9376	19620322

GI For diagram(s), see printed CA Issue.

AB For 24 hrs. O was passed through a gently refluxing solution of I (R = CH2CH2, R' = Me) 20, CoBr2.6H2O 0.195, and MgBr2.4H2O 0.38 in propionic acid 200 to give I (R = CH2CH2, R' = CO2H) 20 parts, m. 301-4°; di-Me ester m. 165-8° (EtOH); bis(acid chloride) (II), m. 116-18° petr. ether). Similarly prepared were the following I (R, R', and m.p. given): CH2, CO2H, --; CH2, CO2Me, 153-5° (EtOH); (CH2)4, CO2H, --; (CH2)4, CO2Me, 156-9° (EtOH); p-C6H4,CO2H, >325°. Bis[2-(p-carboxybenzoyloxy)ethyl] terephthalate m. 270-7°. II 1.975 in CH2Cl2 13.4 was added with stirring to a solution of hexamethylenediamine 0.58 in 4% NaOH 10 parts to give III, m. 304° (decomposition), viscosity ratio 1.42, measured in 1% o-ClC6H4OH at 25°. Films could be cast from III in o-ClC6H4OH. Similarly, II and hydroquinone gave IV and II with (p-HO2C6H4CO2)2(CH2)2 gave V.

IT 2225-00-5P, Terephthalic acid, p-phenylene ester
RL: PREP (Preparation)
(preparation of)

RN 2225-00-5 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 1,4-phenylene ester (9CI) (CA INDEX NAME)



L6 ANSWER 148 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1965:2834 CAPLUS
DOCUMENT NUMBER: 62:2834
ORIGINAL REFERENCE NO.: 62:470d-h,471a-c
TITLE: Aromatic fluoro derivatives. XIV. Tetrafluoroterephthalic acid
AUTHOR(S): Yakobson, G. G.; Odinokov, V. N.; Petrova, T. D.; Vorozhtsov, N. N., Jr.
SOURCE: Zhurnal Obshchei Khimii (1964), 34(9), 2953-8
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 60, 15755a. A mixture of 100 g. terephthalic acid and 10 g. iodine in 550 ml. 20% oleum was chlorinated 14-15 hrs. at 160-70° (120-50 ml. Cl/min.) and then 1 hr. at 180°, cooled, poured onto 1 kg. ice, the precipitate filtered off, washed with 100 ml. H2O, treated with aqueous Na2CO3, C6Cl6 filtered off, and the filtrate acidified to obtain 145-55 g. I. I di-Me ester m. 158-8.5° (MeOH). I (50 g.) with 100 g. PCl5 was heated 1-2 hrs. at 110°, then 3.5 hrs. at 150°, POCl3 distilled, the mixture poured into ice H2O, the whole filtered, and the precipitate treated with 5% Na2CO3 solution to slightly alkaline reaction and filtered off to give 45-50 g. I dichloride (Ia), m. 147.5-48°. I (10 g.) and 2.8 g. NaOH dissolved in 25 ml. H2O, 4.6 g. Me2SO4 added, the mixture stirred and heated 5 hrs. at 60°, cooled, 170 ml. H2O added, the mixture alkalized with Na2CO3 and filtered, the filtrate acidified, filtered, and the filtrate extracted with boiling C6H6 yielded 3.9 g. I mono-Me ester, m. 180-80.5° (C6H6). Ia (7 g.) and 6 g. freshly roasted CsF was heated in a 25 ml. steel bomb 25 hrs. at 190°, and the product cooled and extracted with boiling heptane to give 4.5 g. I difluoride (Ib), m. 129-30°. Ib boiled with MeOH gave I di-Me ester. Ia (36 g.) heated 30 hrs. with 30 g. freshly roasted KF in a steel rotating autoclave at 230° yielded 25.5 g. Ib. Ib (3 g.) and 12.2 g. freshly roasted CsF was heated in a steel bomb 26 hrs. at 220° and then extracted with boiling heptane to obtain 1.2 g. II difluoride (Ic), m. 94-5°. Ia (9 g.) and 31.6 g. freshly roasted CsF heated as above 18 hrs. at 190° and then 30 hrs. at 230° gave 3.5-4.1 g. Ic, m. 95°. Ic (2.4 g.) was boiled 5 hrs. with 35 ml. H2O to yield 1.7-1.8 g. II, m. 284-4.5° (H2O). By boiling Ic with MeOH 5 hrs. was prepared 70-5% II di-Me ester, m. 79-9.5° (MeOH); this was also prepared in 70-4% yield by boiling II with MeOH-H2SO4. Ic (10 g.) and 100 ml. EtOH was boiled 9 hrs. to obtain 6.5 g. of II di-Et ester, b20 155-8°, n23D 1.4591, d23 1.40. To a solution of 4 g. II di-Me ester in 50 ml. MeOH was added with stirring during 1 hr. at 20° a solution of 1 g. NaOH in 15 ml. MeOH, the mixture stirred 30 min., and 30 ml. H2O added. MeOH was distilled, the residue filtered off, the filtrate acidified and filtered, and the dry precipitate extracted with boiling C6H6 to give 2 g. II

L6 ANSWER 148 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
mono-Me ester, m. 110-11° (C6H6). Similarly was obtained II mono-Et ester, m. 74.5-5.5°, in 66% yield. II di-Me ester (0.5 g.) and 20 ml. of 3N MeOH soln. of NH3 was heated 2 hrs. at 60° to yield 0.35 g. II diamide, m. 315° (C5H5N). To a mixt. of 0.96 g. II, 4 ml. 18.5% oleum, and 6 ml. abs. CHCl3 was added with stirring 0.8 g. NaN3 at 40° and at such a rate that the temp. did not rise >45°, the mixt. was stirred at 45° until no more gas was liberated, cooled, the CHCl3 layer sepd., and the aq. layer poured onto ice to yield 0.45 g. 2,3,5,6-tetrafluorophenylene-1,4-diamine (III.H2SO4), m. 222-3° (EtOH). Treating the filtrate with 40% NaOH gave 0.3 g. III, m. 143.5-4.5° (C6H6). Similarly, 3 g. II mono-Me ester yielded 2.1 g. Me tetrafluoroparaaminobenzoate (IV), m. 116.5-17° (50% MeOH) and the filtrate gave 0.3 g. III. To a soln. of 1 g. IV in 5 ml. MeOH was added 0.6 g. KOH in 5 ml. MeOH and 10 ml. H2O, the mixt. heated to dissolve the ppt., MeOH distd., and the residue cooled, acidified with concd. H2SO4, and filtered off to give 0.9 g. tetrafluoroparaaminobenzoic acid (V), m. 192-2.5° (C6H6). V (0.1 g.) in 1 ml. AcOH-1 ml. 10% HCl was added to 0.04 g. NaNO2 in 2 ml. H2O at 5° and to this soln. was added 0.07 g. β-naphthol and 0.02 g. NaOH in 2 ml. H2O to obtain 0.1 g. product, m. 211-12° (EtOH). To 2.4 g. II, 10 ml. 18.5% oleum, and 10 ml. abs. CHCl3 was added 0.8 g. NaN3 at 40° and the mixt. stirred 3 hrs. at 45°. After cooling, the CHCl3 layer was sepd., the remaining layer poured onto ice, and the ppt. filtered off, dried, and extd. with boiling C6H6 to obtain 0.9 g. V, m. 182°. The filtrate treated with 40% NaOH gave 0.5 g. III. Boiling V with MeOH-H2SO4 produced IV in 85% yield. Similarly was prepd. V Et ester, m. 80.5-1.5° (50% EtOH) in 89% yield. V Et ester was also prepd. from Ia mono-Et ester in the same manner as IV, in 10% yield. V (0.5 g.) was boiled 3.5 hrs. with 4 ml. SOCl2, SOCl2 distd. in vacuo under N, 4 ml. C6H6 added to the residue, and the mixt. filtered. To the filtrate was added 1.4 ml. Et2NCH2CH2OH, the mixt. boiled 4 hrs., dry HCl passed through, and the ppt. filtered off, worked up with 20 ml. H2O, and the filtrate alkalized with Na2CO3 to give 0.34 g. V diethylaminoethyl ester, m. 92-3° (50% EtOH); HCl salt m. 197-8° (EtOH).
IT 990-93-2P, o-Toluic acid, α,α'-[isopropylidenebis(p-phenyleneoxy)]di-
RL: PREP (Preparation)
(preparation of)
RN 990-93-2 CAPLUS
CN o-Toluic acid, α,α'-[isopropylidenebis(p-phenyleneoxy)]di- (7CI, 8CI) (CA INDEX NAME)



L6 ANSWER 149 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:447668 CAPLUS
DOCUMENT NUMBER: 61:47668
ORIGINAL REFERENCE NO.: 61:8239a-c
TITLE: Phenyl benzoates
PATENT ASSIGNEE(S): Chemische Werke Witten G.m.b.H.
SOURCE: 19 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 634563		19631119	BE	
FR 1359002			FR	
GB 982499			GB	
NL 290030			NL	
PRIORITY APPLN. INFO.:			DE	19620706

AB Me benzoates are heated with a phenol at 180-250° in the presence of a mineral acid, an inorg. base, or a tertiary amine as the MeOH is distilled to give the title esters. A mixture of 372 parts BzOMe, 338 parts PhOH, and 14.2 parts Zn salt of a fatty acid is heated 29 hrs. at 184-203° under N as the MeOH continuously distilled to give 364 parts PhOBz, b18 178°, m. 70-70.5°, 99.2% yield. Similarly prepared are 1,4-(PhO2C)2-C6H4, 1,3-(PhO2C)2C6H4, di-Ph methylterephthalate (b0.15-0.2 205-25°, m. 146°), 2,5,1,4-C12C6H2(CO2Ph)2 [m. 175.5-6° (xylene)], 1-C10H7CO2Ph [m. 95.5-6.0° (EtOH)], (4-PhO2C-C6H4)2 (m. 215°), p-MeC6H4CO2Ph (m. 66-7°), tri-Ph trimellitate, 1,4-(p-MeC6H4O2C)C6H4 (b1 250°), p-MeC6H4CO2C6H4-Me-m (b18 196-8°), p-MeC6H4CO2C6H4Bu-tert-p (b15 216-19°, m. 75-6°), o-cresyl dibromobenzoate (b0.6 180-90°), bis(octylphenyl) terephthalate [m. 180-3° (xylene)], Me dimethylphenylene-phthalate, 1,4-(2-C10H7O2C)2C6H4 [m. 230-2° (xylene)], 1,4-(p-PhCH2C6H4O2C)2C6H4 (m. 165-7°), 1,4-(p-tert-BuC6H4O2C)2-C6H4 [m. 224-5° (xylene)], bis(o-cresyl)methylterephthalate [m. 80-2° (xylene)], 3,4-Cl(Me)C6H3CO2C6H4CH2Ph-p.
IT 858831-13-7P, p-Cresol, α-phenyl-, terephthalate
RL: PREP (Preparation)
(preparation of)
RN 858831-13-7 CAPLUS
CN p-Cresol, α-phenyl-, terephthalate (7CI) (CA INDEX NAME)



L6 ANSWER 150 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:60676 CAPLUS
DOCUMENT NUMBER: 60:60676
ORIGINAL REFERENCE NO.: 60:10606f-h
TITLE: Biscarboxybenzoic esters of diols
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: 8 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 629490		19631021	BE	19630312
FR 1353223			FR	
PRIORITY APPLN. INFO.:			GB	19620312

GI For diagram(s), see printed CA Issue.
AB The oxidation of polymethylene di-p-toluates to polymethylene di-p-carboxybenzoates is described. This procedure was modified and extended. Thus, I [X = (CH2)2, R = Me3] 20 in EtCO2H 200 containing CoBr2.6H2O 0.195 and MnBr2.4H2O 0.38 parts by weight was treated at reflux 20 hrs. with O. The solids were filtered off periodically to give a total yield of 1,2-di(p-carboxybenzoyloxy)ethane (II) [I, X = (CH2)2, R = CO2H], m. 301-4° 20 parts. II was esterified with CH2N2 in Et2O to give 1,2-di(p-methoxycarbonylbenzoyloxy)ethane (I, X = (CH2)2, R = CO2Me), m. 165-8° (EtOH). Similarly, the following I (R = CO2H) were prepared (X, parts starting material, parts product, m.p., m.p. di-Me ester): CH2, 20, 17, -, 153-5°; (CH2)4, 20, 11.4, -, 156-9°; p-OC6H4O, 15, 15.1, 325° (sublimes), -; and p-CH2CH2O2CC6H4CO2CH2CH2, 20, 6.8, 270-7°, -. II was refluxed 2 hrs. with SOCl2 and a trace of HCONMe2 to give after distillation of excess SOCl2 and recrystn. of the residue from petr. ether (b. 100-200°) 1,2-di(p-chlorocarbonylbenzoyloxy)ethane (III) [I, X = (CH2)2, R = COCl], m. 116-18°. A solution of III 1.975 in CH2Cl2 13.4 parts was added with stirring to a solution of H2N(CH2)6NH2 0.58 in 4% aqueous NaOH 10 parts. The precipitated copolyesteramide, m. 304° (decomposition), had a viscosity of 1.42 at 25° in a 1% solution of o-ClC6H4OH. A similar reaction between III and hydroquinone 0.55 part gave a copolyester which decomposed without melting. Also, III 1.975 in anhydrous HCONMe2 15 parts was added with stirring to a solution of II in HCONMe2 15 and pyridine 5 parts to give a copolyester anhydride, m. 262-6°.
IT 2225-00-5P, Hydroquinone, diterephthalate
RL: PREP (Preparation)
(preparation of)
RN 2225-00-5 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 1,4-phenylene ester (9CI) (CA INDEX NAME)

L6 ANSWER 150 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 151 OF 151 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1945:15587 CAPLUS
DOCUMENT NUMBER: 39:15587
ORIGINAL REFERENCE NO.: 39:2427c-d,2428a-b
TITLE: Antioxidants for rubber, etc.
INVENTOR(S): Hart, Edward J.; Armstrong, Robert T.
PATENT ASSIGNEE(S): United States Rubber Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2361543		19441031	US 1941-418042	19411106

AB A new class of antioxidants is represented by the general formula ArNH-Ar'-O-Y-COOX, where Ar and Ar' are aromatic radicals, Y is a hydrocarbon radical, and X is H or a salt-forming radical, preferably Zn. Some of these compds., in their acid form, are (p-anilinophenoxy)acetic acid, (p-2-naphthylaminophenoxy)acetic acid, p-(p-toluinophenoxy)acetic acid, α-(p-anilinophenoxy)stearic acid, γ- and K-(p-anilinophenoxy) butyric acid, α-(p-anilinophenoxy)-p-toluic acid, and 2-(p-anilinophenoxy)tridecanedioic acid. The Zn salts of these compds. are preferable in milled rubber, while the NH4, or alkylammonium salts are preferred for use in latex. In rubber these salts are used in quantities of 0.1-3% by weight of rubber. These compds. do not bleed from the rubber and are less readily extractable by organic solvents, e.g., dry-cleaners, than are other common antioxidants.
IT 854646-57-4, p-Toluic acid, α-(p-anilinophenoxy)-
(and salts, as rubber antioxidants)
RN 854646-57-4 CAPLUS
CN p-Toluic acid, α-(p-anilinophenoxy)- (4CI) (CA INDEX NAME)



=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	797.18	970.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-117.78	-117.78

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:48:01 ON 07 DEC 2007